participantId,ImmPort Accession,Visit,Study Identifier,Treatment,Treatment (Numeric),Informed Consent Date,Randomization Date,Randomized?,Intent-to-Treat Sample,Safety Sample,Analysis Sample,Age,Age Group,Age Group.1,Age Group.2,Gender,Primary Race,Secondary RAce,Ethnicity,First Dose Date, Treatment Cycle 1,First Dose Date, Treatment Cycle 2,Last Dose Date,Completed Study,Terminated Study Reason,Terminated Study Date,Terminated Study Day,Completed Study Therapy,Discontinued Study Therapy Reason,Discontinued Study Therapy Reason(Short),Discontinued Study Therapy Date,Discontinued Study Therapy Day,Study Status,Study Therapy Status,Completed Treatment Cycle 1,Completed Treatment Cycle 2,Date of Last Follow-up,Day of Last Follow-up,Last Study Visit,Date of T1DM diagnosis,Day of T1DM diagnosis,Protocol Version Under Which ICF Signed,Consent to Genetic Tests,Consent to Other Tests,Consent to Future Use,Visit.1,Visit (Numeric),Phase,Laboratory date,Study Day,Study Day in Months,Test Name,Time Point,Result in Original Units (Char),Result in Original Units,Original Result Unit,C-peptide (pmol/mL),2 Hour Peak C-peptide For the Visit,2 Hour Baseline Peak C-peptide,2 Hour Change from BL Peak C-peptide,2 Hour Time Peak C-peptide For the Visit,4 Hour Peak C-peptide For the Visit,4 Hour Baseline Peak C-peptide,4 Hour Change from BL Peak C-peptide,4 Hour Time Peak C-peptide For the Visit,Height (cm) at Visit,Weight (kg) at Visit,Insulin Secretion Rate (nmol/L),Peak Insulin Secretion Rate (nmol/L),Peak Insulin Secretion Rate Timepoint,Glucose,Data Snapshot Date,visitnum
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,-10.0,2.19,2.19,NG/ML,0.72489,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,,301.394,30.0,159.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,0.0,1.94,1.94,NG/ML,0.64214,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,243.98,301.394,30.0,157.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,15.0,2.41,2.41,NG/ML,0.79771,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,232.344,301.394,30.0,187.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,30.0,2.46,2.46,NG/ML,0.81426,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,301.394,301.394,30.0,207.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,60.0,2.94,2.94,NG/ML,0.97314,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,239.557,301.394,30.0,248.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,90.0,3.07,3.07,NG/ML,1.01617,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,246.034,301.394,30.0,240.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,120.0,2.88,2.88,NG/ML,0.95328,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,217.05,301.394,30.0,216.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,150.0,2.7,2.7,NG/ML,0.8937,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,196.028,301.394,30.0,194.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,180.0,2.53,2.53,NG/ML,0.83743,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,181.95,301.394,30.0,171.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,210.0,2.18,2.18,NG/ML,0.72158,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,150.303,301.394,30.0,157.0,2014-11-11,-1
T1DAL_137962,SUB168890,-1,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-03,-16.0,-0.526315789,C-PEPTIDE,240.0,1.84,1.84,NG/ML,0.60904,1.01617,1.01617,0.0,90.0,1.01617,1.01617,0.0,90.0,183.0,78.4,121.252,301.394,30.0,140.0,2014-11-11,-1
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,-10.0,0.81,0.81,NG/ML,0.26811,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,,299.482,30.0,115.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,0.0,0.84,0.84,NG/ML,0.27804,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,126.151,299.482,30.0,126.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,15.0,1.11,1.11,NG/ML,0.36741,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,182.89,299.482,30.0,115.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,30.0,1.53,1.53,NG/ML,0.50643,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,299.482,299.482,30.0,178.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,60.0,2.36,2.36,NG/ML,0.78116,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,217.17,299.482,30.0,235.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,90.0,2.38,2.38,NG/ML,0.78778,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,203.976,299.482,30.0,258.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 24,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-06,169.0,5.5592105263,C-PEPTIDE,120.0,2.77,2.77,NG/ML,0.91687,0.91687,1.01617,-0.0993,120.0,,1.01617,,,,84.1,230.017,299.482,30.0,215.0,2014-11-11,15
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,-10.0,0.87,0.87,NG/ML,0.28797,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,,212.626,30.0,170.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,0.0,0.89,0.89,NG/ML,0.29459,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,74.092,212.626,30.0,172.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,15.0,0.85,0.85,NG/ML,0.28135,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,155.815,212.626,30.0,178.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,30.0,1.33,1.33,NG/ML,0.44023,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,212.626,212.626,30.0,238.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,60.0,1.79,1.79,NG/ML,0.59249,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,160.606,212.626,30.0,320.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,90.0,1.81,1.81,NG/ML,0.59911,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,150.92,212.626,30.0,328.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,120.0,1.99,1.99,NG/ML,0.65869,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,160.588,212.626,30.0,320.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,150.0,1.94,1.94,NG/ML,0.64214,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,151.444,212.626,30.0,300.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,180.0,1.61,1.61,NG/ML,0.53291,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,113.633,212.626,30.0,272.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,210.0,1.54,1.54,NG/ML,0.50974,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,109.024,212.626,30.0,249.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 52,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,369.0,12.138157895,C-PEPTIDE,240.0,1.51,1.51,NG/ML,0.49981,0.65869,1.01617,-0.35748,120.0,0.65869,1.01617,-0.35748,120.0,,82.2,111.732,212.626,30.0,239.0,2014-11-11,28
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,-10.0,0.73,0.73,NG/ML,0.24163,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,,154.537,30.0,198.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,0.0,0.73,0.73,NG/ML,0.24163,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,86.411,154.537,30.0,188.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,15.0,0.86,0.86,NG/ML,0.28466,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,151.088,154.537,30.0,193.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,30.0,1.26,1.26,NG/ML,0.41706,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,154.537,154.537,30.0,236.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,60.0,1.43,1.43,NG/ML,0.47333,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,122.14,154.537,30.0,272.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,90.0,1.72,1.72,NG/ML,0.56932,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,144.989,154.537,30.0,263.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 78,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-22,551.0,18.125,C-PEPTIDE,120.0,1.54,1.54,NG/ML,0.50974,0.56932,1.01617,-0.44685,90.0,,1.01617,,,,81.4,119.28,154.537,30.0,234.0,2014-11-11,29
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,-10.0,0.46,0.46,NG/ML,0.15226,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,,123.752,30.0,173.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,0.0,0.54,0.54,NG/ML,0.17874,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,73.798,123.752,30.0,168.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,15.0,0.65,0.65,NG/ML,0.21515,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,86.256,123.752,30.0,193.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,30.0,0.78,0.78,NG/ML,0.25818,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,123.752,123.752,30.0,241.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,60.0,1.05,1.05,NG/ML,0.34755,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,93.152,123.752,30.0,319.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,90.0,1.05,1.05,NG/ML,0.34755,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,87.994,123.752,30.0,350.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,120.0,1.21,1.21,NG/ML,0.40051,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,99.026,123.752,30.0,314.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,150.0,1.15,1.15,NG/ML,0.38065,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,90.17,123.752,30.0,292.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,180.0,0.93,0.93,NG/ML,0.30783,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,65.454,123.752,30.0,281.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,210.0,0.93,0.93,NG/ML,0.30783,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,67.623,123.752,30.0,263.0,2014-11-11,30
T1DAL_137962,SUB168890,Week 104,ITN045AI-Rigby,P,2.0,2010-11-28,2010-12-19,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2010-12-19,2011-06-06,2011-08-22,Yes,,2012-12-24,736.0,Yes,,,2011-08-22,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-24,736.0,Week 104/Visit 30,2010-09-14,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-24,736.0,24.210526316,C-PEPTIDE,240.0,0.7,0.7,NG/ML,0.2317,0.40051,1.01617,-0.61566,120.0,0.40051,1.01617,-0.61566,120.0,185.0,82.95,45.401,123.752,30.0,238.0,2014-11-11,30
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,-10.0,1.09,1.09,NG/ML,0.36079,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,,256.679,30.0,116.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,0.0,1.17,1.17,NG/ML,0.38727,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,130.891,256.679,30.0,114.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,15.0,1.33,1.33,NG/ML,0.44023,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,231.422,256.679,30.0,128.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,30.0,2.03,2.03,NG/ML,0.67193,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,256.679,256.679,30.0,185.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,60.0,2.4,2.4,NG/ML,0.7944,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,200.698,256.679,30.0,218.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,90.0,2.76,2.76,NG/ML,0.91356,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,222.581,256.679,30.0,216.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,120.0,2.42,2.42,NG/ML,0.80102,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,178.848,256.679,30.0,190.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,150.0,2.86,2.86,NG/ML,0.94666,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,217.735,256.679,30.0,173.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,180.0,2.5,2.5,NG/ML,0.8275,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,182.593,256.679,30.0,146.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,210.0,2.31,2.31,NG/ML,0.76461,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,160.681,256.679,30.0,129.0,2014-11-11,-1
T1DAL_142037,SUB168891,-1,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-05,-27.0,-0.888157895,C-PEPTIDE,240.0,1.87,1.87,NG/ML,0.61897,0.91356,0.91356,0.0,90.0,0.94666,0.94666,0.0,150.0,165.5,93.5,122.414,256.679,30.0,112.0,2014-11-11,-1
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,-10.0,0.64,0.64,NG/ML,0.21184,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,,191.265,15.0,144.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,0.0,0.69,0.69,NG/ML,0.22839,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,168.514,191.265,15.0,146.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,15.0,1.34,1.34,NG/ML,0.44354,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,191.265,191.265,15.0,203.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,30.0,1.68,1.68,NG/ML,0.55608,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,163.346,191.265,15.0,250.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,60.0,1.68,1.68,NG/ML,0.55608,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,132.81,191.265,15.0,271.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,90.0,1.68,1.68,NG/ML,0.55608,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,125.206,191.265,15.0,259.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 24,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-18,168.0,5.5263157895,C-PEPTIDE,120.0,1.8,1.8,NG/ML,0.5958,0.5958,0.91356,-0.31776,120.0,,0.94666,,,165.3,92.1,135.333,191.265,15.0,258.0,2014-11-11,15
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,-10.0,0.39,0.39,NG/ML,0.12909,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,,55.718,30.0,214.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,0.0,0.38,0.38,NG/ML,0.12578,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,49.262,55.718,30.0,209.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,15.0,0.48,0.48,NG/ML,0.15888,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,47.563,55.718,30.0,227.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,30.0,0.5,0.5,NG/ML,0.1655,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,55.718,55.718,30.0,275.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,60.0,0.57,0.57,NG/ML,0.18867,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,44.989,55.718,30.0,318.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,90.0,0.54,0.54,NG/ML,0.17874,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,40.727,55.718,30.0,320.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,120.0,0.47,0.47,NG/ML,0.15557,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,32.789,55.718,30.0,311.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,150.0,0.47,0.47,NG/ML,0.15557,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,33.439,55.718,30.0,299.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,180.0,0.49,0.49,NG/ML,0.16219,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,36.475,55.718,30.0,286.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,210.0,0.47,0.47,NG/ML,0.15557,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,34.582,55.718,30.0,262.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 52,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,393.0,12.927631579,C-PEPTIDE,240.0,0.48,0.48,NG/ML,0.15888,0.18867,0.91356,-0.72489,60.0,0.18867,0.94666,-0.75799,60.0,166.3,95.5,35.474,55.718,30.0,253.0,2014-11-11,28
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,-10.0,0.33,0.33,NG/ML,0.10923,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,,49.858,15.0,159.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,0.0,0.34,0.34,NG/ML,0.11254,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,38.673,49.858,15.0,151.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,15.0,0.38,0.38,NG/ML,0.12578,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,49.858,49.858,15.0,167.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,30.0,0.49,0.49,NG/ML,0.16219,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,49.457,49.858,15.0,221.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,60.0,0.5,0.5,NG/ML,0.1655,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,40.632,49.858,15.0,265.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,90.0,0.46,0.46,NG/ML,0.15226,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,32.775,49.858,15.0,263.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 78,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-05-22,537.0,17.664473684,C-PEPTIDE,120.0,0.43,0.43,NG/ML,0.14233,0.1655,0.91356,-0.74806,60.0,,0.94666,,,166.4,93.6,29.399,49.858,15.0,258.0,2014-11-11,29
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,-10.0,0.12,0.12,NG/ML,0.03972,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,,33.039,30.0,195.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,0.0,0.13,0.13,NG/ML,0.04303,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,20.479,33.039,30.0,193.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,15.0,0.17,0.17,NG/ML,0.05627,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,27.21,33.039,30.0,211.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,30.0,0.24,0.24,NG/ML,0.07944,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,33.039,33.039,30.0,267.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,60.0,0.3,0.3,NG/ML,0.0993,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,25.238,33.039,30.0,314.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,90.0,0.29,0.29,NG/ML,0.09599,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,23.67,33.039,30.0,339.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,120.0,0.3,0.3,NG/ML,0.0993,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,22.542,33.039,30.0,339.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,150.0,0.25,0.25,NG/ML,0.08275,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,16.309,33.039,30.0,303.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,180.0,0.23,0.23,NG/ML,0.07613,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,16.673,33.039,30.0,270.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,210.0,0.19,0.19,NG/ML,0.06289,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,11.55,33.039,30.0,223.0,2014-11-11,30
T1DAL_142037,SUB168891,Week 104,ITN045AI-Rigby,P,2.0,2011-11-05,2011-12-02,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-12-02,2012-05-18,2012-08-04,Yes,,2013-12-03,732.0,Yes,,,2012-08-04,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-03,732.0,Week 104/Visit 30,2011-10-07,-56.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-03,732.0,24.078947368,C-PEPTIDE,240.0,0.15,0.15,NG/ML,0.04965,0.0993,0.91356,-0.81426,60.0,0.0993,0.94666,-0.84736,60.0,165.6,95.1,9.166,33.039,30.0,207.0,2014-11-11,30
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,-10.0,0.79,0.79,NG/ML,0.26149,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,,226.765,30.0,105.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,0.0,0.77,0.77,NG/ML,0.25487,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,91.862,226.765,30.0,102.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,15.0,0.92,0.92,NG/ML,0.30452,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,184.985,226.765,30.0,118.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,30.0,1.54,1.54,NG/ML,0.50974,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,226.765,226.765,30.0,174.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,60.0,1.98,1.98,NG/ML,0.65538,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,171.831,226.765,30.0,245.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,90.0,1.85,1.85,NG/ML,0.61235,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,145.308,226.765,30.0,242.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,120.0,1.88,1.88,NG/ML,0.62228,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,140.461,226.765,30.0,222.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,150.0,1.64,1.64,NG/ML,0.54284,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,116.008,226.765,30.0,197.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,180.0,1.45,1.45,NG/ML,0.47995,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,98.16,226.765,30.0,175.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,210.0,1.43,1.43,NG/ML,0.47333,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,101.035,226.765,30.0,153.0,2014-11-11,-1
T1DAL_161919,SUB168892,-1,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-10,-21.0,-0.690789474,C-PEPTIDE,240.0,1.21,1.21,NG/ML,0.40051,0.65538,0.65538,0.0,60.0,0.65538,0.65538,0.0,60.0,190.1,67.6,82.603,226.765,30.0,120.0,2014-11-11,-1
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,-10.0,0.44,0.44,NG/ML,0.14564,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,,250.515,30.0,118.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,0.0,0.46,0.46,NG/ML,0.15226,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,59.746,250.515,30.0,117.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,15.0,0.57,0.57,NG/ML,0.18867,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,180.564,250.515,30.0,134.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,30.0,1.35,1.35,NG/ML,0.44685,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,250.515,250.515,30.0,225.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,60.0,2,2.0,NG/ML,0.662,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,181.987,250.515,30.0,276.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,90.0,2.05,2.05,NG/ML,0.67855,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,169.883,250.515,30.0,285.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 24,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-18,171.0,5.625,C-PEPTIDE,120.0,2.41,2.41,NG/ML,0.79771,0.79771,0.65538,0.14233,120.0,,0.65538,,,190.1,67.9,193.414,250.515,30.0,264.0,2014-11-11,15
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,-10.0,0.94,0.94,NG/ML,0.31114,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,,216.2,15.0,143.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,0.0,0.86,0.86,NG/ML,0.28466,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,106.716,216.2,15.0,136.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,15.0,1.06,1.06,NG/ML,0.35086,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,216.2,216.2,15.0,155.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,30.0,1.78,1.78,NG/ML,0.58918,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,171.311,216.2,15.0,245.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,60.0,1.72,1.72,NG/ML,0.56932,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,142.543,216.2,15.0,316.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,90.0,1.61,1.61,NG/ML,0.53291,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,119.811,216.2,15.0,301.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,120.0,1.61,1.61,NG/ML,0.53291,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,118.893,216.2,15.0,290.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,150.0,1.56,1.56,NG/ML,0.51636,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,115.075,216.2,15.0,268.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,180.0,1.37,1.37,NG/ML,0.45347,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,96.36,216.2,15.0,248.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,210.0,1.25,1.25,NG/ML,0.41375,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,86.385,216.2,15.0,227.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 52,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-01,367.0,12.072368421,C-PEPTIDE,240.0,1.21,1.21,NG/ML,0.40051,0.58918,0.65538,-0.0662,30.0,0.58918,0.65538,-0.0662,30.0,190.7,69.4,86.285,216.2,15.0,207.0,2014-11-11,28
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,-10.0,0.95,0.95,NG/ML,0.31445,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,,179.786,15.0,220.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,0.0,0.91,0.91,NG/ML,0.30121,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,114.651,179.786,15.0,218.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,15.0,1.12,1.12,NG/ML,0.37072,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,179.786,179.786,15.0,232.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,30.0,1.57,1.57,NG/ML,0.51967,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,135.455,179.786,15.0,308.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,60.0,1.46,1.46,NG/ML,0.48326,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,116.69,179.786,15.0,341.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,90.0,1.39,1.39,NG/ML,0.46009,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,103.305,179.786,15.0,348.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 78,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-13,532.0,17.5,C-PEPTIDE,120.0,1.37,1.37,NG/ML,0.45347,0.51967,0.65538,-0.13571,30.0,,0.65538,,,190.4,71.4,100.71,179.786,15.0,332.0,2014-11-11,29
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,-10.0,0.32,0.32,NG/ML,0.10592,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,,73.366,30.0,207.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,0.0,0.34,0.34,NG/ML,0.11254,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,29.482,73.366,30.0,200.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,15.0,0.34,0.34,NG/ML,0.11254,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,69.077,73.366,30.0,207.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,30.0,0.57,0.57,NG/ML,0.18867,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,73.366,73.366,30.0,268.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,60.0,0.65,0.65,NG/ML,0.21515,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,57.581,73.366,30.0,359.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,90.0,0.58,0.58,NG/ML,0.19198,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,43.669,73.366,30.0,351.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,120.0,0.52,0.52,NG/ML,0.17212,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,35.891,73.366,30.0,328.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,150.0,0.47,0.47,NG/ML,0.15557,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,34.142,73.366,30.0,303.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,180.0,0.43,0.43,NG/ML,0.14233,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,29.285,73.366,30.0,277.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,210.0,0.41,0.41,NG/ML,0.13571,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,30.472,73.366,30.0,258.0,2014-11-11,30
T1DAL_161919,SUB168892,Week 104,ITN045AI-Rigby,P,2.0,2011-07-10,2011-07-31,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-07-31,2012-01-18,2012-04-04,Yes,,2013-08-11,742.0,Yes,,,2012-04-04,248.0,Completed study,Completed study drug,Yes,Yes,2013-08-11,742.0,Week 104/Visit 30,2011-05-11,-81.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-11,742.0,24.407894737,C-PEPTIDE,240.0,0.4,0.4,NG/ML,0.1324,0.21515,0.65538,-0.44023,60.0,0.21515,0.65538,-0.44023,60.0,191.1,71.1,28.453,73.366,30.0,240.0,2014-11-11,30
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,-10.0,1.12,1.12,NG/ML,0.37072,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,,225.457,15.0,112.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,0.0,1.12,1.12,NG/ML,0.37072,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,112.521,225.457,15.0,111.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,15.0,1.32,1.32,NG/ML,0.43692,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,225.457,225.457,15.0,115.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,30.0,2.21,2.21,NG/ML,0.73151,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,189.828,225.457,15.0,160.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,60.0,2.21,2.21,NG/ML,0.73151,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,156.62,225.457,15.0,189.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,90.0,2.27,2.27,NG/ML,0.75137,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,149.781,225.457,15.0,183.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,120.0,2.5,2.5,NG/ML,0.8275,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,166.448,225.457,15.0,162.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,150.0,2.82,2.82,NG/ML,0.93342,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,191.14,225.457,15.0,133.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,180.0,2.21,2.21,NG/ML,0.73151,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,134.159,225.457,15.0,109.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,210.0,1.86,1.86,NG/ML,0.61566,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,103.14,225.457,15.0,98.0,2014-11-11,-1
T1DAL_185333,SUB168893,-1,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-01-09,-12.0,-0.394736842,C-PEPTIDE,240.0,1.54,1.54,NG/ML,0.50974,0.8275,0.8275,0.0,120.0,0.93342,0.93342,0.0,150.0,159.3,48.7,84.299,225.457,15.0,82.0,2014-11-11,-1
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,-10.0,1.12,1.12,NG/ML,0.37072,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,,448.122,30.0,90.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,0.0,1.1,1.1,NG/ML,0.3641,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,146.694,448.122,30.0,88.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,15.0,1.55,1.55,NG/ML,0.51305,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,326.912,448.122,30.0,104.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,30.0,2.99,2.99,NG/ML,0.98969,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,448.122,448.122,30.0,142.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,60.0,4.3,4.3,NG/ML,1.4233,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,329.172,448.122,30.0,182.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,90.0,3.5,3.5,NG/ML,1.1585,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,233.291,448.122,30.0,126.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 24,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-07-08,169.0,5.5592105263,C-PEPTIDE,120.0,3.97,3.97,NG/ML,1.31407,1.4233,0.8275,0.5958,60.0,,0.93342,,,159.9,49.9,257.677,448.122,30.0,131.0,2014-11-11,15
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,-10.0,1.66,1.66,NG/ML,0.54946,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,,374.702,15.0,110.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,0.0,1.59,1.59,NG/ML,0.52629,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,225.948,374.702,15.0,113.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,15.0,2.33,2.33,NG/ML,0.77123,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,374.702,374.702,15.0,135.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,30.0,3.61,3.61,NG/ML,1.19491,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,302.592,374.702,15.0,191.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,60.0,3.52,3.52,NG/ML,1.16512,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,250.287,374.702,15.0,204.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,90.0,3.68,3.68,NG/ML,1.21808,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,245.782,374.702,15.0,216.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,120.0,4.43,4.43,NG/ML,1.46633,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,306.857,374.702,15.0,209.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,150.0,4.56,4.56,NG/ML,1.50936,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,311.063,374.702,15.0,182.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,180.0,4,4.0,NG/ML,1.324,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,251.748,374.702,15.0,156.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,210.0,3.41,3.41,NG/ML,1.12871,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,200.045,374.702,15.0,127.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 52,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-01-14,359.0,11.809210526,C-PEPTIDE,240.0,2.89,2.89,NG/ML,0.95659,1.46633,0.8275,0.63883,120.0,1.50936,0.93342,0.57594,150.0,161.0,52.2,164.595,374.702,15.0,97.0,2014-11-11,28
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,-10.0,1.04,1.04,NG/ML,0.34424,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,,273.844,15.0,115.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,0.0,1.16,1.16,NG/ML,0.38396,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,171.712,273.844,15.0,112.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,15.0,1.7,1.7,NG/ML,0.5627,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,273.844,273.844,15.0,150.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,30.0,2.6,2.6,NG/ML,0.8606,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,242.153,273.844,15.0,216.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,60.0,2.68,2.68,NG/ML,0.88708,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,194.919,273.844,15.0,258.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,90.0,2.48,2.48,NG/ML,0.82088,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,162.001,273.844,15.0,240.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 78,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,532.0,17.5,C-PEPTIDE,120.0,2.49,2.49,NG/ML,0.82419,0.88708,0.8275,0.05958,60.0,,0.93342,,,161.2,54.5,159.065,273.844,15.0,211.0,2014-11-11,29
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,-10.0,0.82,0.82,NG/ML,0.27142,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,,162.454,30.0,150.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,0.0,0.84,0.84,NG/ML,0.27804,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,75.975,162.454,30.0,150.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,15.0,0.91,0.91,NG/ML,0.30121,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,139.564,162.454,30.0,155.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,30.0,1.4,1.4,NG/ML,0.4634,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,162.454,162.454,30.0,220.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,60.0,1.69,1.69,NG/ML,0.55939,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,126.165,162.454,30.0,258.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,90.0,1.94,1.94,NG/ML,0.64214,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,138.797,162.454,30.0,283.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,120.0,1.96,1.96,NG/ML,0.64876,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,134.642,162.454,30.0,250.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,150.0,1.99,1.99,NG/ML,0.65869,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,132.85,162.454,30.0,249.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,180.0,1.87,1.87,NG/ML,0.61897,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,120.728,162.454,30.0,231.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,210.0,1.79,1.79,NG/ML,0.59249,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,112.819,162.454,30.0,227.0,2014-11-11,30
T1DAL_185333,SUB168893,Week 104,ITN045AI-Rigby,P,2.0,2012-01-09,2012-01-21,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2012-01-21,2012-07-08,2012-09-22,Yes,,2014-01-11,721.0,Yes,,,2012-09-22,245.0,Completed study,Completed study drug,Yes,Yes,2014-01-11,721.0,Week 104/Visit 30,2011-12-16,-36.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-01-11,721.0,23.717105263,C-PEPTIDE,240.0,1.81,1.81,NG/ML,0.59911,0.64876,0.8275,-0.17874,120.0,0.65869,0.93342,-0.27473,150.0,162.0,55.4,117.414,162.454,30.0,196.0,2014-11-11,30
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,-10.0,0.61,0.61,NG/ML,0.20191,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,,100.428,30.0,205.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,0.0,0.61,0.61,NG/ML,0.20191,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,92.034,100.428,30.0,203.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,15.0,0.91,0.91,NG/ML,0.30121,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,67.433,100.428,30.0,239.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,30.0,0.83,0.83,NG/ML,0.27473,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,100.428,100.428,30.0,281.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,60.0,1.08,1.08,NG/ML,0.35748,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,77.027,100.428,30.0,334.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,90.0,1.08,1.08,NG/ML,0.35748,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,75.193,100.428,30.0,365.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,120.0,1.03,1.03,NG/ML,0.34093,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,67.387,100.428,30.0,342.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,150.0,0.95,0.95,NG/ML,0.31445,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,59.837,100.428,30.0,311.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,180.0,0.89,0.89,NG/ML,0.29459,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,55.506,100.428,30.0,268.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,210.0,0.81,0.81,NG/ML,0.26811,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,49.933,100.428,30.0,247.0,2014-11-11,-1
T1DAL_243767,SUB168894,-1,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-21,-34.0,-1.118421053,C-PEPTIDE,240.0,0.56,0.56,NG/ML,0.18536,0.35748,0.35748,0.0,60.0,0.35748,0.35748,0.0,60.0,173.6,55.9,29.218,100.428,30.0,219.0,2014-11-11,-1
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,-10.0,0.85,0.85,NG/ML,0.28135,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,,231.589,30.0,104.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,0.0,0.75,0.75,NG/ML,0.24825,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,70.48,231.589,30.0,93.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,15.0,0.85,0.85,NG/ML,0.28135,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,122.947,231.589,30.0,107.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,30.0,1.23,1.23,NG/ML,0.40713,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,231.589,231.589,30.0,143.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,60.0,2.08,2.08,NG/ML,0.68848,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,166.676,231.589,30.0,201.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,90.0,2.48,2.48,NG/ML,0.82088,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,191.664,231.589,30.0,209.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 24,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-10,167.0,5.4934210526,C-PEPTIDE,120.0,3.08,3.08,NG/ML,1.01948,1.01948,0.35748,0.662,120.0,,0.35748,,,174.5,58.7,230.757,231.589,30.0,214.0,2014-11-11,15
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,-10.0,1.01,1.01,NG/ML,0.33431,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,,194.517,15.0,136.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,0.0,1.08,1.08,NG/ML,0.35748,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,117.071,194.517,15.0,137.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,15.0,1.26,1.26,NG/ML,0.41706,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,194.517,194.517,15.0,147.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,30.0,1.85,1.85,NG/ML,0.61235,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,189.04,194.517,15.0,202.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,60.0,2,2.0,NG/ML,0.662,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,151.671,194.517,15.0,252.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,90.0,1.92,1.92,NG/ML,0.63552,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,133.899,194.517,15.0,251.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,120.0,2.19,2.19,NG/ML,0.72489,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,155.312,194.517,15.0,249.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,150.0,2.06,2.06,NG/ML,0.68186,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,141.593,194.517,15.0,237.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,180.0,1.89,1.89,NG/ML,0.62559,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,123.059,194.517,15.0,222.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,210.0,1.78,1.78,NG/ML,0.58918,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,115.015,194.517,15.0,210.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 52,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-01-16,357.0,11.743421053,C-PEPTIDE,240.0,1.77,1.77,NG/ML,0.58587,0.72489,0.35748,0.36741,120.0,0.72489,0.35748,0.36741,120.0,174.8,61.6,117.408,194.517,15.0,183.0,2014-11-11,28
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,-10.0,0.94,0.94,NG/ML,0.31114,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,,180.281,15.0,146.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,0.0,0.94,0.94,NG/ML,0.31114,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,111.345,180.281,15.0,157.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,15.0,1.17,1.17,NG/ML,0.38727,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,180.281,180.281,15.0,169.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,30.0,1.71,1.71,NG/ML,0.56601,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,176.309,180.281,15.0,222.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,60.0,1.86,1.86,NG/ML,0.61566,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,140.711,180.281,15.0,265.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,90.0,1.89,1.89,NG/ML,0.62559,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,133.732,180.281,15.0,306.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 78,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-17,540.0,17.763157895,C-PEPTIDE,120.0,2.1,2.1,NG/ML,0.6951,0.6951,0.35748,0.33762,120.0,,0.35748,,,174.8,60.1,148.912,180.281,15.0,303.0,2014-11-11,29
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,-10.0,1.13,1.13,NG/ML,0.37403,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,,166.665,15.0,227.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,0.0,1.03,1.03,NG/ML,0.34093,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,95.203,166.665,15.0,234.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,15.0,1.14,1.14,NG/ML,0.37734,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,166.665,166.665,15.0,256.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,30.0,1.65,1.65,NG/ML,0.54615,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,140.45,166.665,15.0,303.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,60.0,1.62,1.62,NG/ML,0.53622,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,118.385,166.665,15.0,346.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,90.0,1.72,1.72,NG/ML,0.56932,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,119.2,166.665,15.0,377.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,120.0,1.74,1.74,NG/ML,0.57594,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,120.038,166.665,15.0,375.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,150.0,1.55,1.55,NG/ML,0.51305,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,98.952,166.665,15.0,369.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,180.0,1.5,1.5,NG/ML,0.4965,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,96.894,166.665,15.0,344.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,210.0,1.32,1.32,NG/ML,0.43692,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,83.247,166.665,15.0,333.0,2014-11-11,30
T1DAL_243767,SUB168894,Week 104,ITN045AI-Rigby,A,1.0,2010-12-21,2011-01-24,Yes,Yes,Yes,S/I,19.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2011-01-24,2011-07-10,2011-09-28,Yes,,2013-01-17,724.0,Yes,,,2011-09-28,247.0,Completed study,Completed study drug,Yes,Yes,2013-01-17,724.0,Week 104/Visit 30,2010-12-08,-47.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-17,724.0,23.815789474,C-PEPTIDE,240.0,1.29,1.29,NG/ML,0.42699,0.57594,0.35748,0.21846,120.0,0.57594,0.35748,0.21846,120.0,174.8,59.6,82.756,166.665,15.0,299.0,2014-11-11,30
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,-10.0,1.46,1.46,NG/ML,0.48326,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,,428.172,120.0,85.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,0.0,1.55,1.55,NG/ML,0.51305,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,130.693,428.172,120.0,86.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,15.0,1.49,1.49,NG/ML,0.49319,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,235.191,428.172,120.0,81.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,30.0,2.14,2.14,NG/ML,0.70834,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,416.178,428.172,120.0,86.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,60.0,3.42,3.42,NG/ML,1.13202,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,304.566,428.172,120.0,159.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,90.0,4.47,4.47,NG/ML,1.47957,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,391.875,428.172,120.0,156.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,120.0,5.11,5.11,NG/ML,1.69141,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,428.172,428.172,120.0,155.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,150.0,4.41,4.41,NG/ML,1.45971,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,332.271,428.172,120.0,127.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,180.0,4.74,4.74,NG/ML,1.56894,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,356.79,428.172,120.0,113.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,210.0,3.92,3.92,NG/ML,1.29752,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,278.472,428.172,120.0,95.0,2014-11-11,-1
T1DAL_267590,SUB168895,-1,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Screening,-1.0,1000,2011-03-05,-34.0,-1.118421053,C-PEPTIDE,240.0,2.98,2.98,NG/ML,0.98638,1.69141,1.69141,0.0,120.0,1.69141,1.69141,0.0,120.0,190.1,68.5,185.539,428.172,120.0,83.0,2014-11-11,-1
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,-10.0,1.01,1.01,NG/ML,0.33431,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,,588.223,30.0,76.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,0.0,1.01,1.01,NG/ML,0.33431,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,147.807,588.223,30.0,72.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,15.0,1.33,1.33,NG/ML,0.44023,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,352.636,588.223,30.0,81.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,30.0,2.65,2.65,NG/ML,0.87715,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,588.223,588.223,30.0,100.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,60.0,4.44,4.44,NG/ML,1.46964,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,419.816,588.223,30.0,147.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,90.0,4.67,4.67,NG/ML,1.54577,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,408.949,588.223,30.0,138.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 24,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 24,15.0,2015,2011-09-24,169.0,5.5592105263,C-PEPTIDE,120.0,4.06,4.06,NG/ML,1.34386,1.54577,1.69141,-0.14564,90.0,,1.69141,,,190.6,73.3,311.6,588.223,30.0,101.0,2014-11-11,15
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,-10.0,1.37,1.37,NG/ML,0.45347,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,,615.599,30.0,87.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,0.0,1.37,1.37,NG/ML,0.45347,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,224.552,615.599,30.0,83.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,15.0,1.92,1.92,NG/ML,0.63552,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,484.738,615.599,30.0,96.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,30.0,3.61,3.61,NG/ML,1.19491,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,615.599,615.599,30.0,131.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,60.0,4.89,4.89,NG/ML,1.61859,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,457.143,615.599,30.0,137.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,90.0,5.29,5.29,NG/ML,1.75099,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,460.792,615.599,30.0,144.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,120.0,4.79,4.79,NG/ML,1.58549,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,378.299,615.599,30.0,131.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,150.0,3.47,3.47,NG/ML,1.14857,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,229.863,615.599,30.0,100.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,180.0,2.74,2.74,NG/ML,0.90694,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,167.439,615.599,30.0,84.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,210.0,1.92,1.92,NG/ML,0.63552,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,107.592,615.599,30.0,74.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 52,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 52,28.0,2028,2012-04-12,370.0,12.171052632,C-PEPTIDE,240.0,1.96,1.96,NG/ML,0.64876,1.75099,1.69141,0.05958,90.0,1.75099,1.69141,0.05958,90.0,191.4,76.6,134.195,615.599,30.0,71.0,2014-11-11,28
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,-10.0,1.25,1.25,NG/ML,0.41375,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,,466.245,30.0,81.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,0.0,1.28,1.28,NG/ML,0.42368,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,166.331,466.245,30.0,86.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,15.0,1.55,1.55,NG/ML,0.51305,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,410.868,466.245,30.0,87.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,30.0,3.05,3.05,NG/ML,1.00955,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,466.245,466.245,30.0,133.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,60.0,3.8,3.8,NG/ML,1.2578,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,353.942,466.245,30.0,157.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,90.0,4.65,4.65,NG/ML,1.53915,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,412.964,466.245,30.0,157.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 78,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 78,29.0,2029,2012-10-11,552.0,18.157894737,C-PEPTIDE,120.0,4.86,4.86,NG/ML,1.60866,1.60866,1.69141,-0.08275,120.0,,1.69141,,,191.6,77.8,411.487,466.245,30.0,159.0,2014-11-11,29
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,-10.0,1.38,1.38,NG/ML,0.45678,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,,485.163,15.0,97.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,0.0,1.37,1.37,NG/ML,0.45347,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,197.805,485.163,15.0,99.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,15.0,1.75,1.75,NG/ML,0.57925,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,485.163,485.163,15.0,112.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,30.0,3.49,3.49,NG/ML,1.15519,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,454.209,485.163,15.0,169.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,60.0,3.83,3.83,NG/ML,1.26773,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,357.202,485.163,15.0,213.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,90.0,4.12,4.12,NG/ML,1.36372,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,353.894,485.163,15.0,209.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,120.0,4.23,4.23,NG/ML,1.40013,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,352.865,485.163,15.0,184.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,150.0,3.74,3.74,NG/ML,1.23794,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,292.187,485.163,15.0,173.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,180.0,3.66,3.66,NG/ML,1.21146,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,282.606,485.163,15.0,142.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,210.0,3.11,3.11,NG/ML,1.02941,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,231.045,485.163,15.0,123.0,2014-11-11,30
T1DAL_267590,SUB168895,Week 104,ITN045AI-Rigby,P,2.0,2011-03-05,2011-04-08,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-04-08,2011-09-24,2011-12-09,Yes,,2013-05-04,757.0,Yes,,,2011-12-09,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-04,757.0,Week 104/Visit 30,2011-01-21,-77.0,7,No,No,Yes,Week 104,30.0,2030,2013-05-04,757.0,24.901315789,C-PEPTIDE,240.0,2.82,2.82,NG/ML,0.93342,1.40013,1.69141,-0.29128,120.0,1.40013,1.69141,-0.29128,120.0,192.4,81.7,205.401,485.163,15.0,103.0,2014-11-11,30
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,-10.0,1.22,1.22,NG/ML,0.40382,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,,403.996,30.0,92.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,0.0,1.25,1.25,NG/ML,0.41375,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,121.849,403.996,30.0,93.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,15.0,1.27,1.27,NG/ML,0.42037,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,290.775,403.996,30.0,96.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,30.0,2.25,2.25,NG/ML,0.74475,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,403.996,403.996,30.0,105.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,60.0,3.16,3.16,NG/ML,1.04596,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,299.627,403.996,30.0,141.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,90.0,2.73,2.73,NG/ML,0.90363,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,227.835,403.996,30.0,121.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,120.0,3.14,3.14,NG/ML,1.03934,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,257.416,403.996,30.0,115.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,150.0,2.26,2.26,NG/ML,0.74806,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,160.659,403.996,30.0,88.0,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,180.0,1.74,1.74,NG/ML,0.57594,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,105.283,403.996,30.0,,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,210.0,1.1,1.1,NG/ML,0.3641,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,53.059,403.996,30.0,,2014-11-11,-1
T1DAL_270794,SUB168896,-1,ITN045AI-Rigby,P,2.0,2010-12-30,2011-02-08,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-08,,2011-04-06,No,Failure to Return/Lost to Follow-Up,2011-08-17,190.0,No,Lost to Follow-up,Lost to Follow-up,2011-04-06,57.0,Terminated study early,Discontinued study drug early,Yes,No,2011-08-17,190.0,Week 19/Visit 13,2010-10-31,-100.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-12-30,-40.0,-1.315789474,C-PEPTIDE,240.0,0.79,0.79,NG/ML,0.26149,1.04596,1.04596,0.0,60.0,1.04596,1.04596,0.0,60.0,181.0,92.1,36.287,403.996,30.0,,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,-10.0,2.51,2.51,NG/ML,0.83081,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,,397.935,0.0,233.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,0.0,2.54,2.54,NG/ML,0.84074,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,397.935,397.935,0.0,231.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,15.0,3.21,3.21,NG/ML,1.06251,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,350.08,397.935,0.0,260.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,30.0,3.18,3.18,NG/ML,1.05258,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,311.35,397.935,0.0,282.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,60.0,3.07,3.07,NG/ML,1.01617,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,271.479,397.935,0.0,313.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,90.0,3.35,3.35,NG/ML,1.10885,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,301.893,397.935,0.0,338.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,120.0,2.9,2.9,NG/ML,0.9599,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,246.975,397.935,0.0,332.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,150.0,3.02,3.02,NG/ML,0.99962,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,260.45,397.935,0.0,312.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,180.0,3,3.0,NG/ML,0.993,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,263.905,397.935,0.0,300.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,210.0,2.8,2.8,NG/ML,0.9268,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,239.674,397.935,0.0,278.0,2014-11-11,-1
T1DAL_295813,SUB168897,-1,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Screening,-1.0,1000,2011-05-15,-34.0,-1.118421053,C-PEPTIDE,240.0,2.99,2.99,NG/ML,0.98969,1.10885,1.10885,0.0,90.0,1.10885,1.10885,0.0,90.0,188.0,108.0,264.239,397.935,0.0,274.0,2014-11-11,-1
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,-10.0,3.25,3.25,NG/ML,1.07575,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,,768.992,15.0,176.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,0.0,3.23,3.23,NG/ML,1.06913,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,420.608,768.992,15.0,167.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,15.0,3.53,3.53,NG/ML,1.16843,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,768.992,768.992,15.0,169.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,30.0,5.34,5.34,NG/ML,1.76754,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,577.173,768.992,15.0,221.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,60.0,4.93,4.93,NG/ML,1.63183,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,498.346,768.992,15.0,237.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,90.0,5.55,5.55,NG/ML,1.83705,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,543.929,768.992,15.0,255.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 24,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-12-04,169.0,5.5592105263,C-PEPTIDE,120.0,5.46,5.46,NG/ML,1.80726,1.83705,1.10885,0.7282,90.0,,1.10885,,,188.0,129.7,526.209,768.992,15.0,250.0,2014-11-11,15
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,-10.0,2.72,2.72,NG/ML,0.90032,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,,518.571,30.0,161.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,0.0,2.63,2.63,NG/ML,0.87053,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,425.589,518.571,30.0,160.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,15.0,3.24,3.24,NG/ML,1.07244,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,438.777,518.571,30.0,178.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,30.0,3.49,3.49,NG/ML,1.15519,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,518.571,518.571,30.0,209.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,60.0,4.02,4.02,NG/ML,1.33062,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,415.753,518.571,30.0,258.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,90.0,4.13,4.13,NG/ML,1.36703,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,415.864,518.571,30.0,267.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,120.0,4.81,4.81,NG/ML,1.59211,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,491.169,518.571,30.0,261.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,150.0,3.71,3.71,NG/ML,1.22801,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,336.453,518.571,30.0,247.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,180.0,3.9,3.9,NG/ML,1.2909,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,357.505,518.571,30.0,234.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,210.0,3.62,3.62,NG/ML,1.19822,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,337.292,518.571,30.0,217.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 52,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,240.0,3.84,3.84,NG/ML,1.27104,1.59211,1.10885,0.48326,120.0,1.59211,1.10885,0.48326,120.0,188.0,137.3,368.987,518.571,30.0,209.0,2014-11-11,28
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,-10.0,1.19,1.19,NG/ML,0.39389,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,,567.965,30.0,108.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,0.0,1.13,1.13,NG/ML,0.37403,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,392.912,567.965,30.0,110.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,15.0,2.39,2.39,NG/ML,0.79109,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,423.992,567.965,30.0,155.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,30.0,2.89,2.89,NG/ML,0.95659,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,567.965,567.965,30.0,209.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,60.0,3.9,3.9,NG/ML,1.2909,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,420.736,567.965,30.0,245.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,90.0,4.84,4.84,NG/ML,1.60204,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,514.453,567.965,30.0,229.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,120.0,4.83,4.83,NG/ML,1.59873,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,482.902,567.965,30.0,220.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,150.0,4.61,4.61,NG/ML,1.52591,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,433.007,567.965,30.0,191.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,180.0,4.52,4.52,NG/ML,1.49612,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,418.345,567.965,30.0,171.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,210.0,4.02,4.02,NG/ML,1.33062,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,356.461,567.965,30.0,153.0,2014-11-11,30
T1DAL_295813,SUB168897,Week 104,ITN045AI-Rigby,A,1.0,2011-05-15,2011-06-18,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-18,2011-12-04,2012-02-19,Yes,,2013-07-01,744.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,744.0,Week 104/Visit 30,2011-03-12,-98.0,7,No,Yes,Yes,Week 104,30.0,2030,2013-07-01,744.0,24.473684211,C-PEPTIDE,240.0,3.64,3.64,NG/ML,1.20484,1.60204,1.10885,0.49319,90.0,1.60204,1.10885,0.49319,90.0,188.0,130.9,313.516,567.965,30.0,135.0,2014-11-11,30
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,-10.0,2.01,2.01,NG/ML,0.66531,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,,754.465,15.0,87.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,0.0,1.99,1.99,NG/ML,0.65869,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,463.327,754.465,15.0,87.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,15.0,3.97,3.97,NG/ML,1.31407,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,754.465,754.465,15.0,103.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,30.0,6.51,6.51,NG/ML,2.15481,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,651.596,754.465,15.0,145.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,60.0,6.75,6.75,NG/ML,2.23425,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,514.015,754.465,15.0,128.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,90.0,6.44,6.44,NG/ML,2.13164,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,440.498,754.465,15.0,125.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,120.0,5.44,5.44,NG/ML,1.80064,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,337.616,754.465,15.0,99.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,150.0,4.58,4.58,NG/ML,1.51598,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,266.977,754.465,15.0,90.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,180.0,4.14,4.14,NG/ML,1.37034,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,246.835,754.465,15.0,81.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,210.0,3.08,3.08,NG/ML,1.01948,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,167.529,754.465,15.0,73.0,2014-11-11,-1
T1DAL_323347,SUB168898,-1,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-18,-17.0,-0.559210526,C-PEPTIDE,240.0,2.42,2.42,NG/ML,0.80102,2.23425,2.23425,0.0,60.0,2.23425,2.23425,0.0,60.0,167.2,67.9,123.852,754.465,15.0,68.0,2014-11-11,-1
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,-10.0,2.74,2.74,NG/ML,0.90694,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,,870.812,15.0,95.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,0.0,2.7,2.7,NG/ML,0.8937,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,590.708,870.812,15.0,95.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,15.0,5.09,5.09,NG/ML,1.68479,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,870.812,870.812,15.0,116.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,30.0,7.65,7.65,NG/ML,2.53215,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,609.453,870.812,15.0,149.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,60.0,6.91,6.91,NG/ML,2.28721,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,510.12,870.812,15.0,134.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,90.0,7.12,7.12,NG/ML,2.35672,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,489.169,870.812,15.0,117.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 24,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-22,169.0,5.5592105263,C-PEPTIDE,120.0,6.95,6.95,NG/ML,2.30045,2.53215,2.23425,0.2979,30.0,,2.23425,,,169.8,70.9,471.918,870.812,15.0,111.0,2014-11-11,15
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,-10.0,2.27,2.27,NG/ML,0.75137,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,,854.55,15.0,86.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,0.0,2.16,2.16,NG/ML,0.71496,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,675.079,854.55,15.0,86.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,15.0,5.37,5.37,NG/ML,1.77747,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,854.55,854.55,15.0,115.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,30.0,7.48,7.48,NG/ML,2.47588,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,829.458,854.55,15.0,160.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,60.0,8.29,8.29,NG/ML,2.74399,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,638.924,854.55,15.0,155.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,90.0,7.85,7.85,NG/ML,2.59835,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,549.185,854.55,15.0,147.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,120.0,7.39,7.39,NG/ML,2.44609,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,488.294,854.55,15.0,129.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,150.0,6.94,6.94,NG/ML,2.29714,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,451.074,854.55,15.0,109.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,180.0,5.57,5.57,NG/ML,1.84367,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,332.991,854.55,15.0,99.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,210.0,3.88,3.88,NG/ML,1.28428,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,192.787,854.55,15.0,78.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 52,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-10-07,368.0,12.105263158,C-PEPTIDE,240.0,3.05,3.05,NG/ML,1.00955,2.74399,2.23425,0.50974,60.0,2.74399,2.23425,0.50974,60.0,168.4,72.9,148.779,854.55,15.0,64.0,2014-11-11,28
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,-10.0,2.65,2.65,NG/ML,0.87715,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,,930.487,15.0,101.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,0.0,2.69,2.69,NG/ML,0.89039,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,574.434,930.487,15.0,100.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,15.0,4.91,4.91,NG/ML,1.62521,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,930.487,930.487,15.0,122.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,30.0,7.96,7.96,NG/ML,2.63476,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,831.311,930.487,15.0,167.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,60.0,8.38,8.38,NG/ML,2.77378,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,659.044,930.487,15.0,163.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,90.0,7.99,7.99,NG/ML,2.64469,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,569.341,930.487,15.0,150.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 78,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2013-04-10,553.0,18.190789474,C-PEPTIDE,120.0,8.19,8.19,NG/ML,2.71089,2.77378,2.23425,0.53953,60.0,,2.23425,,,169.5,70.8,574.907,930.487,15.0,140.0,2014-11-11,29
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,-10.0,3.53,3.53,NG/ML,1.16843,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,,1189.522,15.0,112.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,0.0,3.17,3.17,NG/ML,1.04927,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,551.565,1189.522,15.0,114.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,15.0,5.12,5.12,NG/ML,1.69472,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,1189.522,1189.522,15.0,139.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,30.0,9.84,9.84,NG/ML,3.25704,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,629.943,1189.522,15.0,213.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,60.0,7.61,7.61,NG/ML,2.51891,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,571.873,1189.522,15.0,187.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,90.0,7.57,7.57,NG/ML,2.50567,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,511.236,1189.522,15.0,186.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,120.0,11.16,11.16,NG/ML,3.69396,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,861.023,1189.522,15.0,195.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,150.0,10.97,10.97,NG/ML,3.63107,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,824.596,1189.522,15.0,184.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,180.0,10.08,10.08,NG/ML,3.33648,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,695.56,1189.522,15.0,168.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,210.0,6.93,6.93,NG/ML,2.29383,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,395.1,1189.522,15.0,128.0,2014-11-11,30
T1DAL_323347,SUB168898,Week 104,ITN045AI-Rigby,A,1.0,2011-09-18,2011-10-05,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Female,White,,Not Hispanic or Latino,2011-10-05,2012-03-22,2012-06-07,Yes,,2013-09-23,719.0,Yes,,,2012-06-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-09-23,719.0,Week 104/Visit 30,2011-08-07,-59.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-23,719.0,23.651315789,C-PEPTIDE,240.0,5.56,5.56,NG/ML,1.84036,3.69396,2.23425,1.45971,120.0,3.69396,2.23425,1.45971,120.0,169.8,71.2,298.044,1189.522,15.0,106.0,2014-11-11,30
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,-10.0,0.93,0.93,NG/ML,0.30783,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,,225.483,30.0,120.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,0.0,0.94,0.94,NG/ML,0.31114,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,84.289,225.483,30.0,130.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,15.0,0.93,0.93,NG/ML,0.30783,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,200.629,225.483,30.0,118.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,30.0,1.62,1.62,NG/ML,0.53622,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,225.483,225.483,30.0,141.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,60.0,1.95,1.95,NG/ML,0.64545,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,174.852,225.483,30.0,193.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,90.0,1.92,1.92,NG/ML,0.63552,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,157.713,225.483,30.0,207.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,120.0,1.78,1.78,NG/ML,0.58918,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,135.4,225.483,30.0,204.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,150.0,1.69,1.69,NG/ML,0.55939,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,125.748,225.483,30.0,186.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,180.0,1.57,1.57,NG/ML,0.51967,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,115.713,225.483,30.0,171.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,210.0,1.57,1.57,NG/ML,0.51967,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,118.527,225.483,30.0,139.0,2014-11-11,-1
T1DAL_325261,SUB168899,-1,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-10,-22.0,-0.723684211,C-PEPTIDE,240.0,1.69,1.69,NG/ML,0.55939,0.64545,0.64545,0.0,60.0,0.64545,0.64545,0.0,60.0,182.0,83.1,133.527,225.483,30.0,117.0,2014-11-11,-1
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,-10.0,0.97,0.97,NG/ML,0.32107,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,,191.97,15.0,167.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,0.0,0.97,0.97,NG/ML,0.32107,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,98.194,191.97,15.0,173.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,15.0,1.03,1.03,NG/ML,0.34093,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,191.97,191.97,15.0,165.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,30.0,1.61,1.61,NG/ML,0.53291,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,133.563,191.97,15.0,208.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,60.0,1.43,1.43,NG/ML,0.47333,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,117.216,191.97,15.0,230.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,90.0,1.52,1.52,NG/ML,0.50312,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,118.259,191.97,15.0,236.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 24,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-16,168.0,5.5263157895,C-PEPTIDE,120.0,1.44,1.44,NG/ML,0.47664,0.53291,0.64545,-0.11254,30.0,,0.64545,,,183.0,81.0,109.771,191.97,15.0,233.0,2014-11-11,15
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,-10.0,0.98,0.98,NG/ML,0.32438,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,,196.703,30.0,134.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,0.0,1.04,1.04,NG/ML,0.34424,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,95.714,196.703,30.0,139.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,15.0,1.04,1.04,NG/ML,0.34424,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,119.451,196.703,30.0,153.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,30.0,1.2,1.2,NG/ML,0.3972,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,196.703,196.703,30.0,162.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,60.0,1.71,1.71,NG/ML,0.56601,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,148.367,196.703,30.0,247.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,90.0,1.8,1.8,NG/ML,0.5958,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,150.581,196.703,30.0,286.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,120.0,1.66,1.66,NG/ML,0.54946,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,126.595,196.703,30.0,266.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,150.0,1.64,1.64,NG/ML,0.54284,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,122.278,196.703,30.0,243.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,180.0,1.55,1.55,NG/ML,0.51305,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,114.505,196.703,30.0,230.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,210.0,1.57,1.57,NG/ML,0.51967,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,117.943,196.703,30.0,207.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 52,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-07,372.0,12.236842105,C-PEPTIDE,240.0,1.49,1.49,NG/ML,0.49319,0.5958,0.64545,-0.04965,90.0,0.5958,0.64545,-0.04965,90.0,183.0,79.2,111.001,196.703,30.0,184.0,2014-11-11,28
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,-10.0,0.8,0.8,NG/ML,0.2648,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,,159.24,15.0,163.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,0.0,0.76,0.76,NG/ML,0.25156,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,81.488,159.24,15.0,166.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,15.0,0.85,0.85,NG/ML,0.28135,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,159.24,159.24,15.0,115.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,30.0,1.34,1.34,NG/ML,0.44354,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,140.854,159.24,15.0,205.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,60.0,1.35,1.35,NG/ML,0.44685,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,115.521,159.24,15.0,253.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,90.0,1.05,1.05,NG/ML,0.34755,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,75.232,159.24,15.0,217.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 78,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-29,547.0,17.993421053,C-PEPTIDE,120.0,1.38,1.38,NG/ML,0.45678,0.45678,0.64545,-0.18867,120.0,,0.64545,,,182.0,82.0,110.288,159.24,15.0,275.0,2014-11-11,29
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,-10.0,0.57,0.57,NG/ML,0.18867,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,,140.55,15.0,108.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,0.0,0.57,0.57,NG/ML,0.18867,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,98.759,140.55,15.0,119.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,15.0,0.85,0.85,NG/ML,0.28135,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,140.55,140.55,15.0,173.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,30.0,1.18,1.18,NG/ML,0.39058,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,104.308,140.55,15.0,328.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,60.0,1.09,1.09,NG/ML,0.36079,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,88.198,140.55,15.0,299.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,90.0,1.09,1.09,NG/ML,0.36079,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,82.338,140.55,15.0,290.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,120.0,1.06,1.06,NG/ML,0.35086,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,79.144,140.55,15.0,281.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,150.0,1,1.0,NG/ML,0.331,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,73.095,140.55,15.0,268.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,180.0,0.91,0.91,NG/ML,0.30121,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,64.633,140.55,15.0,250.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,210.0,0.88,0.88,NG/ML,0.29128,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,63.279,140.55,15.0,236.0,2014-11-11,30
T1DAL_325261,SUB168899,Week 104,ITN045AI-Rigby,A,1.0,2011-05-10,2011-06-01,Yes,Yes,Yes,S/I,21.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-06-01,2011-11-16,2012-02-02,Yes,,2013-07-02,762.0,Yes,,,2012-02-02,246.0,Completed study,Completed study drug,Yes,Yes,2013-07-02,762.0,Week 104/Visit 30,2011-03-28,-65.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-02,762.0,25.065789474,C-PEPTIDE,240.0,0.88,0.88,NG/ML,0.29128,0.39058,0.64545,-0.25487,30.0,0.39058,0.64545,-0.25487,30.0,182.88,78.9,65.182,140.55,15.0,225.0,2014-11-11,30
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,-10.0,0.48,0.48,NG/ML,0.15888,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,,241.8,30.0,86.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,0.0,0.49,0.49,NG/ML,0.16219,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,80.308,241.8,30.0,84.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,15.0,0.76,0.76,NG/ML,0.25156,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,82.731,241.8,30.0,101.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,30.0,0.86,0.86,NG/ML,0.28466,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,241.8,241.8,30.0,134.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,60.0,2,2.0,NG/ML,0.662,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,164.637,241.8,30.0,137.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,90.0,1.87,1.87,NG/ML,0.61897,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,141.816,241.8,30.0,141.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,120.0,1.53,1.53,NG/ML,0.50643,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,95.155,241.8,30.0,102.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,150.0,1.41,1.41,NG/ML,0.46671,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,84.761,241.8,30.0,81.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,180.0,1.2,1.2,NG/ML,0.3972,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,70.735,241.8,30.0,75.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,210.0,0.66,0.66,NG/ML,0.21846,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,25.49,241.8,30.0,66.0,2014-11-11,-1
T1DAL_365106,SUB168900,-1,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-02,-26.0,-0.855263158,C-PEPTIDE,240.0,0.56,0.56,NG/ML,0.18536,0.662,0.662,0.0,60.0,0.662,0.662,0.0,60.0,173.0,62.6,23.808,241.8,30.0,68.0,2014-11-11,-1
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,-10.0,1.45,1.45,NG/ML,0.47995,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,,346.383,30.0,133.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,0.0,1.47,1.47,NG/ML,0.48657,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,150.421,346.383,30.0,129.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,15.0,1.69,1.69,NG/ML,0.55939,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,276.778,346.383,30.0,147.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,30.0,2.62,2.62,NG/ML,0.86722,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,346.383,346.383,30.0,190.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,60.0,3.37,3.37,NG/ML,1.11547,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,262.27,346.383,30.0,275.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,90.0,3.83,3.83,NG/ML,1.26773,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,284.61,346.383,30.0,308.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 24,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-15,168.0,5.5263157895,C-PEPTIDE,120.0,3.57,3.57,NG/ML,1.18167,1.26773,0.662,0.60573,90.0,,0.662,,,,64.4,243.504,346.383,30.0,307.0,2014-11-11,15
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,-10.0,1.14,1.14,NG/ML,0.37734,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,,312.389,30.0,99.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,0.0,1.15,1.15,NG/ML,0.38065,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,111.997,312.389,30.0,94.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,15.0,1.29,1.29,NG/ML,0.42699,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,156.052,312.389,30.0,,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,30.0,1.64,1.64,NG/ML,0.54284,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,312.389,312.389,30.0,136.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,60.0,2.81,2.81,NG/ML,0.93011,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,223.75,312.389,30.0,194.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,90.0,3.32,3.32,NG/ML,1.09892,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,255.964,312.389,30.0,209.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,120.0,3.52,3.52,NG/ML,1.16512,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,252.75,312.389,30.0,220.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,150.0,3.43,3.43,NG/ML,1.13533,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,231.817,312.389,30.0,184.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,180.0,4.33,4.33,NG/ML,1.43323,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,309.803,312.389,30.0,191.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,210.0,3.58,3.58,NG/ML,1.18498,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,234.306,312.389,30.0,159.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 52,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-06,372.0,12.236842105,C-PEPTIDE,240.0,2.79,2.79,NG/ML,0.92349,1.16512,0.662,0.50312,120.0,1.43323,0.662,0.77123,180.0,173.0,63.8,154.685,312.389,30.0,137.0,2014-11-11,28
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,-10.0,0.91,0.91,NG/ML,0.30121,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,,219.418,30.0,73.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,0.0,0.87,0.87,NG/ML,0.28797,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,123.998,219.418,30.0,71.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,15.0,1.23,1.23,NG/ML,0.40713,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,160.873,219.418,30.0,97.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,30.0,1.6,1.6,NG/ML,0.5296,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,219.418,219.418,30.0,116.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,60.0,2.16,2.16,NG/ML,0.71496,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,163.927,219.418,30.0,151.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,90.0,2.85,2.85,NG/ML,0.94335,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,216.629,219.418,30.0,199.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 78,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-29,548.0,18.026315789,C-PEPTIDE,120.0,2.97,2.97,NG/ML,0.98307,0.98307,0.662,0.32107,120.0,,0.662,,,,62.2,213.402,219.418,30.0,171.0,2014-11-11,29
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,-10.0,1.06,1.06,NG/ML,0.35086,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,,234.988,30.0,103.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,0.0,0.98,0.98,NG/ML,0.32438,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,66.686,234.988,30.0,103.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,15.0,0.94,0.94,NG/ML,0.31114,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,164.054,234.988,30.0,110.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,30.0,1.58,1.58,NG/ML,0.52298,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,234.988,234.988,30.0,142.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,60.0,2.2,2.2,NG/ML,0.7282,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,175.254,234.988,30.0,198.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,90.0,2.2,2.2,NG/ML,0.7282,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,161.301,234.988,30.0,232.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,120.0,2.45,2.45,NG/ML,0.81095,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,172.585,234.988,30.0,241.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,150.0,2.53,2.53,NG/ML,0.83743,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,176.639,234.988,30.0,225.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,180.0,2.31,2.31,NG/ML,0.76461,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,149.551,234.988,30.0,213.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,210.0,2.32,2.32,NG/ML,0.76792,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,151.987,234.988,30.0,193.0,2014-11-11,30
T1DAL_365106,SUB168900,Week 104,ITN045AI-Rigby,A,1.0,2011-02-02,2011-02-28,Yes,Yes,Yes,S/I,25.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-01,2011-08-15,2011-11-01,Yes,,2013-03-06,737.0,Yes,,,2011-11-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-06,737.0,Week 104/Visit 30,2010-12-24,-66.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-06,737.0,24.243421053,C-PEPTIDE,240.0,2.18,2.18,NG/ML,0.72158,0.81095,0.662,0.14895,120.0,0.83743,0.662,0.17543,150.0,173.0,66.7,140.713,234.988,30.0,178.0,2014-11-11,30
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,-10.0,1.59,1.59,NG/ML,0.52629,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,,307.328,15.0,150.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,0.0,1.69,1.69,NG/ML,0.55939,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,145.105,307.328,15.0,137.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,15.0,1.82,1.82,NG/ML,0.60242,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,307.328,307.328,15.0,142.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,30.0,3.1,3.1,NG/ML,1.0261,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,241.916,307.328,15.0,191.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,60.0,2.97,2.97,NG/ML,0.98307,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,203.856,307.328,15.0,171.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,90.0,2.67,2.67,NG/ML,0.88377,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,163.255,307.328,15.0,231.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,120.0,3.03,3.03,NG/ML,1.00293,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,192.793,307.328,15.0,230.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,150.0,2.83,2.83,NG/ML,0.93673,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,177.335,307.328,15.0,213.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,180.0,3.28,3.28,NG/ML,1.08568,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,212.241,307.328,15.0,195.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,210.0,2.81,2.81,NG/ML,0.93011,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,172.306,307.328,15.0,234.0,2014-11-11,-1
T1DAL_366170,SUB168901,-1,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-14,-23.0,-0.756578947,C-PEPTIDE,240.0,2.38,2.38,NG/ML,0.78778,1.0261,1.0261,0.0,30.0,1.08568,1.08568,0.0,180.0,161.5,41.25,134.09,307.328,15.0,133.0,2014-11-11,-1
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,-10.0,2.22,2.22,NG/ML,0.73482,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,,324.535,15.0,161.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,0.0,2.19,2.19,NG/ML,0.72489,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,258.916,324.535,15.0,162.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,15.0,2.89,2.89,NG/ML,0.95659,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,324.535,324.535,15.0,173.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,30.0,3.59,3.59,NG/ML,1.18829,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,275.007,324.535,15.0,222.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,60.0,3.5,3.5,NG/ML,1.1585,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,232.791,324.535,15.0,250.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,90.0,3.55,3.55,NG/ML,1.17505,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,226.145,324.535,15.0,273.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 24,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-05-23,168.0,5.5263157895,C-PEPTIDE,120.0,3.53,3.53,NG/ML,1.16843,1.18829,1.0261,0.16219,30.0,,1.08568,,,165.5,41.8,222.788,324.535,15.0,260.0,2014-11-11,15
T1DAL_366170,SUB168901,Week 52,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-11-30,359.0,11.809210526,C-PEPTIDE,-10.0,1.92,1.92,NG/ML,0.63552,1.05258,1.0261,0.02648,30.0,1.05258,1.08568,-0.0331,30.0,,46.83,,314.325,15.0,174.0,2014-11-11,28
T1DAL_366170,SUB168901,Week 52,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-11-30,359.0,11.809210526,C-PEPTIDE,0.0,1.86,1.86,NG/ML,0.61566,1.05258,1.0261,0.02648,30.0,1.05258,1.08568,-0.0331,30.0,,46.83,156.674,314.325,15.0,176.0,2014-11-11,28
T1DAL_366170,SUB168901,Week 52,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-11-30,359.0,11.809210526,C-PEPTIDE,15.0,1.99,1.99,NG/ML,0.65869,1.05258,1.0261,0.02648,30.0,1.05258,1.08568,-0.0331,30.0,,46.83,314.325,314.325,15.0,179.0,2014-11-11,28
T1DAL_366170,SUB168901,Week 52,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-11-30,359.0,11.809210526,C-PEPTIDE,30.0,3.18,3.18,NG/ML,1.05258,1.05258,1.0261,0.02648,30.0,1.05258,1.08568,-0.0331,30.0,,46.83,,314.325,15.0,240.0,2014-11-11,28
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,-10.0,1.53,1.53,NG/ML,0.50643,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,,313.813,30.0,198.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,0.0,1.55,1.55,NG/ML,0.51305,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,146.182,313.813,30.0,196.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,15.0,1.73,1.73,NG/ML,0.57263,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,300.057,313.813,30.0,200.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,30.0,2.87,2.87,NG/ML,0.94997,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,313.813,313.813,30.0,234.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,60.0,3.28,3.28,NG/ML,1.08568,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,247.255,313.813,30.0,303.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,90.0,3.41,3.41,NG/ML,1.12871,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,239.56,313.813,30.0,295.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 78,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-12,553.0,18.190789474,C-PEPTIDE,120.0,2.77,2.77,NG/ML,0.91687,1.12871,1.0261,0.10261,90.0,,1.08568,,,168.0,53.6,173.862,313.813,30.0,279.0,2014-11-11,29
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,-10.0,0.87,0.87,NG/ML,0.28797,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,,172.209,30.0,139.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,0.0,0.81,0.81,NG/ML,0.26811,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,93.068,172.209,30.0,135.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,15.0,1.04,1.04,NG/ML,0.34424,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,149.507,172.209,30.0,166.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,30.0,1.47,1.47,NG/ML,0.48657,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,172.209,172.209,30.0,321.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,60.0,1.78,1.78,NG/ML,0.58918,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,134.065,172.209,30.0,360.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,90.0,1.85,1.85,NG/ML,0.61235,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,130.873,172.209,30.0,362.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,120.0,1.85,1.85,NG/ML,0.61235,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,125.135,172.209,30.0,350.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,150.0,2,2.0,NG/ML,0.662,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,136.63,172.209,30.0,337.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,180.0,1.93,1.93,NG/ML,0.63883,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,129.909,172.209,30.0,315.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,210.0,1.93,1.93,NG/ML,0.63883,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,128.233,172.209,30.0,297.0,2014-11-11,30
T1DAL_366170,SUB168901,Week 104,ITN045AI-Rigby,A,1.0,2011-11-14,2011-12-07,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-12-07,,2012-08-08,Yes,,2013-12-06,730.0,Yes,,,2012-08-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-12-06,730.0,Week 104/Visit 30,2011-09-03,-95.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-05,729.0,23.980263158,C-PEPTIDE,240.0,1.7,1.7,NG/ML,0.5627,0.61235,1.0261,-0.41375,90.0,0.662,1.08568,-0.42368,150.0,169.0,55.1,107.036,172.209,30.0,279.0,2014-11-11,30
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,-10.0,0.97,0.97,NG/ML,0.32107,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,,361.6,30.0,79.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,0.0,0.98,0.98,NG/ML,0.32438,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,162.477,361.6,30.0,80.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,15.0,1.5,1.5,NG/ML,0.4965,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,309.405,361.6,30.0,90.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,30.0,2.62,2.62,NG/ML,0.86722,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,361.6,361.6,30.0,150.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,60.0,3.33,3.33,NG/ML,1.10223,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,270.343,361.6,30.0,184.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,90.0,3.69,3.69,NG/ML,1.22139,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,280.349,361.6,30.0,205.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,120.0,3.54,3.54,NG/ML,1.17174,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,248.881,361.6,30.0,202.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,150.0,4.41,4.41,NG/ML,1.45971,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,323.942,361.6,30.0,214.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,180.0,4.25,4.25,NG/ML,1.40675,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,302.385,361.6,30.0,207.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,210.0,3.65,3.65,NG/ML,1.20815,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,234.221,361.6,30.0,188.0,2014-11-11,-1
T1DAL_368470,SUB168902,-1,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-15,-15.0,-0.493421053,C-PEPTIDE,240.0,3.49,3.49,NG/ML,1.15519,1.22139,1.22139,0.0,90.0,1.45971,1.45971,0.0,150.0,186.5,65.0,223.154,361.6,30.0,179.0,2014-11-11,-1
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,-10.0,1.27,1.27,NG/ML,0.42037,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,,398.334,30.0,92.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,0.0,1.17,1.17,NG/ML,0.38727,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,244.088,398.334,30.0,92.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,15.0,2.12,2.12,NG/ML,0.70172,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,276.445,398.334,30.0,131.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,30.0,2.6,2.6,NG/ML,0.8606,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,398.334,398.334,30.0,169.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,60.0,3.64,3.64,NG/ML,1.20484,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,292.575,398.334,30.0,218.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,90.0,3.6,3.6,NG/ML,1.1916,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,269.742,398.334,30.0,230.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 24,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-16,169.0,5.5592105263,C-PEPTIDE,120.0,3.47,3.47,NG/ML,1.14857,1.20484,1.22139,-0.01655,60.0,,1.45971,,,,67.5,239.955,398.334,30.0,245.0,2014-11-11,15
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,-10.0,2.15,2.15,NG/ML,0.71165,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,,429.736,15.0,139.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,0.0,2.09,2.09,NG/ML,0.69179,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,259.23,429.736,15.0,141.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,15.0,2.65,2.65,NG/ML,0.87715,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,429.736,429.736,15.0,159.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,30.0,3.92,3.92,NG/ML,1.29752,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,312.181,429.736,15.0,212.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,60.0,3.58,3.58,NG/ML,1.18498,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,266.63,429.736,15.0,229.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,90.0,3.64,3.64,NG/ML,1.20484,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,253.312,429.736,15.0,247.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,120.0,3.61,3.61,NG/ML,1.19491,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,250.068,429.736,15.0,262.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,150.0,3.45,3.45,NG/ML,1.14195,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,234.054,429.736,15.0,259.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,180.0,2.84,2.84,NG/ML,0.94004,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,176.892,429.736,15.0,244.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,210.0,3.12,3.12,NG/ML,1.03272,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,211.056,429.736,15.0,229.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 52,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-29,365.0,12.006578947,C-PEPTIDE,240.0,2.88,2.88,NG/ML,0.95328,1.29752,1.22139,0.07613,30.0,1.29752,1.45971,-0.16219,30.0,,70.0,195.339,429.736,15.0,218.0,2014-11-11,28
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,-10.0,1.16,1.16,NG/ML,0.38396,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,,231.972,120.0,139.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,0.0,1.18,1.18,NG/ML,0.39058,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,158.901,231.972,120.0,135.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,15.0,1.58,1.58,NG/ML,0.52298,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,106.957,231.972,120.0,157.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,30.0,1.36,1.36,NG/ML,0.45016,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,200.095,231.972,120.0,205.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,60.0,1.96,1.96,NG/ML,0.64876,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,149.726,231.972,120.0,261.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,90.0,2.06,2.06,NG/ML,0.68186,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,154.74,231.972,120.0,288.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 78,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-06-22,540.0,17.763157895,C-PEPTIDE,120.0,2.95,2.95,NG/ML,0.97645,0.97645,1.22139,-0.24494,120.0,,1.45971,,,,67.8,231.972,231.972,120.0,295.0,2014-11-11,29
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,-10.0,1.01,1.01,NG/ML,0.33431,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,,239.592,30.0,105.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,0.0,0.91,0.91,NG/ML,0.30121,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,152.472,239.592,30.0,105.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,15.0,1.43,1.43,NG/ML,0.47333,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,196.499,239.592,30.0,132.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,30.0,1.83,1.83,NG/ML,0.60573,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,239.592,239.592,30.0,164.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,60.0,2.3,2.3,NG/ML,0.7613,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,181.801,239.592,30.0,214.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,90.0,2.99,2.99,NG/ML,0.98969,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,236.578,239.592,30.0,252.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,120.0,2.99,2.99,NG/ML,0.98969,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,222.366,239.592,30.0,268.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,150.0,3.18,3.18,NG/ML,1.05258,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,227.519,239.592,30.0,279.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,180.0,2.62,2.62,NG/ML,0.86722,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,170.948,239.592,30.0,263.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,210.0,2.65,2.65,NG/ML,0.87715,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,174.876,239.592,30.0,241.0,2014-11-11,30
T1DAL_368470,SUB168902,Week 104,ITN045AI-Rigby,A,1.0,2011-12-15,2011-12-30,Yes,Yes,Yes,S/I,26.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-12-31,2012-06-16,2012-09-01,Yes,,2013-12-27,728.0,Yes,,,2012-09-01,246.0,Completed study,Completed study drug,Yes,Yes,2013-12-27,728.0,Week 104/Visit 30,2011-10-09,-82.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-27,728.0,23.947368421,C-PEPTIDE,240.0,2.16,2.16,NG/ML,0.71496,0.98969,1.22139,-0.2317,90.0,1.05258,1.45971,-0.40713,150.0,,70.4,132.538,239.592,30.0,218.0,2014-11-11,30
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,-10.0,0.84,0.84,NG/ML,0.27804,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,,157.075,30.0,101.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,0.0,0.79,0.79,NG/ML,0.26149,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,84.158,157.075,30.0,102.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,15.0,1.11,1.11,NG/ML,0.36741,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,128.769,157.075,30.0,132.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,30.0,1.6,1.6,NG/ML,0.5296,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,157.075,157.075,30.0,180.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,60.0,2.02,2.02,NG/ML,0.66862,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,120.194,157.075,30.0,209.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,90.0,2.15,2.15,NG/ML,0.71165,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,121.463,157.075,30.0,221.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,120.0,2.18,2.18,NG/ML,0.72158,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,117.5,157.075,30.0,192.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,150.0,2.29,2.29,NG/ML,0.75799,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,122.519,157.075,30.0,173.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,180.0,2.56,2.56,NG/ML,0.84736,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,139.934,157.075,30.0,134.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,210.0,1.52,1.52,NG/ML,0.50312,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,65.188,157.075,30.0,94.0,2014-11-11,-1
T1DAL_412226,SUB168903,-1,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-09-11,-11.0,-0.361842105,C-PEPTIDE,240.0,1.34,1.34,NG/ML,0.44354,0.72158,0.72158,0.0,120.0,0.84736,0.84736,0.0,180.0,144.2,36.7,54.437,157.075,30.0,68.0,2014-11-11,-1
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,-10.0,0.41,0.41,NG/ML,0.13571,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,,135.179,90.0,103.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,0.0,0.41,0.41,NG/ML,0.13571,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,60.087,135.179,90.0,102.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,15.0,0.7,0.7,NG/ML,0.2317,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,90.303,135.179,90.0,154.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,30.0,1.05,1.05,NG/ML,0.34755,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,130.459,135.179,90.0,213.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,60.0,1.53,1.53,NG/ML,0.50643,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,95.709,135.179,90.0,240.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,90.0,2.18,2.18,NG/ML,0.72158,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,135.179,135.179,90.0,229.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 24,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-03-09,169.0,5.5592105263,C-PEPTIDE,120.0,1.85,1.85,NG/ML,0.61235,0.72158,0.72158,0.0,90.0,,0.84736,,,,39.1,102.91,135.179,90.0,175.0,2014-11-11,15
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,,99.957,15.0,63.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,58.725,99.957,15.0,63.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,15.0,0.49,0.49,NG/ML,0.16219,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,99.957,99.957,15.0,98.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,30.0,0.97,0.97,NG/ML,0.32107,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,83.217,99.957,15.0,142.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,60.0,1.01,1.01,NG/ML,0.33431,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,64.276,99.957,15.0,173.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,90.0,1.17,1.17,NG/ML,0.38727,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,69.49,99.957,15.0,186.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,120.0,1.2,1.2,NG/ML,0.3972,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,69.104,99.957,15.0,167.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,150.0,1.16,1.16,NG/ML,0.38396,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,63.944,99.957,15.0,136.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,180.0,0.93,0.93,NG/ML,0.30783,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,46.513,99.957,15.0,101.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,210.0,0.54,0.54,NG/ML,0.17874,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,19.307,99.957,15.0,70.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 52,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-09-21,365.0,12.006578947,C-PEPTIDE,240.0,0.36,0.36,NG/ML,0.11916,0.3972,0.72158,-0.32438,120.0,0.3972,0.84736,-0.45016,120.0,148.7,40.9,10.497,99.957,15.0,54.0,2014-11-11,28
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,-10.0,0.09,0.09,NG/ML,0.02979,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,,59.012,30.0,54.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,0.0,0.06,0.06,NG/ML,0.01986,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,7.671,59.012,30.0,52.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,15.0,0.08,0.08,NG/ML,0.02648,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,24.57,59.012,30.0,72.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,30.0,0.23,0.23,NG/ML,0.07613,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,59.012,59.012,30.0,107.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,60.0,0.57,0.57,NG/ML,0.18867,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,40.169,59.012,30.0,180.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,90.0,0.56,0.56,NG/ML,0.18536,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,36.826,59.012,30.0,224.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 78,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-15,540.0,17.763157895,C-PEPTIDE,120.0,0.72,0.72,NG/ML,0.23832,0.23832,0.72158,-0.48326,120.0,,0.84736,,,150.3,41.3,44.089,59.012,30.0,234.0,2014-11-11,29
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,-10.0,0.37,0.37,NG/ML,0.12247,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,,113.456,180.0,112.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,0.0,0.37,0.37,NG/ML,0.12247,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,48.371,113.456,180.0,115.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,15.0,0.53,0.53,NG/ML,0.17543,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,75.603,113.456,180.0,139.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,30.0,0.83,0.83,NG/ML,0.27473,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,94.017,113.456,180.0,204.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,60.0,1.06,1.06,NG/ML,0.35086,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,70.978,113.456,180.0,301.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,90.0,1.08,1.08,NG/ML,0.35748,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,68.357,113.456,180.0,348.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,120.0,1.24,1.24,NG/ML,0.41044,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,76.421,113.456,180.0,332.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,150.0,1.51,1.51,NG/ML,0.49981,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,95.671,113.456,180.0,314.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,180.0,1.79,1.79,NG/ML,0.59249,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,113.456,113.456,180.0,303.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,210.0,1.61,1.61,NG/ML,0.53291,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,94.431,113.456,180.0,277.0,2014-11-11,30
T1DAL_412226,SUB168903,Week 104,ITN045AI-Rigby,A,1.0,2011-09-11,2011-09-22,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-09-23,2012-03-09,2012-05-11,Yes,,2013-09-28,737.0,No,Other AE, Specify,Other AE,2012-05-11,232.0,Completed study,Discontinued study drug early,Yes,No,2013-09-28,737.0,Week 104/Visit 30,2011-06-18,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-28,737.0,24.243421053,C-PEPTIDE,240.0,1.31,1.31,NG/ML,0.43361,0.41044,0.72158,-0.31114,120.0,0.59249,0.84736,-0.25487,180.0,,48.0,68.046,113.456,180.0,245.0,2014-11-11,30
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,-10.0,0.83,0.83,NG/ML,0.27473,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,,201.722,30.0,124.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,0.0,0.83,0.83,NG/ML,0.27473,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,92.802,201.722,30.0,128.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,15.0,0.93,0.93,NG/ML,0.30783,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,125.351,201.722,30.0,137.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,30.0,1.16,1.16,NG/ML,0.38396,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,201.722,201.722,30.0,161.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,60.0,1.69,1.69,NG/ML,0.55939,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,150.418,201.722,30.0,211.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,90.0,1.78,1.78,NG/ML,0.58918,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,151.508,201.722,30.0,185.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,120.0,2.18,2.18,NG/ML,0.72158,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,183.499,201.722,30.0,185.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,150.0,2.24,2.24,NG/ML,0.74144,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,183.344,201.722,30.0,168.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,180.0,2.11,2.11,NG/ML,0.69841,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,162.388,201.722,30.0,143.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,210.0,2.08,2.08,NG/ML,0.68848,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,157.775,201.722,30.0,132.0,2014-11-11,-1
T1DAL_430783,SUB168904,-1,ITN045AI-Rigby,A,1.0,2011-11-21,2011-11-29,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-11-30,,2011-12-14,No,Other AE,2012-01-09,41.0,No,Other AE, Specify,Other AE,2011-12-14,15.0,Terminated study early,Discontinued study drug early,No,No,2012-01-09,41.0,Early Termination,2011-10-18,-42.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-11-21,-8.0,-0.263157895,C-PEPTIDE,240.0,1.87,1.87,NG/ML,0.61897,0.72158,0.72158,0.0,120.0,0.74144,0.74144,0.0,150.0,184.5,78.2,137.518,201.722,30.0,112.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,-10.0,1.11,1.11,NG/ML,0.36741,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,,273.769,15.0,91.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,0.0,1.1,1.1,NG/ML,0.3641,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,97.268,273.769,15.0,88.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,15.0,1.19,1.19,NG/ML,0.39389,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,273.769,273.769,15.0,102.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,30.0,2.48,2.48,NG/ML,0.82088,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,254.368,273.769,15.0,130.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,60.0,2.69,2.69,NG/ML,0.89039,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,202.458,273.769,15.0,126.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,90.0,3.13,3.13,NG/ML,1.03603,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,222.793,273.769,15.0,130.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,120.0,3.03,3.03,NG/ML,1.00293,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,205.148,273.769,15.0,131.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,150.0,2.95,2.95,NG/ML,0.97645,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,191.81,273.769,15.0,109.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,180.0,2.63,2.63,NG/ML,0.87053,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,164.041,273.769,15.0,98.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,210.0,2.1,2.1,NG/ML,0.6951,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,120.517,273.769,15.0,79.0,2014-11-11,-1
T1DAL_441960,SUB168905,-1,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-13,-23.0,-0.756578947,C-PEPTIDE,240.0,1.69,1.69,NG/ML,0.55939,1.03603,1.03603,0.0,90.0,1.03603,1.03603,0.0,90.0,166.3,56.3,91.987,273.769,15.0,69.0,2014-11-11,-1
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,-10.0,2.02,2.02,NG/ML,0.66862,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,,256.184,15.0,166.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,0.0,1.89,1.89,NG/ML,0.62559,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,174.674,256.184,15.0,159.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,15.0,2.09,2.09,NG/ML,0.69179,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,256.184,256.184,15.0,159.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,30.0,2.71,2.71,NG/ML,0.89701,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,242.221,256.184,15.0,198.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,60.0,2.8,2.8,NG/ML,0.9268,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,202.402,256.184,15.0,216.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,90.0,2.98,2.98,NG/ML,0.98638,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,208.792,256.184,15.0,229.0,2014-11-11,15
T1DAL_441960,SUB168905,Week 24,ITN045AI-Rigby,P,2.0,2011-06-13,2011-07-06,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-07-07,2011-12-21,2012-01-20,No,Participant or Guardian Withdrew Consent,2012-01-20,198.0,No,Withdrew Consent,Withdrew Consent,2012-01-20,198.0,Terminated study early,Discontinued study drug early,Yes,No,2012-01-20,198.0,Week 28/Visit 19,2011-04-11,-86.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-21,168.0,5.5263157895,C-PEPTIDE,120.0,2.99,2.99,NG/ML,0.98969,0.98969,1.03603,-0.04634,120.0,,1.03603,,,171.8,58.1,205.386,256.184,15.0,222.0,2014-11-11,15
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,-10.0,1.54,1.54,NG/ML,0.50974,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,,689.881,30.0,106.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,0.0,1.62,1.62,NG/ML,0.53622,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,232.984,689.881,30.0,106.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,15.0,1.95,1.95,NG/ML,0.64545,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,449.524,689.881,30.0,119.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,30.0,3.21,3.21,NG/ML,1.06251,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,689.881,689.881,30.0,182.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,60.0,4.86,4.86,NG/ML,1.60866,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,501.659,689.881,30.0,216.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,90.0,5.55,5.55,NG/ML,1.83705,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,542.884,689.881,30.0,206.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,120.0,5.18,5.18,NG/ML,1.71458,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,458.042,689.881,30.0,169.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,150.0,5.11,5.11,NG/ML,1.69141,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,433.077,689.881,30.0,142.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,180.0,4.56,4.56,NG/ML,1.50936,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,371.013,689.881,30.0,124.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,210.0,3.96,3.96,NG/ML,1.31076,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,307.082,689.881,30.0,112.0,2014-11-11,-1
T1DAL_442289,SUB168906,-1,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-13,-47.0,-1.546052632,C-PEPTIDE,240.0,3.32,3.32,NG/ML,1.09892,1.83705,1.83705,0.0,90.0,1.83705,1.83705,0.0,90.0,192.0,102.0,247.354,689.881,30.0,93.0,2014-11-11,-1
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,-10.0,2.17,2.17,NG/ML,0.71827,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,,512.571,0.0,109.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,0.0,2.07,2.07,NG/ML,0.68517,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,512.571,512.571,0.0,107.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,15.0,3.61,3.61,NG/ML,1.19491,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,465.44,512.571,0.0,171.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,30.0,3.81,3.81,NG/ML,1.26111,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,338.058,512.571,0.0,197.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,60.0,3.4,3.4,NG/ML,1.1254,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,294.838,512.571,0.0,195.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,90.0,3.98,3.98,NG/ML,1.31738,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,355.7,512.571,0.0,184.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 24,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,168.0,5.5263157895,C-PEPTIDE,120.0,3.34,3.34,NG/ML,1.10554,1.31738,1.83705,-0.51967,90.0,,1.83705,,,191.0,104.5,279.284,512.571,0.0,156.0,2014-11-11,15
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,-10.0,1.61,1.61,NG/ML,0.53291,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,,784.503,30.0,129.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,0.0,1.67,1.67,NG/ML,0.55277,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,279.926,784.503,30.0,129.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,15.0,2.21,2.21,NG/ML,0.73151,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,486.67,784.503,30.0,148.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,30.0,3.47,3.47,NG/ML,1.14857,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,784.503,784.503,30.0,222.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,60.0,5.44,5.44,NG/ML,1.80064,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,565.323,784.503,30.0,268.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,90.0,5.04,5.04,NG/ML,1.66824,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,473.388,784.503,30.0,248.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,120.0,4.56,4.56,NG/ML,1.50936,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,378.977,784.503,30.0,221.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,150.0,4.38,4.38,NG/ML,1.44978,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,360.057,784.503,30.0,202.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,180.0,4.02,4.02,NG/ML,1.33062,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,327.257,784.503,30.0,173.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,210.0,3.64,3.64,NG/ML,1.20484,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,290.672,784.503,30.0,163.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 52,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-25,361.0,11.875,C-PEPTIDE,240.0,3.26,3.26,NG/ML,1.07906,1.80064,1.83705,-0.03641,60.0,1.80064,1.83705,-0.03641,60.0,192.0,103.7,256.815,784.503,30.0,146.0,2014-11-11,28
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,-10.0,1.86,1.86,NG/ML,0.61566,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,,482.752,30.0,150.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,0.0,1.92,1.92,NG/ML,0.63552,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,180.54,482.752,30.0,146.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,15.0,1.82,1.82,NG/ML,0.60242,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,378.839,482.752,30.0,151.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,30.0,2.81,2.81,NG/ML,0.93011,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,482.752,482.752,30.0,200.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,60.0,3.61,3.61,NG/ML,1.19491,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,370.142,482.752,30.0,232.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,90.0,2.91,2.91,NG/ML,0.96321,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,258.453,482.752,30.0,258.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 78,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-03,553.0,18.190789474,C-PEPTIDE,120.0,3.16,3.16,NG/ML,1.04596,1.19491,1.83705,-0.64214,60.0,,1.83705,,,191.0,114.1,279.537,482.752,30.0,241.0,2014-11-11,29
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,-10.0,0.62,0.62,NG/ML,0.20522,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,,324.8,90.0,132.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,0.0,0.63,0.63,NG/ML,0.20853,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,74.047,324.8,90.0,132.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,15.0,0.66,0.66,NG/ML,0.21846,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,150.316,324.8,90.0,137.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,30.0,1.06,1.06,NG/ML,0.35086,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,274.438,324.8,90.0,182.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,60.0,1.78,1.78,NG/ML,0.58918,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,196.541,324.8,90.0,243.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,90.0,2.93,2.93,NG/ML,0.96983,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,324.8,324.8,90.0,268.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,120.0,2.52,2.52,NG/ML,0.83412,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,244.873,324.8,90.0,270.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,150.0,2.43,2.43,NG/ML,0.80433,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,212.379,324.8,90.0,236.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,180.0,2.39,2.39,NG/ML,0.79109,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,211.857,324.8,90.0,209.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,210.0,2.17,2.17,NG/ML,0.71827,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,187.983,324.8,90.0,193.0,2014-11-11,30
T1DAL_442289,SUB168906,Week 104,ITN045AI-Rigby,A,1.0,2011-04-13,2011-05-30,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-05-30,2011-11-14,2012-01-29,Yes,,2013-07-01,763.0,Yes,,,2012-01-29,244.0,Completed study,Completed study drug,Yes,Yes,2013-07-01,763.0,Week 104/Visit 30,2011-04-12,-48.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-01,763.0,25.098684211,C-PEPTIDE,240.0,2.14,2.14,NG/ML,0.70834,0.96983,1.83705,-0.86722,90.0,0.96983,1.83705,-0.86722,90.0,191.0,121.0,187.4,324.8,90.0,169.0,2014-11-11,30
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,-10.0,0.56,0.56,NG/ML,0.18536,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,,168.709,120.0,124.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,0.0,0.46,0.46,NG/ML,0.15226,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,55.987,168.709,120.0,125.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,15.0,0.59,0.59,NG/ML,0.19529,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,110.555,168.709,120.0,161.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,30.0,0.96,0.96,NG/ML,0.31776,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,102.403,168.709,120.0,227.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,60.0,1.02,1.02,NG/ML,0.33762,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,81.879,168.709,120.0,309.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,90.0,1.61,1.61,NG/ML,0.53291,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,133.422,168.709,120.0,298.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,120.0,2.04,2.04,NG/ML,0.67524,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,168.709,168.709,120.0,300.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,150.0,1.54,1.54,NG/ML,0.50974,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,106.319,168.709,120.0,272.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,180.0,1.86,1.86,NG/ML,0.61566,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,133.284,168.709,120.0,238.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,210.0,1.7,1.7,NG/ML,0.5627,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,120.525,168.709,120.0,219.0,2014-11-11,-1
T1DAL_446704,SUB168907,-1,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-13,-21.0,-0.690789474,C-PEPTIDE,240.0,1.73,1.73,NG/ML,0.57263,0.67524,0.67524,0.0,120.0,0.67524,0.67524,0.0,120.0,177.0,72.9,121.196,168.709,120.0,189.0,2014-11-11,-1
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,-10.0,0.36,0.36,NG/ML,0.11916,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,,192.136,30.0,121.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,0.0,0.36,0.36,NG/ML,0.11916,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,47.57,192.136,30.0,121.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,15.0,0.46,0.46,NG/ML,0.15226,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,68.285,192.136,30.0,150.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,30.0,0.62,0.62,NG/ML,0.20522,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,192.136,192.136,30.0,242.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,60.0,1.44,1.44,NG/ML,0.47664,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,130.896,192.136,30.0,352.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,90.0,1.72,1.72,NG/ML,0.56932,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,149.116,192.136,30.0,344.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 24,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,170.0,5.5921052632,C-PEPTIDE,120.0,1.59,1.59,NG/ML,0.52629,0.56932,0.67524,-0.10592,90.0,,0.67524,,,,76.4,120.323,192.136,30.0,304.0,2014-11-11,15
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,-10.0,0.56,0.56,NG/ML,0.18536,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,,165.722,30.0,193.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,0.0,0.59,0.59,NG/ML,0.19529,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,85.524,165.722,30.0,195.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,15.0,0.78,0.78,NG/ML,0.25818,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,132.927,165.722,30.0,219.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,30.0,1.13,1.13,NG/ML,0.37403,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,165.722,165.722,30.0,287.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,60.0,1.45,1.45,NG/ML,0.47995,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,124.6,165.722,30.0,360.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,90.0,1.52,1.52,NG/ML,0.50312,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,122.317,165.722,30.0,399.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,120.0,1.4,1.4,NG/ML,0.4634,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,102.757,165.722,30.0,380.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,150.0,1.16,1.16,NG/ML,0.38396,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,76.515,165.722,30.0,364.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,180.0,1.14,1.14,NG/ML,0.37734,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,77.853,165.722,30.0,327.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,210.0,1.13,1.13,NG/ML,0.37403,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,81.125,165.722,30.0,305.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 52,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-04,367.0,12.072368421,C-PEPTIDE,240.0,1.03,1.03,NG/ML,0.34093,0.50312,0.67524,-0.17212,90.0,0.50312,0.67524,-0.17212,90.0,,81.6,72.191,165.722,30.0,289.0,2014-11-11,28
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,-10.0,0.21,0.21,NG/ML,0.06951,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,,124.938,30.0,137.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,0.0,0.27,0.27,NG/ML,0.08937,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,47.246,124.938,30.0,137.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,15.0,0.38,0.38,NG/ML,0.12578,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,64.733,124.938,30.0,160.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,30.0,0.53,0.53,NG/ML,0.17543,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,124.938,124.938,30.0,213.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,60.0,0.96,0.96,NG/ML,0.31776,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,87.581,124.938,30.0,297.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,90.0,1.19,1.19,NG/ML,0.39389,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,102.515,124.938,30.0,,2014-11-11,29
T1DAL_446704,SUB168907,Week 78,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-03,550.0,18.092105263,C-PEPTIDE,120.0,1.29,1.29,NG/ML,0.42699,0.42699,0.67524,-0.24825,120.0,,0.67524,,,,81.8,105.647,124.938,30.0,346.0,2014-11-11,29
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,-10.0,0.22,0.22,NG/ML,0.07282,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,,61.991,30.0,142.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,0.0,0.22,0.22,NG/ML,0.07282,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,39.63,61.991,30.0,141.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,15.0,0.34,0.34,NG/ML,0.11254,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,48.62,61.991,30.0,169.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,30.0,0.43,0.43,NG/ML,0.14233,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,61.991,61.991,30.0,232.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,60.0,0.55,0.55,NG/ML,0.18205,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,46.459,61.991,30.0,306.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,90.0,0.68,0.68,NG/ML,0.22508,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,58.966,61.991,30.0,328.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,120.0,0.65,0.65,NG/ML,0.21515,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,52.079,61.991,30.0,295.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,150.0,0.61,0.61,NG/ML,0.20191,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,43.095,61.991,30.0,272.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,180.0,0.51,0.51,NG/ML,0.16881,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,34.046,61.991,30.0,249.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,210.0,0.57,0.57,NG/ML,0.18867,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,42.038,61.991,30.0,238.0,2014-11-11,30
T1DAL_446704,SUB168907,Week 104,ITN045AI-Rigby,P,2.0,2011-07-13,2011-08-03,Yes,Yes,Yes,S/I,28.0,16-35,22-35,22-35,Male,White,American Indian or Alaska Native,Unknown,2011-08-04,2012-01-20,2012-04-06,Yes,,2013-07-31,728.0,Yes,,,2012-04-06,247.0,Completed study,Completed study drug,Yes,Yes,2013-07-31,728.0,Week 104/Visit 30,2011-06-11,-53.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-31,728.0,23.947368421,C-PEPTIDE,240.0,0.5,0.5,NG/ML,0.1655,0.22508,0.67524,-0.45016,90.0,0.22508,0.67524,-0.45016,90.0,177.0,83.6,36.921,61.991,30.0,209.0,2014-11-11,30
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,-10.0,0.33,0.33,NG/ML,0.10923,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,,194.244,30.0,118.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,0.0,0.37,0.37,NG/ML,0.12247,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,74.693,194.244,30.0,114.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,15.0,0.65,0.65,NG/ML,0.21515,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,113.761,194.244,30.0,111.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,30.0,1,1.0,NG/ML,0.331,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,194.244,194.244,30.0,129.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,60.0,1.67,1.67,NG/ML,0.55277,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,137.622,194.244,30.0,213.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,90.0,1.94,1.94,NG/ML,0.64214,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,151.791,194.244,30.0,208.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,120.0,1.89,1.89,NG/ML,0.62559,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,134.537,194.244,30.0,190.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,150.0,1.84,1.84,NG/ML,0.60904,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,124.102,194.244,30.0,173.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,180.0,1.51,1.51,NG/ML,0.49981,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,93.187,194.244,30.0,153.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,210.0,1.55,1.55,NG/ML,0.51305,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,99.783,194.244,30.0,140.0,2014-11-11,-1
T1DAL_504034,SUB168908,-1,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-15,-13.0,-0.427631579,C-PEPTIDE,240.0,1.21,1.21,NG/ML,0.40051,0.64214,0.64214,0.0,90.0,0.64214,0.64214,0.0,90.0,175.5,64.4,72.702,194.244,30.0,129.0,2014-11-11,-1
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,-10.0,0.59,0.59,NG/ML,0.19529,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,,150.832,15.0,148.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,0.0,0.6,0.6,NG/ML,0.1986,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,101.004,150.832,15.0,145.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,15.0,0.93,0.93,NG/ML,0.30783,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,150.832,150.832,15.0,198.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,30.0,1.36,1.36,NG/ML,0.45016,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,140.394,150.832,15.0,274.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,60.0,1.45,1.45,NG/ML,0.47995,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,111.405,150.832,15.0,318.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,90.0,1.57,1.57,NG/ML,0.51967,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,114.483,150.832,15.0,261.0,2014-11-11,15
T1DAL_504034,SUB168908,Week 24,ITN045AI-Rigby,P,2.0,2011-04-06,2011-04-28,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-04-28,2011-10-15,2011-12-30,No,Failure to Return/Lost to Follow-Up,2012-09-14,505.0,Yes,,,2011-12-30,246.0,Terminated study early,Completed study drug,Yes,Yes,2012-09-14,505.0,Week 35/Visit 26,2011-03-12,-47.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-15,170.0,5.5921052632,C-PEPTIDE,120.0,1.55,1.55,NG/ML,0.51305,0.51967,0.64214,-0.12247,90.0,,0.64214,,,177.0,67.6,108.784,150.832,15.0,326.0,2014-11-11,15
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,-10.0,1.3,1.3,NG/ML,0.4303,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,,165.738,15.0,70.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,0.0,1.04,1.04,NG/ML,0.34424,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,110.447,165.738,15.0,70.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,15.0,1.48,1.48,NG/ML,0.48988,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,165.738,165.738,15.0,81.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,30.0,2.06,2.06,NG/ML,0.68186,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,164.155,165.738,15.0,117.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,60.0,2.24,2.24,NG/ML,0.74144,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,132.182,165.738,15.0,192.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,90.0,2.03,2.03,NG/ML,0.67193,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,109.21,165.738,15.0,178.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,120.0,2.07,2.07,NG/ML,0.68517,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,109.652,165.738,15.0,160.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,150.0,1.81,1.81,NG/ML,0.59911,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,92.309,165.738,15.0,146.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,180.0,1.04,1.04,NG/ML,0.34424,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,38.462,165.738,15.0,124.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,210.0,1.51,1.51,NG/ML,0.49981,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,78.323,165.738,15.0,96.0,2014-11-11,-1
T1DAL_508549,SUB168909,-1,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-17,-11.0,-0.361842105,C-PEPTIDE,240.0,1.45,1.45,NG/ML,0.47995,0.74144,0.74144,0.0,60.0,0.74144,0.74144,0.0,60.0,152.2,36.4,80.3,165.738,15.0,78.0,2014-11-11,-1
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,-10.0,0.44,0.44,NG/ML,0.14564,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,,85.032,15.0,145.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,0.0,0.49,0.49,NG/ML,0.16219,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,53.474,85.032,15.0,148.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,15.0,0.65,0.65,NG/ML,0.21515,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,85.032,85.032,15.0,159.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,30.0,0.97,0.97,NG/ML,0.32107,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,75.714,85.032,15.0,211.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,60.0,1,1.0,NG/ML,0.331,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,61.557,85.032,15.0,261.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,90.0,1.17,1.17,NG/ML,0.38727,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,69.985,85.032,15.0,284.0,2014-11-11,15
T1DAL_508549,SUB168909,Week 24,ITN045AI-Rigby,P,2.0,2011-04-17,2011-04-28,Yes,Yes,Yes,S/I,13.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-28,2011-10-13,2011-11-24,No,Failure to Return/Lost to Follow-Up,2012-05-04,372.0,No,Lost to Follow-up,Lost to Follow-up,2011-11-24,210.0,Terminated study early,Discontinued study drug early,Yes,No,2012-05-04,372.0,Week 30/Visit 21,2011-01-19,-99.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-13,168.0,5.5263157895,C-PEPTIDE,120.0,1,1.0,NG/ML,0.331,0.38727,0.74144,-0.35417,90.0,,0.74144,,,153.9,40.4,55.275,85.032,15.0,275.0,2014-11-11,15
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,-10.0,0.73,0.73,NG/ML,0.24163,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,,312.345,30.0,102.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,0.0,0.66,0.66,NG/ML,0.21846,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,171.488,312.345,30.0,98.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,15.0,1.55,1.55,NG/ML,0.51305,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,238.177,312.345,30.0,136.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,30.0,2.29,2.29,NG/ML,0.75799,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,312.345,312.345,30.0,161.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,60.0,3.14,3.14,NG/ML,1.03934,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,230.698,312.345,30.0,147.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,90.0,3.08,3.08,NG/ML,1.01948,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,209.269,312.345,30.0,126.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,120.0,2.93,2.93,NG/ML,0.96983,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,184.24,312.345,30.0,122.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,150.0,2.01,2.01,NG/ML,0.66531,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,105.81,312.345,30.0,89.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,180.0,1.74,1.74,NG/ML,0.57594,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,0.549,312.345,30.0,77.0,2014-11-11,-1
T1DAL_576351,SUB168910,-1,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-15,-21.0,-0.690789474,C-PEPTIDE,210.0,1.08,1.08,NG/ML,0.35748,1.03934,1.03934,0.0,60.0,1.03934,1.03934,0.0,60.0,161.2,52.7,47.004,312.345,30.0,62.0,2014-11-11,-1
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,-10.0,1.87,1.87,NG/ML,0.61897,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,,252.898,15.0,200.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,0.0,1.72,1.72,NG/ML,0.56932,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,193.706,252.898,15.0,195.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,15.0,2.3,2.3,NG/ML,0.7613,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,252.898,252.898,15.0,207.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,30.0,2.83,2.83,NG/ML,0.93673,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,194.589,252.898,15.0,266.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,60.0,2.59,2.59,NG/ML,0.85729,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,172.517,252.898,15.0,284.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,90.0,2.67,2.67,NG/ML,0.88377,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,172.583,252.898,15.0,310.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 24,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-20,168.0,5.5263157895,C-PEPTIDE,120.0,2.69,2.69,NG/ML,0.89039,0.93673,1.03934,-0.10261,30.0,,1.03934,,,161.7,56.1,175.022,252.898,15.0,301.0,2014-11-11,15
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,-10.0,1.4,1.4,NG/ML,0.4634,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,,252.954,90.0,91.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,0.0,1.37,1.37,NG/ML,0.45347,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,155.39,252.954,90.0,94.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,15.0,1.79,1.79,NG/ML,0.59249,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,183.428,252.954,90.0,133.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,30.0,2.06,2.06,NG/ML,0.68186,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,227.497,252.954,90.0,132.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,60.0,2.47,2.47,NG/ML,0.81757,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,180.629,252.954,90.0,184.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,90.0,3.36,3.36,NG/ML,1.11216,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,252.954,252.954,90.0,222.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,120.0,3.17,3.17,NG/ML,1.04927,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,224.38,252.954,90.0,224.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,150.0,3.46,3.46,NG/ML,1.14526,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,238.593,252.954,90.0,230.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,180.0,2.98,2.98,NG/ML,0.98638,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,193.618,252.954,90.0,208.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,210.0,2.74,2.74,NG/ML,0.90694,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,171.217,252.954,90.0,182.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 52,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-03,364.0,11.973684211,C-PEPTIDE,240.0,2.27,2.27,NG/ML,0.75137,1.11216,1.03934,0.07282,90.0,1.14526,1.03934,0.10592,150.0,164.5,61.0,135.986,252.954,90.0,157.0,2014-11-11,28
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,-10.0,1.15,1.15,NG/ML,0.38065,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,,169.096,30.0,189.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,0.0,1.05,1.05,NG/ML,0.34755,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,96.614,169.096,30.0,173.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,15.0,1.16,1.16,NG/ML,0.38396,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,150.285,169.096,30.0,171.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,30.0,1.53,1.53,NG/ML,0.50643,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,169.096,169.096,30.0,211.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,60.0,1.79,1.79,NG/ML,0.59249,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,135.135,169.096,30.0,249.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,90.0,1.48,1.48,NG/ML,0.48988,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,100.234,169.096,30.0,268.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 78,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-01-18,532.0,17.5,C-PEPTIDE,120.0,1.45,1.45,NG/ML,0.47995,0.59249,1.03934,-0.44685,60.0,,1.03934,,,167.2,63.4,94.857,169.096,30.0,277.0,2014-11-11,29
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,-10.0,0.45,0.45,NG/ML,0.14895,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,,123.305,30.0,139.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,0.0,0.46,0.46,NG/ML,0.15226,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,84.942,123.305,30.0,142.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,15.0,0.77,0.77,NG/ML,0.25487,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,112.572,123.305,30.0,168.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,30.0,1.02,1.02,NG/ML,0.33762,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,123.305,123.305,30.0,229.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,60.0,1.2,1.2,NG/ML,0.3972,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,95.489,123.305,30.0,286.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,90.0,1.35,1.35,NG/ML,0.44685,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,103.613,123.305,30.0,306.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,120.0,1.51,1.51,NG/ML,0.49981,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,113.307,123.305,30.0,308.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,150.0,1.51,1.51,NG/ML,0.49981,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,109.514,123.305,30.0,303.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,180.0,1.65,1.65,NG/ML,0.54615,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,121.039,123.305,30.0,290.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,210.0,1.29,1.29,NG/ML,0.42699,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,85.411,123.305,30.0,274.0,2014-11-11,30
T1DAL_576351,SUB168910,Week 104,ITN045AI-Rigby,A,1.0,2011-07-15,2011-08-05,Yes,Yes,Yes,S/I,12.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-08-05,2012-01-20,2012-04-13,Yes,,2013-07-19,714.0,Yes,,,2012-04-13,252.0,Completed study,Completed study drug,Yes,Yes,2013-07-19,714.0,Unscheduled Visit,2011-06-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-07-19,714.0,23.486842105,C-PEPTIDE,240.0,1.28,1.28,NG/ML,0.42368,0.49981,1.03934,-0.53953,120.0,0.54615,1.03934,-0.49319,180.0,172.2,65.2,82.692,123.305,30.0,243.0,2014-11-11,30
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,-10.0,0.61,0.61,NG/ML,0.20191,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,,237.161,90.0,96.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,0.0,0.57,0.57,NG/ML,0.18867,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,33.513,237.161,90.0,91.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,15.0,0.54,0.54,NG/ML,0.17874,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,89.141,237.161,90.0,95.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,30.0,0.95,0.95,NG/ML,0.31445,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,100.304,237.161,90.0,126.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,60.0,1.14,1.14,NG/ML,0.37734,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,77.485,237.161,90.0,160.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,90.0,3.17,3.17,NG/ML,1.04927,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,237.161,237.161,90.0,166.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,120.0,3.17,3.17,NG/ML,1.04927,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,218.6,237.161,90.0,99.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,150.0,2.68,2.68,NG/ML,0.88708,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,151.172,237.161,90.0,129.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,180.0,2.49,2.49,NG/ML,0.82419,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,132.94,237.161,90.0,115.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,210.0,2.28,2.28,NG/ML,0.75468,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,122.055,237.161,90.0,148.0,2014-11-11,-1
T1DAL_589524,SUB168911,-1,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-22,-11.0,-0.361842105,C-PEPTIDE,240.0,1.99,1.99,NG/ML,0.65869,1.04927,1.04927,0.0,90.0,1.04927,1.04927,0.0,90.0,144.78,49.4,103.416,237.161,90.0,82.0,2014-11-11,-1
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,-10.0,0.29,0.29,NG/ML,0.09599,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,,125.891,120.0,120.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,0.0,0.32,0.32,NG/ML,0.10592,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,17.618,125.891,120.0,110.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,15.0,0.28,0.28,NG/ML,0.09268,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,46.463,125.891,120.0,119.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,30.0,0.49,0.49,NG/ML,0.16219,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,105.119,125.891,120.0,159.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,60.0,0.98,0.98,NG/ML,0.32438,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,72.957,125.891,120.0,236.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,90.0,1.41,1.41,NG/ML,0.46671,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,102.188,125.891,120.0,275.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 24,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-23,171.0,5.625,C-PEPTIDE,120.0,1.82,1.82,NG/ML,0.60242,0.60242,1.04927,-0.44685,120.0,,1.04927,,,149.0,48.4,125.891,125.891,120.0,284.0,2014-11-11,15
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,-10.0,0.58,0.58,NG/ML,0.19198,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,,107.94,120.0,130.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,0.0,0.6,0.6,NG/ML,0.1986,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,38.043,107.94,120.0,135.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,15.0,0.57,0.57,NG/ML,0.18867,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,38.018,107.94,120.0,132.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,30.0,0.57,0.57,NG/ML,0.18867,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,91.83,107.94,120.0,133.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,60.0,0.97,0.97,NG/ML,0.32107,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,66.672,107.94,120.0,177.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,90.0,1.42,1.42,NG/ML,0.47002,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,100.866,107.94,120.0,216.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,120.0,1.61,1.61,NG/ML,0.53291,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,107.94,107.94,120.0,248.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,150.0,1.47,1.47,NG/ML,0.48657,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,87.725,107.94,120.0,251.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,180.0,1.51,1.51,NG/ML,0.49981,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,87.937,107.94,120.0,230.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,210.0,1.26,1.26,NG/ML,0.41706,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,67.783,107.94,120.0,183.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 52,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-18,410.0,13.486842105,C-PEPTIDE,240.0,1.06,1.06,NG/ML,0.35086,0.53291,1.04927,-0.51636,120.0,0.53291,1.04927,-0.51636,120.0,147.0,51.6,52.732,107.94,120.0,161.0,2014-11-11,28
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,-10.0,0.18,0.18,NG/ML,0.05958,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,,51.171,120.0,62.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,0.0,0.16,0.16,NG/ML,0.05296,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,12.484,51.171,120.0,60.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,15.0,0.17,0.17,NG/ML,0.05627,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,12.237,51.171,120.0,58.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,30.0,0.19,0.19,NG/ML,0.06289,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,44.56,51.171,120.0,75.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,60.0,0.41,0.41,NG/ML,0.13571,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,30.608,51.171,120.0,131.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,90.0,0.67,0.67,NG/ML,0.22177,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,48.712,51.171,120.0,170.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 78,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-07,552.0,18.157894737,C-PEPTIDE,120.0,0.75,0.75,NG/ML,0.24825,0.24825,1.04927,-0.80102,120.0,,1.04927,,,146.5,51.2,51.171,51.171,120.0,172.0,2014-11-11,29
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,-10.0,0.24,0.24,NG/ML,0.07944,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,,126.144,30.0,79.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,0.0,0.24,0.24,NG/ML,0.07944,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,29.485,126.144,30.0,77.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,15.0,0.32,0.32,NG/ML,0.10592,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,54.115,126.144,30.0,94.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,30.0,0.54,0.54,NG/ML,0.17874,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,126.144,126.144,30.0,148.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,60.0,1.15,1.15,NG/ML,0.38065,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,86.138,126.144,30.0,249.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,90.0,1.37,1.37,NG/ML,0.45347,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,95.909,126.144,30.0,258.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,120.0,1.7,1.7,NG/ML,0.5627,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,113.16,126.144,30.0,277.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,150.0,1.83,1.83,NG/ML,0.60573,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,118.368,126.144,30.0,263.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,180.0,1.84,1.84,NG/ML,0.60904,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,111.691,126.144,30.0,238.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,210.0,1.21,1.21,NG/ML,0.40051,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,55.653,126.144,30.0,223.0,2014-11-11,30
T1DAL_589524,SUB168911,Week 104,ITN045AI-Rigby,A,1.0,2011-02-22,2011-03-05,Yes,Yes,Yes,S/I,34.0,16-35,22-35,22-35,Female,White,,Not Hispanic or Latino,2011-03-06,,2011-11-06,Yes,,2013-04-06,763.0,Yes,,,2011-11-06,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-06,763.0,Unscheduled Visit,2010-11-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-27,725.0,23.848684211,C-PEPTIDE,240.0,1.94,1.94,NG/ML,0.64214,0.5627,1.04927,-0.48657,120.0,0.64214,1.04927,-0.40713,240.0,147.1,52.2,120.009,126.144,30.0,202.0,2014-11-11,30
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,-10.0,1.35,1.35,NG/ML,0.44685,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,,541.692,30.0,87.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,0.0,1.25,1.25,NG/ML,0.41375,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,212.334,541.692,30.0,89.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,15.0,2.13,2.13,NG/ML,0.70503,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,429.36,541.692,30.0,113.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,30.0,3.97,3.97,NG/ML,1.31407,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,541.692,541.692,30.0,174.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,60.0,5.39,5.39,NG/ML,1.78409,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,398.616,541.692,30.0,199.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,90.0,5.98,5.98,NG/ML,1.97938,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,412.43,541.692,30.0,197.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,120.0,5.72,5.72,NG/ML,1.89332,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,362.468,541.692,30.0,177.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,150.0,4.72,4.72,NG/ML,1.56232,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,266.726,541.692,30.0,158.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,180.0,3.43,3.43,NG/ML,1.13533,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,164.688,541.692,30.0,125.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,210.0,2.93,2.93,NG/ML,0.96983,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,143.758,541.692,30.0,114.0,2014-11-11,-1
T1DAL_615852,SUB168912,-1,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2012-02-03,-21.0,-0.690789474,C-PEPTIDE,240.0,2.45,2.45,NG/ML,0.81095,1.97938,1.97938,0.0,90.0,1.97938,1.97938,0.0,90.0,162.5,46.2,125.821,541.692,30.0,98.0,2014-11-11,-1
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,-10.0,1.38,1.38,NG/ML,0.45678,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,,478.972,30.0,119.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,0.0,1.26,1.26,NG/ML,0.41706,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,131.222,478.972,30.0,121.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,15.0,1.56,1.56,NG/ML,0.51636,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,406.005,478.972,30.0,122.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,30.0,3.63,3.63,NG/ML,1.20153,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,478.972,478.972,30.0,198.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,60.0,4.74,4.74,NG/ML,1.56894,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,356.689,478.972,30.0,222.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,90.0,6,6.0,NG/ML,1.986,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,428.825,478.972,30.0,201.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 24,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-08-03,161.0,5.2960526316,C-PEPTIDE,120.0,5.65,5.65,NG/ML,1.87015,1.986,1.97938,0.00662,90.0,,1.97938,,,163.0,49.2,369.648,478.972,30.0,191.0,2014-11-11,15
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,-10.0,0.81,0.81,NG/ML,0.26811,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,,335.205,90.0,91.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,0.0,0.86,0.86,NG/ML,0.28466,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,169.736,335.205,90.0,93.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,15.0,1.59,1.59,NG/ML,0.52629,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,202.299,335.205,90.0,123.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,30.0,2.05,2.05,NG/ML,0.67855,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,250.178,335.205,90.0,147.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,60.0,2.62,2.62,NG/ML,0.86722,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,187.211,335.205,90.0,232.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,90.0,4.5,4.5,NG/ML,1.4895,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,335.205,335.205,90.0,174.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,120.0,3.52,3.52,NG/ML,1.16512,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,229.432,335.205,90.0,139.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,150.0,4.21,4.21,NG/ML,1.39351,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,268.506,335.205,90.0,124.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,180.0,2.35,2.35,NG/ML,0.77785,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,111.678,335.205,90.0,86.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,210.0,2.55,2.55,NG/ML,0.84405,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,133.855,335.205,90.0,100.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 52,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2013-02-21,363.0,11.940789474,C-PEPTIDE,240.0,2.14,2.14,NG/ML,0.70834,1.4895,1.97938,-0.48988,90.0,1.4895,1.97938,-0.48988,90.0,162.0,49.4,119.926,335.205,90.0,85.0,2014-11-11,28
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,-10.0,0.89,0.89,NG/ML,0.29459,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,,372.03,30.0,88.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,0.0,0.95,0.95,NG/ML,0.31445,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,82.751,372.03,30.0,101.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,15.0,1.02,1.02,NG/ML,0.33762,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,200.773,372.03,30.0,106.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,30.0,1.93,1.93,NG/ML,0.63883,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,372.03,372.03,30.0,151.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,60.0,3.45,3.45,NG/ML,1.14195,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,262.42,372.03,30.0,222.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,90.0,4.12,4.12,NG/ML,1.36372,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,296.037,372.03,30.0,193.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 78,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-09-09,563.0,18.519736842,C-PEPTIDE,120.0,4.53,4.53,NG/ML,1.49943,1.49943,1.97938,-0.47995,120.0,,1.97938,,,166.0,47.2,305.058,372.03,30.0,171.0,2014-11-11,29
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,-10.0,1.7,1.7,NG/ML,0.5627,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,,339.525,15.0,211.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,0.0,1.5,1.5,NG/ML,0.4965,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,173.546,339.525,15.0,214.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,15.0,1.99,1.99,NG/ML,0.65869,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,339.525,339.525,15.0,218.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,30.0,3.32,3.32,NG/ML,1.09892,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,316.353,339.525,15.0,305.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,60.0,3.55,3.55,NG/ML,1.17505,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,251.248,339.525,15.0,339.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,90.0,3.47,3.47,NG/ML,1.14857,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,222.555,339.525,15.0,366.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,120.0,2.9,2.9,NG/ML,0.9599,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,166.578,339.525,15.0,364.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,150.0,2.11,2.11,NG/ML,0.69841,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,102.798,339.525,15.0,330.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,180.0,2.02,2.02,NG/ML,0.66862,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,107.781,339.525,15.0,315.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,210.0,2.04,2.04,NG/ML,0.67524,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,122.888,339.525,15.0,290.0,2014-11-11,30
T1DAL_615852,SUB168912,Week 104,ITN045AI-Rigby,A,1.0,2012-02-03,2012-02-24,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2012-02-24,2012-08-03,2012-10-18,Yes,,2014-02-21,728.0,Yes,,,2012-10-18,237.0,Completed study,Completed study drug,Yes,Yes,2014-02-21,728.0,Week 104/Visit 30,2011-12-18,-68.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2014-02-21,728.0,23.947368421,C-PEPTIDE,240.0,2.11,2.11,NG/ML,0.69841,1.17505,1.97938,-0.80433,60.0,1.17505,1.97938,-0.80433,60.0,163.4,49.1,131.709,339.525,15.0,259.0,2014-11-11,30
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,-10.0,1.76,1.76,NG/ML,0.58256,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,,600.305,30.0,115.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,0.0,1.66,1.66,NG/ML,0.54946,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,236.834,600.305,30.0,112.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,15.0,2.24,2.24,NG/ML,0.74144,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,336.923,600.305,30.0,126.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,30.0,3.02,3.02,NG/ML,0.99962,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,600.305,600.305,30.0,150.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,60.0,4.91,4.91,NG/ML,1.62521,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,429.477,600.305,30.0,170.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,90.0,3.86,3.86,NG/ML,1.27766,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,291.05,600.305,30.0,113.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,120.0,3.77,3.77,NG/ML,1.24787,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,257.573,600.305,30.0,132.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,150.0,3.74,3.74,NG/ML,1.23794,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,264.361,600.305,30.0,119.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,180.0,3.2,3.2,NG/ML,1.0592,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,213.339,600.305,30.0,108.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,210.0,2.59,2.59,NG/ML,0.85729,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,157.457,600.305,30.0,101.0,2014-11-11,-1
T1DAL_616755,SUB168913,-1,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-02,-27.0,-0.888157895,C-PEPTIDE,240.0,2.25,2.25,NG/ML,0.74475,1.62521,1.62521,0.0,60.0,1.62521,1.62521,0.0,60.0,186.5,72.25,137.167,600.305,30.0,97.0,2014-11-11,-1
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,-10.0,1.43,1.43,NG/ML,0.47333,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,,533.111,30.0,114.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,0.0,1.46,1.46,NG/ML,0.48326,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,188.516,533.111,30.0,118.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,15.0,1.79,1.79,NG/ML,0.59249,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,344.095,533.111,30.0,122.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,30.0,2.82,2.82,NG/ML,0.93342,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,533.111,533.111,30.0,164.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,60.0,4.26,4.26,NG/ML,1.41006,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,385.756,533.111,30.0,166.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,90.0,4.25,4.25,NG/ML,1.40675,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,352.331,533.111,30.0,151.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 24,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-14,169.0,5.5592105263,C-PEPTIDE,120.0,4.35,4.35,NG/ML,1.43985,1.43985,1.62521,-0.18536,120.0,,1.62521,,,,79.45,334.775,533.111,30.0,129.0,2014-11-11,15
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,-10.0,1.75,1.75,NG/ML,0.57925,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,,506.516,15.0,120.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,0.0,1.71,1.71,NG/ML,0.56601,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,234.741,506.516,15.0,122.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,15.0,2.18,2.18,NG/ML,0.72158,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,506.516,506.516,15.0,138.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,30.0,3.91,3.91,NG/ML,1.29421,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,494.47,506.516,15.0,179.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,60.0,4.37,4.37,NG/ML,1.44647,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,383.832,506.516,15.0,200.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,90.0,4.55,4.55,NG/ML,1.50605,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,366.984,506.516,15.0,183.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,120.0,4.17,4.17,NG/ML,1.38027,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,310.124,506.516,15.0,157.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,150.0,4.19,4.19,NG/ML,1.38689,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,309.359,506.516,15.0,135.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,180.0,3.49,3.49,NG/ML,1.15519,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,239.82,506.516,15.0,116.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,210.0,2.81,2.81,NG/ML,0.93011,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,174.961,506.516,15.0,101.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 52,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,364.0,11.973684211,C-PEPTIDE,240.0,2.65,2.65,NG/ML,0.87715,1.50605,1.62521,-0.11916,90.0,1.50605,1.62521,-0.11916,90.0,,81.75,176.133,506.516,15.0,86.0,2014-11-11,28
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,-10.0,1.92,1.92,NG/ML,0.63552,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,,543.21,30.0,131.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,0.0,1.95,1.95,NG/ML,0.64545,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,194.845,543.21,30.0,130.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,15.0,2.08,2.08,NG/ML,0.68848,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,306.207,543.21,30.0,141.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,30.0,2.8,2.8,NG/ML,0.9268,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,543.21,543.21,30.0,163.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,60.0,4.43,4.43,NG/ML,1.46633,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,393.315,543.21,30.0,215.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,90.0,3.73,3.73,NG/ML,1.23463,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,289.555,543.21,30.0,207.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 78,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-26,547.0,17.993421053,C-PEPTIDE,120.0,4.3,4.3,NG/ML,1.4233,1.46633,1.62521,-0.15888,60.0,,1.62521,,,,78.45,325.981,543.21,30.0,201.0,2014-11-11,29
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,-10.0,1.74,1.74,NG/ML,0.57594,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,,656.683,30.0,141.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,0.0,1.67,1.67,NG/ML,0.55277,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,197.329,656.683,30.0,142.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,15.0,1.98,1.98,NG/ML,0.65538,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,315.191,656.683,30.0,148.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,30.0,2.8,2.8,NG/ML,0.9268,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,656.683,656.683,30.0,171.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,60.0,5.14,5.14,NG/ML,1.70134,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,461.095,656.683,30.0,213.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,90.0,5.17,5.17,NG/ML,1.71127,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,427.906,656.683,30.0,211.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,120.0,5.39,5.39,NG/ML,1.78409,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,408.187,656.683,30.0,186.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,150.0,4.84,4.84,NG/ML,1.60204,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,340.758,656.683,30.0,175.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,180.0,4.05,4.05,NG/ML,1.34055,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,259.62,656.683,30.0,141.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,210.0,2.01,2.01,NG/ML,0.66531,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,67.091,656.683,30.0,126.0,2014-11-11,30
T1DAL_616755,SUB168913,Week 104,ITN045AI-Rigby,A,1.0,2011-05-02,2011-05-29,Yes,Yes,Yes,S/I,31.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-29,2011-11-14,2012-01-28,Yes,,2013-05-26,728.0,Yes,,,2012-01-28,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-26,728.0,Week 104/Visit 30,2011-02-20,-98.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-26,728.0,23.947368421,C-PEPTIDE,240.0,2.51,2.51,NG/ML,0.83081,1.78409,1.62521,0.15888,120.0,1.78409,1.62521,0.15888,120.0,185.0,75.26,149.229,656.683,30.0,103.0,2014-11-11,30
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,-10.0,1.07,1.07,NG/ML,0.35417,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,,266.525,30.0,125.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,0.0,1.11,1.11,NG/ML,0.36741,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,130.534,266.525,30.0,126.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,15.0,1.38,1.38,NG/ML,0.45678,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,238.106,266.525,30.0,131.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,30.0,2.2,2.2,NG/ML,0.7282,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,266.525,266.525,30.0,171.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,60.0,2.65,2.65,NG/ML,0.87715,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,204.688,266.525,30.0,201.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,90.0,2.79,2.79,NG/ML,0.92349,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,201.474,266.525,30.0,214.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,120.0,2.7,2.7,NG/ML,0.8937,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,183.107,266.525,30.0,210.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,150.0,2.89,2.89,NG/ML,0.95659,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,197.196,266.525,30.0,197.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,180.0,3.2,3.2,NG/ML,1.0592,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,224.634,266.525,30.0,176.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,210.0,2.66,2.66,NG/ML,0.88046,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,170.339,266.525,30.0,150.0,2014-11-11,-1
T1DAL_620652,SUB168914,-1,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-02,-15.0,-0.493421053,C-PEPTIDE,240.0,2.17,2.17,NG/ML,0.71827,0.92349,0.92349,0.0,90.0,1.0592,1.0592,0.0,180.0,171.9,62.0,124.372,266.525,30.0,126.0,2014-11-11,-1
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,-10.0,1.42,1.42,NG/ML,0.47002,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,,186.843,15.0,136.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,0.0,1.3,1.3,NG/ML,0.4303,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,144.137,186.843,15.0,139.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,15.0,1.6,1.6,NG/ML,0.5296,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,186.843,186.843,15.0,151.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,30.0,1.97,1.97,NG/ML,0.65207,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,181.628,186.843,15.0,188.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,60.0,2.07,2.07,NG/ML,0.68517,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,149.102,186.843,15.0,235.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,90.0,1.85,1.85,NG/ML,0.61235,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,121.56,186.843,15.0,232.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 24,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,168.0,5.5263157895,C-PEPTIDE,120.0,2.1,2.1,NG/ML,0.6951,0.6951,0.92349,-0.22839,120.0,,1.0592,,,171.4,62.8,143.261,186.843,15.0,249.0,2014-11-11,15
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,-10.0,0.54,0.54,NG/ML,0.17874,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,,162.347,30.0,137.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,0.0,0.54,0.54,NG/ML,0.17874,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,71.328,162.347,30.0,136.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,15.0,0.72,0.72,NG/ML,0.23832,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,92.873,162.347,30.0,169.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,30.0,0.92,0.92,NG/ML,0.30452,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,162.347,162.347,30.0,204.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,60.0,1.46,1.46,NG/ML,0.48326,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,117.349,162.347,30.0,262.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,90.0,1.77,1.77,NG/ML,0.58587,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,138.565,162.347,30.0,264.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,120.0,1.84,1.84,NG/ML,0.60904,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,134.341,162.347,30.0,256.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,150.0,2.06,2.06,NG/ML,0.68186,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,148.048,162.347,30.0,245.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,180.0,2.06,2.06,NG/ML,0.68186,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,144.032,162.347,30.0,208.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,210.0,1.97,1.97,NG/ML,0.65207,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,131.992,162.347,30.0,201.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 52,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-14,363.0,11.940789474,C-PEPTIDE,240.0,1.63,1.63,NG/ML,0.53953,0.60904,0.92349,-0.31445,120.0,0.68186,1.0592,-0.37734,150.0,173.4,64.0,100.141,162.347,30.0,178.0,2014-11-11,28
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,-10.0,1.09,1.09,NG/ML,0.36079,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,,178.593,15.0,170.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,0.0,1.17,1.17,NG/ML,0.38727,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,177.75,178.593,15.0,170.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,15.0,1.68,1.68,NG/ML,0.55608,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,178.593,178.593,15.0,191.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,30.0,1.86,1.86,NG/ML,0.61566,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,173.002,178.593,15.0,210.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,60.0,1.96,1.96,NG/ML,0.64876,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,140.365,178.593,15.0,255.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,90.0,2.13,2.13,NG/ML,0.70503,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,151.333,178.593,15.0,263.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 78,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-25,558.0,18.355263158,C-PEPTIDE,120.0,1.85,1.85,NG/ML,0.61235,0.70503,0.92349,-0.21846,90.0,,1.0592,,,171.1,64.2,119.615,178.593,15.0,286.0,2014-11-11,29
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,-10.0,0.69,0.69,NG/ML,0.22839,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,,124.49,15.0,213.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,0.0,0.83,0.83,NG/ML,0.27473,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,101.306,124.49,15.0,224.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,15.0,1.03,1.03,NG/ML,0.34093,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,124.49,124.49,15.0,246.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,30.0,1.26,1.26,NG/ML,0.41706,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,73.353,124.49,15.0,297.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,60.0,1.04,1.04,NG/ML,0.34424,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,68.171,124.49,15.0,313.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,90.0,1.09,1.09,NG/ML,0.36079,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,70.805,124.49,15.0,345.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,120.0,1.08,1.08,NG/ML,0.35748,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,72.692,124.49,15.0,336.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,150.0,1.17,1.17,NG/ML,0.38727,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,80.695,124.49,15.0,333.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,180.0,1.21,1.21,NG/ML,0.40051,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,82.733,124.49,15.0,325.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,210.0,1.35,1.35,NG/ML,0.44685,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,95.101,124.49,15.0,310.0,2014-11-11,30
T1DAL_620652,SUB168914,Week 104,ITN045AI-Rigby,P,2.0,2011-03-02,2011-03-17,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-03-17,2011-09-01,2011-11-17,Yes,,2013-03-14,728.0,Yes,,,2011-11-17,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-14,728.0,Week 104/Visit 30,2010-12-13,-94.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-14,728.0,23.947368421,C-PEPTIDE,240.0,1.38,1.38,NG/ML,0.45678,0.41706,0.92349,-0.50643,30.0,0.45678,1.0592,-0.60242,240.0,171.0,63.0,96.056,124.49,15.0,292.0,2014-11-11,30
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,-10.0,0.78,0.78,NG/ML,0.25818,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,,195.938,120.0,105.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,0.0,0.74,0.74,NG/ML,0.24494,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,62.114,195.938,120.0,101.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,15.0,0.74,0.74,NG/ML,0.24494,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,113.561,195.938,120.0,100.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,30.0,1.06,1.06,NG/ML,0.35086,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,190.438,195.938,120.0,124.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,60.0,1.62,1.62,NG/ML,0.53622,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,140.235,195.938,120.0,162.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,90.0,2.08,2.08,NG/ML,0.68848,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,176.966,195.938,120.0,165.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,120.0,2.4,2.4,NG/ML,0.7944,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,195.938,195.938,120.0,173.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,150.0,2.4,2.4,NG/ML,0.7944,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,184.408,195.938,120.0,150.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,180.0,2.53,2.53,NG/ML,0.83743,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,190.589,195.938,120.0,143.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,210.0,2.24,2.24,NG/ML,0.74144,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,158.989,195.938,120.0,124.0,2014-11-11,-1
T1DAL_640516,SUB168915,-1,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-12,-12.0,-0.394736842,C-PEPTIDE,240.0,2.03,2.03,NG/ML,0.67193,0.7944,0.7944,0.0,120.0,0.83743,0.83743,0.0,180.0,178.1,74.6,137.861,195.938,120.0,107.0,2014-11-11,-1
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,-10.0,1.33,1.33,NG/ML,0.44023,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,,266.569,30.0,126.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,0.0,1.4,1.4,NG/ML,0.4634,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,158.439,266.569,30.0,124.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,15.0,1.61,1.61,NG/ML,0.53291,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,248.175,266.569,30.0,134.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,30.0,2.25,2.25,NG/ML,0.74475,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,266.569,266.569,30.0,167.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,60.0,2.57,2.57,NG/ML,0.85067,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,210.438,266.569,30.0,184.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,90.0,2.76,2.76,NG/ML,0.91356,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,215.801,266.569,30.0,173.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 24,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-11-08,168.0,5.5263157895,C-PEPTIDE,120.0,3.15,3.15,NG/ML,1.04265,1.04265,0.7944,0.24825,120.0,,0.83743,,,177.3,74.5,246.011,266.569,30.0,186.0,2014-11-11,15
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,-10.0,0.97,0.97,NG/ML,0.32107,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,,262.162,30.0,114.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,0.0,0.93,0.93,NG/ML,0.30783,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,83.39,262.162,30.0,113.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,15.0,0.96,0.96,NG/ML,0.31776,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,147.753,262.162,30.0,114.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,30.0,1.37,1.37,NG/ML,0.45347,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,262.162,262.162,30.0,137.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,60.0,2.19,2.19,NG/ML,0.72489,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,190.812,262.162,30.0,170.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,90.0,2.62,2.62,NG/ML,0.86722,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,220.873,262.162,30.0,151.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,120.0,3.1,3.1,NG/ML,1.0261,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,251.744,262.162,30.0,151.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,150.0,3.19,3.19,NG/ML,1.05589,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,247.401,262.162,30.0,122.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,180.0,2.52,2.52,NG/ML,0.83412,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,170.081,262.162,30.0,104.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,210.0,2.14,2.14,NG/ML,0.70834,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,133.716,262.162,30.0,95.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 52,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-08,350.0,11.513157895,C-PEPTIDE,240.0,1.68,1.68,NG/ML,0.55608,1.0261,0.7944,0.2317,120.0,1.05589,0.83743,0.21846,150.0,178.1,74.8,99.916,262.162,30.0,87.0,2014-11-11,28
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,-10.0,1.3,1.3,NG/ML,0.4303,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,,286.723,30.0,114.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,0.0,1.41,1.41,NG/ML,0.46671,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,110.732,286.723,30.0,113.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,15.0,1.33,1.33,NG/ML,0.44023,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,172.869,286.723,30.0,113.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,30.0,1.73,1.73,NG/ML,0.57263,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,286.723,286.723,30.0,133.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,60.0,2.55,2.55,NG/ML,0.84405,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,213.673,286.723,30.0,158.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,90.0,2.53,2.53,NG/ML,0.83743,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,201.005,286.723,30.0,143.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 78,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-28,554.0,18.223684211,C-PEPTIDE,120.0,2.86,2.86,NG/ML,0.94666,0.94666,0.7944,0.15226,120.0,,0.83743,,,177.4,73.3,220.344,286.723,30.0,148.0,2014-11-11,29
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,-10.0,0.5,0.5,NG/ML,0.1655,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,,135.13,30.0,91.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,0.0,0.53,0.53,NG/ML,0.17543,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,58.886,135.13,30.0,91.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,15.0,0.59,0.59,NG/ML,0.19529,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,68.445,135.13,30.0,95.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,30.0,0.69,0.69,NG/ML,0.22839,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,135.13,135.13,30.0,102.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,60.0,1.15,1.15,NG/ML,0.38065,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,97.73,135.13,30.0,138.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,90.0,1.51,1.51,NG/ML,0.49981,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,128.284,135.13,30.0,146.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,120.0,1.53,1.53,NG/ML,0.50643,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,121.172,135.13,30.0,136.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,150.0,1.61,1.61,NG/ML,0.53291,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,119.839,135.13,30.0,121.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,180.0,1.69,1.69,NG/ML,0.55939,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,126.329,135.13,30.0,114.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,210.0,1.42,1.42,NG/ML,0.47002,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,97.206,135.13,30.0,102.0,2014-11-11,30
T1DAL_640516,SUB168915,Week 104,ITN045AI-Rigby,A,1.0,2011-05-12,2011-05-24,Yes,Yes,Yes,S/I,22.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-24,2011-11-08,2012-01-24,Yes,,2013-05-15,722.0,Yes,,,2012-01-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-15,722.0,Week 104/Visit 30,2011-02-16,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-15,722.0,23.75,C-PEPTIDE,240.0,1.34,1.34,NG/ML,0.44354,0.50643,0.7944,-0.28797,120.0,0.55939,0.83743,-0.27804,180.0,177.7,73.5,88.645,135.13,30.0,97.0,2014-11-11,30
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,-10.0,0.92,0.92,NG/ML,0.30452,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,,197.454,120.0,109.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,0.0,0.9,0.9,NG/ML,0.2979,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,135.104,197.454,120.0,121.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,15.0,1.4,1.4,NG/ML,0.4634,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,193.359,197.454,120.0,156.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,30.0,1.98,1.98,NG/ML,0.65538,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,188.496,197.454,120.0,215.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,60.0,2.16,2.16,NG/ML,0.71496,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,149.637,197.454,120.0,259.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,90.0,2.44,2.44,NG/ML,0.80764,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,163.106,197.454,120.0,240.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,120.0,2.92,2.92,NG/ML,0.96652,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,197.454,197.454,120.0,225.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,150.0,2.58,2.58,NG/ML,0.85398,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,161.983,197.454,120.0,189.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,180.0,2.25,2.25,NG/ML,0.74475,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,129.592,197.454,120.0,147.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,210.0,2.07,2.07,NG/ML,0.68517,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,119.087,197.454,120.0,125.0,2014-11-11,-1
T1DAL_671942,SUB168916,-1,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-23,-13.0,-0.427631579,C-PEPTIDE,240.0,1.52,1.52,NG/ML,0.50312,0.96652,0.96652,0.0,120.0,0.96652,0.96652,0.0,120.0,156.1,55.3,78.763,197.454,120.0,92.0,2014-11-11,-1
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,-10.0,0.73,0.73,NG/ML,0.24163,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,,147.276,30.0,136.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,0.0,0.68,0.68,NG/ML,0.22508,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,72.561,147.276,30.0,134.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,15.0,0.84,0.84,NG/ML,0.27804,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,117.609,147.276,30.0,155.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,30.0,1.21,1.21,NG/ML,0.40051,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,147.276,147.276,30.0,221.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,60.0,1.54,1.54,NG/ML,0.50974,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,112.867,147.276,30.0,261.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,90.0,1.82,1.82,NG/ML,0.60242,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,129.704,147.276,30.0,288.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 24,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-19,167.0,5.4934210526,C-PEPTIDE,120.0,2.04,2.04,NG/ML,0.67524,0.67524,0.96652,-0.29128,120.0,,0.96652,,,158.3,58.9,141.69,147.276,30.0,266.0,2014-11-11,15
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,-10.0,1.33,1.33,NG/ML,0.44023,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,,176.915,15.0,163.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,0.0,1.26,1.26,NG/ML,0.41706,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,152.386,176.915,15.0,165.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,15.0,1.66,1.66,NG/ML,0.54946,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,176.915,176.915,15.0,182.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,30.0,1.95,1.95,NG/ML,0.64545,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,171.617,176.915,15.0,237.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,60.0,2.04,2.04,NG/ML,0.67524,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,141.507,176.915,15.0,261.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,90.0,2.16,2.16,NG/ML,0.71496,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,146.068,176.915,15.0,270.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,120.0,2.31,2.31,NG/ML,0.76461,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,156.119,176.915,15.0,272.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,150.0,2.2,2.2,NG/ML,0.7282,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,143.528,176.915,15.0,243.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,180.0,2.05,2.05,NG/ML,0.67855,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,128.707,176.915,15.0,227.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,210.0,1.7,1.7,NG/ML,0.5627,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,99.883,176.915,15.0,203.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 52,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-28,358.0,11.776315789,C-PEPTIDE,240.0,1.63,1.63,NG/ML,0.53953,0.76461,0.96652,-0.20191,120.0,0.76461,0.96652,-0.20191,120.0,159.7,60.8,98.011,176.915,15.0,181.0,2014-11-11,28
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,-10.0,1.06,1.06,NG/ML,0.35086,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,,145.427,30.0,196.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,0.0,1,1.0,NG/ML,0.331,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,101.807,145.427,30.0,192.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,15.0,1.17,1.17,NG/ML,0.38727,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,133.043,145.427,30.0,201.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,30.0,1.45,1.45,NG/ML,0.47995,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,145.427,145.427,30.0,258.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,60.0,1.63,1.63,NG/ML,0.53953,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,117.148,145.427,30.0,298.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,90.0,1.53,1.53,NG/ML,0.50643,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,103.583,145.427,30.0,303.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 78,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-17,531.0,17.467105263,C-PEPTIDE,120.0,1.54,1.54,NG/ML,0.50974,0.53953,0.96652,-0.42699,60.0,,0.96652,,,160.9,62.2,100.825,145.427,30.0,282.0,2014-11-11,29
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,-10.0,1.07,1.07,NG/ML,0.35417,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,,129.56,30.0,223.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,0.0,0.98,0.98,NG/ML,0.32438,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,88.937,129.56,30.0,227.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,15.0,1.09,1.09,NG/ML,0.36079,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,124.135,129.56,30.0,247.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,30.0,1.35,1.35,NG/ML,0.44685,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,129.56,129.56,30.0,299.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,60.0,1.49,1.49,NG/ML,0.49319,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,106.16,129.56,30.0,342.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,90.0,1.53,1.53,NG/ML,0.50643,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,106.625,129.56,30.0,377.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,120.0,1.53,1.53,NG/ML,0.50643,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,103.733,129.56,30.0,350.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,150.0,1.37,1.37,NG/ML,0.45347,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,86.181,129.56,30.0,314.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,180.0,1.1,1.1,NG/ML,0.3641,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,62.726,129.56,30.0,286.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,210.0,1.08,1.08,NG/ML,0.35748,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,66.765,129.56,30.0,258.0,2014-11-11,30
T1DAL_671942,SUB168916,Week 104,ITN045AI-Rigby,A,1.0,2011-03-23,2011-04-05,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,,Not Hispanic or Latino,2011-04-05,2011-09-19,2011-12-07,Yes,,2013-03-19,714.0,Yes,,,2011-12-07,246.0,Completed study,Completed study drug,Yes,Yes,2013-03-19,714.0,Week 104/Visit 30,2011-01-20,-75.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-19,714.0,23.486842105,C-PEPTIDE,240.0,0.99,0.99,NG/ML,0.32769,0.50643,0.96652,-0.46009,90.0,0.50643,0.96652,-0.46009,90.0,161.5,63.5,62.742,129.56,30.0,240.0,2014-11-11,30
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,0.0,1.12,1.12,NG/ML,0.37072,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,110.326,291.283,30.0,139.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,15.0,1.24,1.24,NG/ML,0.41044,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,165.738,291.283,30.0,149.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,30.0,1.64,1.64,NG/ML,0.54284,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,291.283,291.283,30.0,198.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,60.0,2.57,2.57,NG/ML,0.85067,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,211.162,291.283,30.0,249.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,90.0,2.29,2.29,NG/ML,0.75799,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,169.073,291.283,30.0,260.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,120.0,2.2,2.2,NG/ML,0.7282,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,146.944,291.283,30.0,229.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,150.0,2.3,2.3,NG/ML,0.7613,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,158.036,291.283,30.0,211.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,180.0,2.19,2.19,NG/ML,0.72489,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,148.076,291.283,30.0,188.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,210.0,1.9,1.9,NG/ML,0.6289,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,119.806,291.283,30.0,166.0,2014-11-11,-1
T1DAL_681972,SUB168917,-1,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-18,-15.0,-0.493421053,C-PEPTIDE,240.0,1.8,1.8,NG/ML,0.5958,0.85067,0.85067,0.0,60.0,0.85067,0.85067,0.0,60.0,173.0,72.1,114.023,291.283,30.0,150.0,2014-11-11,-1
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,-10.0,0.63,0.63,NG/ML,0.20853,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,,154.185,120.0,126.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,0.0,0.62,0.62,NG/ML,0.20522,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,93.279,154.185,120.0,,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,15.0,0.97,0.97,NG/ML,0.32107,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,98.92,154.185,120.0,150.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,30.0,1.41,1.41,NG/ML,0.46671,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,102.334,154.185,120.0,225.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,60.0,1.69,1.69,NG/ML,0.55939,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,132.672,154.185,120.0,271.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,90.0,1.68,1.68,NG/ML,0.55608,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,121.069,154.185,120.0,276.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 24,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-20,168.0,5.5263157895,C-PEPTIDE,120.0,2.09,2.09,NG/ML,0.69179,0.69179,0.85067,-0.15888,120.0,,0.85067,,,173.0,69.7,154.185,154.185,120.0,267.0,2014-11-11,15
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,-10.0,0.56,0.56,NG/ML,0.18536,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,,102.334,30.0,124.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,0.0,0.51,0.51,NG/ML,0.16881,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,93.279,102.334,30.0,124.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,15.0,0.84,0.84,NG/ML,0.27804,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,98.92,102.334,30.0,183.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,30.0,0.97,0.97,NG/ML,0.32107,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,102.334,102.334,30.0,198.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,60.0,1.07,1.07,NG/ML,0.35417,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,80.427,102.334,30.0,277.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,90.0,1.1,1.1,NG/ML,0.3641,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,78.988,102.334,30.0,275.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,120.0,1.27,1.27,NG/ML,0.42037,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,92.859,102.334,30.0,231.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,150.0,1.29,1.29,NG/ML,0.42699,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,92.331,102.334,30.0,253.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,180.0,1.33,1.33,NG/ML,0.44023,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,93.193,102.334,30.0,232.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,210.0,1.22,1.22,NG/ML,0.40382,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,81.237,102.334,30.0,214.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 52,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-01,364.0,11.973684211,C-PEPTIDE,240.0,1.25,1.25,NG/ML,0.41375,0.42037,0.85067,-0.4303,120.0,0.44023,0.85067,-0.41044,180.0,173.0,72.6,84.26,102.334,30.0,192.0,2014-11-11,28
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,-10.0,0.25,0.25,NG/ML,0.08275,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,,165.354,30.0,120.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,0.0,0.24,0.24,NG/ML,0.07944,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,44.445,165.354,30.0,115.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,15.0,0.38,0.38,NG/ML,0.12578,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,60.931,165.354,30.0,144.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,30.0,0.54,0.54,NG/ML,0.17874,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,165.354,165.354,30.0,192.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,60.0,1.26,1.26,NG/ML,0.41706,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,111.627,165.354,30.0,305.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,90.0,1.3,1.3,NG/ML,0.4303,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,105.222,165.354,30.0,277.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 78,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-08-13,558.0,18.355263158,C-PEPTIDE,120.0,1.42,1.42,NG/ML,0.47002,0.47002,0.85067,-0.38065,120.0,,0.85067,,,173.0,73.2,104.829,165.354,30.0,257.0,2014-11-11,29
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,-10.0,0.47,0.47,NG/ML,0.15557,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,,190.458,30.0,137.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,0.0,0.49,0.49,NG/ML,0.16219,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,54.508,190.458,30.0,134.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,15.0,0.58,0.58,NG/ML,0.19198,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,87.92,190.458,30.0,156.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,30.0,0.82,0.82,NG/ML,0.27142,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,190.458,190.458,30.0,181.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,60.0,1.53,1.53,NG/ML,0.50643,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,132.838,190.458,30.0,279.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,90.0,1.84,1.84,NG/ML,0.60904,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,151.647,190.458,30.0,293.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,120.0,2.36,2.36,NG/ML,0.78116,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,186.962,190.458,30.0,289.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,150.0,2.4,2.4,NG/ML,0.7944,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,177.843,190.458,30.0,270.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,180.0,2,2.0,NG/ML,0.662,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,129.372,190.458,30.0,240.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,210.0,1.96,1.96,NG/ML,0.64876,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,127.179,190.458,30.0,215.0,2014-11-11,30
T1DAL_681972,SUB168917,Week 104,ITN045AI-Rigby,A,1.0,2011-01-18,2011-02-02,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-02-02,2011-07-20,2011-10-05,Yes,,2013-01-22,720.0,Yes,,,2011-10-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-01-22,720.0,Week 104/Visit 30,2010-10-29,-96.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-01-22,720.0,23.684210526,C-PEPTIDE,240.0,1.9,1.9,NG/ML,0.6289,0.78116,0.85067,-0.06951,120.0,0.7944,0.85067,-0.05627,150.0,173.0,75.0,127.035,190.458,30.0,197.0,2014-11-11,30
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,-10.0,1.97,1.97,NG/ML,0.65207,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,,372.259,15.0,69.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,0.0,1.86,1.86,NG/ML,0.61566,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,270.84,372.259,15.0,70.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,15.0,2.38,2.38,NG/ML,0.78778,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,372.259,372.259,15.0,91.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,30.0,3.1,3.1,NG/ML,1.0261,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,278.846,372.259,15.0,136.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,60.0,2.83,2.83,NG/ML,0.93673,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,243.229,372.259,15.0,136.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,90.0,3.01,3.01,NG/ML,0.99631,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,250.752,372.259,15.0,138.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,120.0,2.77,2.77,NG/ML,0.91687,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,224.0,372.259,15.0,147.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,150.0,2.42,2.42,NG/ML,0.80102,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,184.514,372.259,15.0,130.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,180.0,2.47,2.47,NG/ML,0.81757,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,196.037,372.259,15.0,120.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,210.0,2.11,2.11,NG/ML,0.69841,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,162.231,372.259,15.0,111.0,2014-11-11,-1
T1DAL_684595,SUB168918,-1,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-12-16,-14.0,-0.460526316,C-PEPTIDE,240.0,2.13,2.13,NG/ML,0.70503,1.0261,1.0261,0.0,30.0,1.0261,1.0261,0.0,30.0,177.3,97.3,167.823,372.259,15.0,106.0,2014-11-11,-1
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,-10.0,1.05,1.05,NG/ML,0.34755,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,,184.324,30.0,121.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,0.0,1.01,1.01,NG/ML,0.33431,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,143.507,184.324,30.0,125.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,15.0,1.26,1.26,NG/ML,0.41706,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,160.573,184.324,30.0,155.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,30.0,1.43,1.43,NG/ML,0.47333,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,184.324,184.324,30.0,205.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,60.0,1.64,1.64,NG/ML,0.54284,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,147.513,184.324,30.0,254.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,90.0,1.67,1.67,NG/ML,0.55277,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,144.94,184.324,30.0,232.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 24,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-06-17,170.0,5.5921052632,C-PEPTIDE,120.0,1.81,1.81,NG/ML,0.59911,0.59911,1.0261,-0.42699,120.0,,1.0261,,,176.4,101.7,155.979,184.324,30.0,211.0,2014-11-11,15
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,-10.0,1.15,1.15,NG/ML,0.38065,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,,365.618,30.0,112.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,0.0,1.14,1.14,NG/ML,0.37734,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,220.362,365.618,30.0,109.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,15.0,1.68,1.68,NG/ML,0.55608,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,319.239,365.618,30.0,159.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,30.0,2.37,2.37,NG/ML,0.78447,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,365.618,365.618,30.0,206.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,60.0,2.87,2.87,NG/ML,0.94997,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,281.208,365.618,30.0,212.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,90.0,2.78,2.78,NG/ML,0.92018,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,251.905,365.618,30.0,158.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,120.0,2.71,2.71,NG/ML,0.89701,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,232.716,365.618,30.0,150.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,150.0,2.23,2.23,NG/ML,0.73813,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,176.387,365.618,30.0,127.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,180.0,1.92,1.92,NG/ML,0.63552,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,145.248,365.618,30.0,104.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,210.0,1.36,1.36,NG/ML,0.45016,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,91.073,365.618,30.0,76.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 52,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-12-20,356.0,11.710526316,C-PEPTIDE,240.0,1.02,1.02,NG/ML,0.33762,0.94997,1.0261,-0.07613,60.0,0.94997,1.0261,-0.07613,60.0,177.2,112.0,63.299,365.618,30.0,70.0,2014-11-11,28
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,-10.0,1.28,1.28,NG/ML,0.42368,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,,284.338,90.0,105.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,0.0,1.25,1.25,NG/ML,0.41375,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,231.569,284.338,90.0,110.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,15.0,1.81,1.81,NG/ML,0.59911,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,217.501,284.338,90.0,133.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,30.0,1.9,1.9,NG/ML,0.6289,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,277.516,284.338,90.0,164.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,60.0,2.34,2.34,NG/ML,0.77454,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,215.987,284.338,90.0,216.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,90.0,2.98,2.98,NG/ML,0.98638,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,284.338,284.338,90.0,186.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 78,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-07-06,554.0,18.223684211,C-PEPTIDE,120.0,3.02,3.02,NG/ML,0.99962,0.99962,1.0261,-0.02648,120.0,,1.0261,,,177.5,108.3,274.122,284.338,90.0,141.0,2014-11-11,29
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,-10.0,1.28,1.28,NG/ML,0.42368,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,,384.591,30.0,99.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,0.0,1.11,1.11,NG/ML,0.36741,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,266.524,384.591,30.0,117.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,15.0,1.92,1.92,NG/ML,0.63552,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,334.169,384.591,30.0,126.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,30.0,2.51,2.51,NG/ML,0.83081,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,384.591,384.591,30.0,168.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,60.0,3.03,3.03,NG/ML,1.00293,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,295.824,384.591,30.0,198.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,90.0,3.17,3.17,NG/ML,1.04927,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,295.423,384.591,30.0,186.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,120.0,3,3.0,NG/ML,0.993,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,260.861,384.591,30.0,162.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,150.0,3.52,3.52,NG/ML,1.16512,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,321.069,384.591,30.0,146.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,180.0,3.2,3.2,NG/ML,1.0592,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,279.357,384.591,30.0,123.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,210.0,2.46,2.46,NG/ML,0.81426,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,184.374,384.591,30.0,106.0,2014-11-11,30
T1DAL_684595,SUB168918,Week 104,ITN045AI-Rigby,A,1.0,2011-12-16,2011-12-30,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,White,Not Hispanic or Latino,2012-01-02,2012-06-17,2012-09-02,Yes,,2013-12-19,720.0,Yes,,,2012-09-02,247.0,Completed study,Completed study drug,Yes,Yes,2013-12-19,720.0,Week 104/Visit 30,2011-10-11,-80.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-12-19,720.0,23.684210526,C-PEPTIDE,240.0,2.04,2.04,NG/ML,0.67524,1.04927,1.0261,0.02317,90.0,1.16512,1.0261,0.13902,150.0,177.8,114.8,148.372,384.591,30.0,90.0,2014-11-11,30
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,-10.0,1.19,1.19,NG/ML,0.39389,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,,284.489,30.0,133.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,0.0,1.14,1.14,NG/ML,0.37734,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,138.93,284.489,30.0,133.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,15.0,1.47,1.47,NG/ML,0.48657,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,155.375,284.489,30.0,143.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,30.0,1.68,1.68,NG/ML,0.55608,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,284.489,284.489,30.0,179.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,60.0,2.66,2.66,NG/ML,0.88046,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,208.105,284.489,30.0,225.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,90.0,3.04,3.04,NG/ML,1.00624,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,232.153,284.489,30.0,230.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,120.0,3.01,3.01,NG/ML,0.99631,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,213.045,284.489,30.0,221.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,150.0,3.26,3.26,NG/ML,1.07906,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,227.844,284.489,30.0,212.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,180.0,2.79,2.79,NG/ML,0.92349,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,182.115,284.489,30.0,198.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,210.0,3,3.0,NG/ML,0.993,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,200.572,284.489,30.0,181.0,2014-11-11,-1
T1DAL_700663,SUB168919,-1,ITN045AI-Rigby,A,1.0,2011-06-06,2011-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,Asian,Hispanic or Latino,2011-07-03,,2011-09-21,No,Failure to Return/Lost to Follow-Up,2012-09-18,443.0,No,Other,Other,2011-09-21,80.0,Terminated study early,Discontinued study drug early,Yes,No,2012-09-18,443.0,Week 15/Visit 12,2011-03-31,-94.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-06,-27.0,-0.888157895,C-PEPTIDE,240.0,1.64,1.64,NG/ML,0.54284,1.00624,1.00624,0.0,90.0,1.07906,1.07906,0.0,150.0,159.5,67.9,80.991,284.489,30.0,155.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,-10.0,2.01,2.01,NG/ML,0.66531,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,,818.788,30.0,97.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,0.0,2.41,2.41,NG/ML,0.79771,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,344.794,818.788,30.0,99.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,15.0,2.76,2.76,NG/ML,0.91356,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,546.343,818.788,30.0,105.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,30.0,3.97,3.97,NG/ML,1.31407,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,818.788,818.788,30.0,137.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,60.0,5.76,5.76,NG/ML,1.90656,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,605.429,818.788,30.0,162.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,90.0,7.17,7.17,NG/ML,2.37327,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,735.677,818.788,30.0,159.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,120.0,7.6,7.6,NG/ML,2.5156,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,738.239,818.788,30.0,136.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,150.0,4.51,4.51,NG/ML,1.49281,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,326.796,818.788,30.0,112.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,180.0,5.07,5.07,NG/ML,1.67817,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,406.215,818.788,30.0,94.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,210.0,3.58,3.58,NG/ML,1.18498,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,272.502,818.788,30.0,77.0,2014-11-11,-1
T1DAL_707887,SUB168920,-1,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2010-11-13,-33.0,-1.085526316,C-PEPTIDE,240.0,3.18,3.18,NG/ML,1.05258,2.5156,2.5156,0.0,120.0,2.5156,2.5156,0.0,120.0,186.8,114.2,238.313,818.788,30.0,75.0,2014-11-11,-1
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,-10.0,1.77,1.77,NG/ML,0.58587,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,,884.337,30.0,81.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,0.0,1.87,1.87,NG/ML,0.61897,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,434.993,884.337,30.0,82.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,15.0,3.1,3.1,NG/ML,1.0261,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,839.185,884.337,30.0,99.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,30.0,5.63,5.63,NG/ML,1.86353,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,884.337,884.337,30.0,127.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,60.0,6.7,6.7,NG/ML,2.2177,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,673.998,884.337,30.0,126.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,90.0,6.67,6.67,NG/ML,2.20777,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,611.388,884.337,30.0,102.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 24,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-06-03,169.0,5.5592105263,C-PEPTIDE,120.0,4.32,4.32,NG/ML,1.42992,2.2177,2.5156,-0.2979,60.0,,2.5156,,,187.7,102.4,308.047,884.337,30.0,88.0,2014-11-11,15
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,-10.0,2.43,2.43,NG/ML,0.80433,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,,1103.558,30.0,91.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,0.0,2.3,2.3,NG/ML,0.7613,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,723.013,1103.558,30.0,102.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,15.0,4.81,4.81,NG/ML,1.59211,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,725.678,1103.558,30.0,134.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,30.0,5.54,5.54,NG/ML,1.83374,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,1103.558,1103.558,30.0,167.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,60.0,8.05,8.05,NG/ML,2.66455,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,805.692,1103.558,30.0,172.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,90.0,7.01,7.01,NG/ML,2.32031,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,637.094,1103.558,30.0,139.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,120.0,6.2,6.2,NG/ML,2.0522,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,501.705,1103.558,30.0,108.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,150.0,4.78,4.78,NG/ML,1.58218,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,349.095,1103.558,30.0,92.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,180.0,3.96,3.96,NG/ML,1.31076,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,280.708,1103.558,30.0,84.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,210.0,2.38,2.38,NG/ML,0.78778,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,130.421,1103.558,30.0,74.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 52,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2011-12-23,372.0,12.236842105,C-PEPTIDE,240.0,2.6,2.6,NG/ML,0.8606,2.66455,2.5156,0.14895,60.0,2.66455,2.5156,0.14895,60.0,188.1,104.1,190.384,1103.558,30.0,76.0,2014-11-11,28
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,-10.0,3.24,3.24,NG/ML,1.07244,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,,6422.537,0.0,114.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,0.0,2.86,2.86,NG/ML,0.94666,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,6422.537,6422.537,0.0,109.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,15.0,4.77,4.77,NG/ML,1.57887,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,669.904,6422.537,0.0,142.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,30.0,5.45,5.45,NG/ML,1.80395,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,1074.128,6422.537,0.0,166.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,60.0,8.01,8.01,NG/ML,2.65131,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,789.244,6422.537,0.0,188.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,90.0,6.29,6.29,NG/ML,2.08199,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,546.921,6422.537,0.0,152.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 78,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-06-24,556.0,18.289473684,C-PEPTIDE,120.0,6.82,6.82,NG/ML,2.25742,2.65131,2.5156,0.13571,60.0,,2.5156,,,188.4,100.6,575.925,6422.537,0.0,106.0,2014-11-11,29
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,-10.0,3.38,3.38,NG/ML,1.11878,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,,701.406,0.0,189.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,0.0,2.89,2.89,NG/ML,0.95659,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,701.406,701.406,0.0,186.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,15.0,5.03,5.03,NG/ML,1.66493,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,627.723,701.406,0.0,202.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,30.0,5.2,5.2,NG/ML,1.7212,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,545.936,701.406,0.0,243.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,60.0,5.08,5.08,NG/ML,1.68148,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,459.215,701.406,0.0,286.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,90.0,4.66,4.66,NG/ML,1.54246,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,396.202,701.406,0.0,301.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,120.0,3.84,3.84,NG/ML,1.27104,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,301.534,701.406,0.0,276.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,150.0,3.7,3.7,NG/ML,1.2247,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,298.067,701.406,0.0,263.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,180.0,3.53,3.53,NG/ML,1.16843,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,297.508,701.406,0.0,240.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,210.0,3.63,3.63,NG/ML,1.20153,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,315.984,701.406,0.0,227.0,2014-11-11,30
T1DAL_707887,SUB168920,Week 104,ITN045AI-Rigby,A,1.0,2010-11-04,2010-12-16,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Male,White,,Hispanic or Latino,2010-12-16,,2011-08-19,Yes,,2012-12-27,742.0,Yes,,,2011-08-19,246.0,Completed study,Completed study drug,Yes,Yes,2012-12-27,742.0,Week 104/Visit 30,2010-09-16,-91.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2012-12-27,742.0,24.407894737,C-PEPTIDE,240.0,3.58,3.58,NG/ML,1.18498,1.7212,2.5156,-0.7944,30.0,1.7212,2.5156,-0.7944,30.0,188.5,109.2,312.041,701.406,0.0,214.0,2014-11-11,30
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,-10.0,0.53,0.53,NG/ML,0.17543,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,,180.814,30.0,96.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,0.0,0.56,0.56,NG/ML,0.18536,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,50.669,180.814,30.0,96.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,15.0,0.62,0.62,NG/ML,0.20522,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,109.096,180.814,30.0,113.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,30.0,1.07,1.07,NG/ML,0.35417,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,180.814,180.814,30.0,180.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,60.0,1.72,1.72,NG/ML,0.56932,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,130.078,180.814,30.0,235.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,90.0,1.93,1.93,NG/ML,0.63883,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,137.357,180.814,30.0,236.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,120.0,2.22,2.22,NG/ML,0.73482,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,150.89,180.814,30.0,242.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,150.0,2.03,2.03,NG/ML,0.67193,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,127.758,180.814,30.0,224.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,180.0,2.03,2.03,NG/ML,0.67193,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,124.166,180.814,30.0,210.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,210.0,1.97,1.97,NG/ML,0.65207,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,120.409,180.814,30.0,194.0,2014-11-11,-1
T1DAL_765619,SUB168921,-1,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-07-09,-29.0,-0.953947368,C-PEPTIDE,240.0,1.96,1.96,NG/ML,0.64876,0.73482,0.73482,0.0,120.0,0.73482,0.73482,0.0,120.0,153.0,54.6,120.265,180.814,30.0,177.0,2014-11-11,-1
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,-10.0,0.36,0.36,NG/ML,0.11916,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,,81.658,30.0,116.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,0.0,0.39,0.39,NG/ML,0.12909,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,41.662,81.658,30.0,116.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,15.0,0.47,0.47,NG/ML,0.15557,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,58.346,81.658,30.0,147.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,30.0,0.62,0.62,NG/ML,0.20522,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,81.658,81.658,30.0,202.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,60.0,0.84,0.84,NG/ML,0.27804,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,61.177,81.658,30.0,261.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,90.0,1,1.0,NG/ML,0.331,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,71.077,81.658,30.0,303.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 24,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-01-23,169.0,5.5592105263,C-PEPTIDE,120.0,1.11,1.11,NG/ML,0.36741,0.36741,0.73482,-0.36741,120.0,,0.73482,,,,59.1,76.05,81.658,30.0,308.0,2014-11-11,15
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,-10.0,0.62,0.62,NG/ML,0.20522,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,,79.981,30.0,177.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,0.0,0.6,0.6,NG/ML,0.1986,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,58.181,79.981,30.0,182.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,15.0,0.7,0.7,NG/ML,0.2317,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,78.88,79.981,30.0,195.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,30.0,0.88,0.88,NG/ML,0.29128,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,79.981,79.981,30.0,241.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,60.0,0.95,0.95,NG/ML,0.31445,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,64.92,79.981,30.0,281.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,90.0,0.93,0.93,NG/ML,0.30783,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,59.784,79.981,30.0,298.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,120.0,0.97,0.97,NG/ML,0.32107,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,61.803,79.981,30.0,308.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,150.0,1.09,1.09,NG/ML,0.36079,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,71.819,79.981,30.0,319.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,180.0,0.99,0.99,NG/ML,0.32769,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,61.788,79.981,30.0,317.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,210.0,0.98,0.98,NG/ML,0.32438,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,59.907,79.981,30.0,290.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 52,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-06,365.0,12.006578947,C-PEPTIDE,240.0,0.96,0.96,NG/ML,0.31776,0.32107,0.73482,-0.41375,120.0,0.36079,0.73482,-0.37403,150.0,153.0,58.3,59.181,79.981,30.0,277.0,2014-11-11,28
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,-10.0,0.52,0.52,NG/ML,0.17212,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,,52.94,15.0,214.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,0.0,0.57,0.57,NG/ML,0.18867,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,35.623,52.94,15.0,202.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,15.0,0.52,0.52,NG/ML,0.17212,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,52.94,52.94,15.0,191.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,30.0,0.62,0.62,NG/ML,0.20522,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,52.886,52.94,15.0,198.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,60.0,0.65,0.65,NG/ML,0.21515,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,44.371,52.94,15.0,191.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,90.0,0.66,0.66,NG/ML,0.21846,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,42.452,52.94,15.0,175.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 78,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-02-11,554.0,18.223684211,C-PEPTIDE,120.0,0.63,0.63,NG/ML,0.20853,0.21846,0.73482,-0.51636,90.0,,0.73482,,,,58.1,39.057,52.94,15.0,171.0,2014-11-11,29
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,-10.0,0.28,0.28,NG/ML,0.09268,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,,54.497,30.0,166.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,0.0,0.27,0.27,NG/ML,0.08937,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,24.414,54.497,30.0,166.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,15.0,0.31,0.31,NG/ML,0.10261,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,43.922,54.497,30.0,171.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,30.0,0.45,0.45,NG/ML,0.14895,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,54.497,54.497,30.0,214.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,60.0,0.56,0.56,NG/ML,0.18536,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,41.551,54.497,30.0,290.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,90.0,0.63,0.63,NG/ML,0.20853,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,43.718,54.497,30.0,323.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,120.0,0.59,0.59,NG/ML,0.19529,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,38.587,54.497,30.0,339.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,150.0,0.58,0.58,NG/ML,0.19198,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,34.915,54.497,30.0,339.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,180.0,0.59,0.59,NG/ML,0.19529,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,37.85,54.497,30.0,342.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,210.0,0.62,0.62,NG/ML,0.20522,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,40.676,54.497,30.0,323.0,2014-11-11,30
T1DAL_765619,SUB168921,Week 104,ITN045AI-Rigby,A,1.0,2011-07-09,2011-08-07,Yes,Yes,Yes,S/I,24.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-08-08,2012-01-23,2012-04-10,Yes,,2013-08-05,729.0,Yes,,,2012-04-10,247.0,Completed study,Completed study drug,Yes,Yes,2013-08-05,729.0,Week 104/Visit 30,2011-06-03,-65.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-08-05,729.0,23.980263158,C-PEPTIDE,240.0,0.58,0.58,NG/ML,0.19198,0.20853,0.73482,-0.52629,90.0,0.20853,0.73482,-0.52629,90.0,153.0,58.1,34.938,54.497,30.0,301.0,2014-11-11,30
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,-10.0,0.77,0.77,NG/ML,0.25487,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,,480.516,30.0,105.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,0.0,0.81,0.81,NG/ML,0.26811,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,172.334,480.516,30.0,106.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,15.0,1.57,1.57,NG/ML,0.51967,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,329.758,480.516,30.0,130.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,30.0,2.93,2.93,NG/ML,0.96983,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,480.516,480.516,30.0,183.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,60.0,4.47,4.47,NG/ML,1.47957,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,345.896,480.516,30.0,208.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,90.0,4.4,4.4,NG/ML,1.4564,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,310.359,480.516,30.0,168.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,120.0,5.21,5.21,NG/ML,1.72451,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,356.747,480.516,30.0,152.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,150.0,4.18,4.18,NG/ML,1.38358,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,258.489,480.516,30.0,108.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,180.0,3.36,3.36,NG/ML,1.11216,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,182.801,480.516,30.0,84.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,210.0,2.53,2.53,NG/ML,0.83743,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,126.763,480.516,30.0,66.0,2014-11-11,-1
T1DAL_769151,SUB168922,-1,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-08,-19.0,-0.625,C-PEPTIDE,240.0,2.23,2.23,NG/ML,0.73813,1.72451,1.72451,0.0,120.0,1.72451,1.72451,0.0,120.0,162.5,50.6,118.684,480.516,30.0,58.0,2014-11-11,-1
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,-10.0,1.35,1.35,NG/ML,0.44685,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,,368482.0,15.0,109.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,0.0,1.41,1.41,NG/ML,0.46671,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,149.828,368482.0,15.0,110.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,15.0,1.69,1.69,NG/ML,0.55939,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,368482.0,368482.0,15.0,113.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,30.0,3.35,3.35,NG/ML,1.10885,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,425.053,368482.0,15.0,168.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,60.0,4.23,4.23,NG/ML,1.40013,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,321.831,368482.0,15.0,182.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,90.0,4.63,4.63,NG/ML,1.53253,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,328.464,368482.0,15.0,186.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 24,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-15,170.0,5.5921052632,C-PEPTIDE,120.0,4.04,4.04,NG/ML,1.33724,1.53253,1.72451,-0.19198,90.0,,1.72451,,,163.2,52.6,258.342,368482.0,15.0,168.0,2014-11-11,15
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,-10.0,1.41,1.41,NG/ML,0.46671,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,,615.674,30.0,109.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,0.0,1.31,1.31,NG/ML,0.43361,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,194.554,615.674,30.0,109.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,15.0,1.99,1.99,NG/ML,0.65869,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,348.407,615.674,30.0,127.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,30.0,3.28,3.28,NG/ML,1.08568,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,615.674,615.674,30.0,173.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,60.0,5.61,5.61,NG/ML,1.85691,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,437.57,615.674,30.0,206.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,90.0,5.19,5.19,NG/ML,1.71789,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,367.329,615.674,30.0,179.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,120.0,4.16,4.16,NG/ML,1.37696,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,246.331,615.674,30.0,134.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,150.0,4.37,4.37,NG/ML,1.44647,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,268.868,615.674,30.0,123.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,180.0,3.59,3.59,NG/ML,1.18829,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,212.483,615.674,30.0,106.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,210.0,2.94,2.94,NG/ML,0.97314,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,161.007,615.674,30.0,84.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 52,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-10-14,352.0,11.578947368,C-PEPTIDE,240.0,2.47,2.47,NG/ML,0.81757,1.85691,1.72451,0.1324,60.0,1.85691,1.72451,0.1324,60.0,162.8,52.5,134.261,615.674,30.0,64.0,2014-11-11,28
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,-10.0,2.03,2.03,NG/ML,0.67193,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,,571.645,30.0,127.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,0.0,1.98,1.98,NG/ML,0.65538,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,274.908,571.645,30.0,121.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,15.0,2.84,2.84,NG/ML,0.94004,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,527.332,571.645,30.0,142.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,30.0,4.89,4.89,NG/ML,1.61859,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,571.645,571.645,30.0,180.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,60.0,5.86,5.86,NG/ML,1.93966,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,438.112,571.645,30.0,182.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,90.0,5.6,5.6,NG/ML,1.8536,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,378.317,571.645,30.0,139.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 78,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-22,543.0,17.861842105,C-PEPTIDE,120.0,4.69,4.69,NG/ML,1.55239,1.93966,1.72451,0.21515,60.0,,1.72451,,,163.0,53.4,281.877,571.645,30.0,115.0,2014-11-11,29
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,-10.0,1.24,1.24,NG/ML,0.41044,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,,483.441,30.0,105.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,0.0,1.26,1.26,NG/ML,0.41706,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,182.935,483.441,30.0,99.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,15.0,1.84,1.84,NG/ML,0.60904,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,366.151,483.441,30.0,114.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,30.0,3.33,3.33,NG/ML,1.10223,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,483.441,483.441,30.0,168.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,60.0,4.62,4.62,NG/ML,1.52922,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,356.118,483.441,30.0,196.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,90.0,4.96,4.96,NG/ML,1.64176,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,355.177,483.441,30.0,151.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,120.0,5.97,5.97,NG/ML,1.97607,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,421.35,483.441,30.0,139.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,150.0,3.98,3.98,NG/ML,1.31738,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,230.914,483.441,30.0,106.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,180.0,3.7,3.7,NG/ML,1.2247,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,201.873,483.441,30.0,90.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,210.0,3.03,3.03,NG/ML,1.00293,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,168.06,483.441,30.0,77.0,2014-11-11,30
T1DAL_769151,SUB168922,Week 104,ITN045AI-Rigby,A,1.0,2010-10-08,2010-10-27,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-10-28,2011-04-15,2011-06-30,Yes,,2012-10-19,723.0,Yes,,,2011-06-30,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-19,723.0,Week 104/Visit 30,2010-09-10,-47.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-19,723.0,23.782894737,C-PEPTIDE,240.0,1.93,1.93,NG/ML,0.63883,1.97607,1.72451,0.25156,120.0,1.97607,1.72451,0.25156,120.0,162.8,54.9,85.946,483.441,30.0,63.0,2014-11-11,30
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,-10.0,1.08,1.08,NG/ML,0.35748,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,,227.239,30.0,95.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,0.0,1.28,1.28,NG/ML,0.42368,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,128.856,227.239,30.0,101.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,15.0,1.49,1.49,NG/ML,0.49319,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,162.408,227.239,30.0,94.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,30.0,1.84,1.84,NG/ML,0.60904,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,227.239,227.239,30.0,123.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,60.0,2.46,2.46,NG/ML,0.81426,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,172.534,227.239,30.0,113.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,90.0,2.61,2.61,NG/ML,0.86391,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,175.851,227.239,30.0,84.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,120.0,2.53,2.53,NG/ML,0.83743,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,159.63,227.239,30.0,90.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,150.0,2.38,2.38,NG/ML,0.78778,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,143.897,227.239,30.0,75.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,180.0,2.2,2.2,NG/ML,0.7282,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,129.947,227.239,30.0,61.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,210.0,2.5,2.5,NG/ML,0.8275,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,157.738,227.239,30.0,62.0,2014-11-11,-1
T1DAL_773800,SUB168923,-1,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-19,-19.0,-0.625,C-PEPTIDE,240.0,1.84,1.84,NG/ML,0.60904,0.86391,0.86391,0.0,90.0,0.86391,0.86391,0.0,90.0,161.1,41.6,103.78,227.239,30.0,56.0,2014-11-11,-1
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,-10.0,2.52,2.52,NG/ML,0.83412,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,,310.625,15.0,116.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,0.0,2.57,2.57,NG/ML,0.85067,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,219.907,310.625,15.0,116.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,15.0,2.79,2.79,NG/ML,0.92349,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,310.625,310.625,15.0,116.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,30.0,3.56,3.56,NG/ML,1.17836,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,298.239,310.625,15.0,146.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,60.0,3.71,3.71,NG/ML,1.22801,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,247.949,310.625,15.0,133.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,90.0,3.88,3.88,NG/ML,1.28428,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,250.265,310.625,15.0,132.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 24,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,167.0,5.4934210526,C-PEPTIDE,120.0,4.3,4.3,NG/ML,1.4233,1.4233,0.86391,0.55939,120.0,,0.86391,,,160.4,43.0,280.098,310.625,15.0,125.0,2014-11-11,15
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,-10.0,1.92,1.92,NG/ML,0.63552,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,,293.996,30.0,86.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,0.0,1.91,1.91,NG/ML,0.63221,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,183.663,293.996,30.0,85.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,15.0,2.23,2.23,NG/ML,0.73813,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,248.497,293.996,30.0,94.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,30.0,2.82,2.82,NG/ML,0.93342,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,293.996,293.996,30.0,122.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,60.0,3.36,3.36,NG/ML,1.11216,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,231.497,293.996,30.0,135.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,90.0,3.78,3.78,NG/ML,1.25118,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,254.561,293.996,30.0,135.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,120.0,4.24,4.24,NG/ML,1.40344,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,281.995,293.996,30.0,134.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,150.0,4.15,4.15,NG/ML,1.37365,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,264.777,293.996,30.0,98.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,180.0,3.89,3.89,NG/ML,1.28759,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,236.418,293.996,30.0,87.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,210.0,3.52,3.52,NG/ML,1.16512,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,206.541,293.996,30.0,72.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 52,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-28,356.0,11.710526316,C-PEPTIDE,240.0,2.92,2.92,NG/ML,0.96652,1.40344,0.86391,0.53953,120.0,1.40344,0.86391,0.53953,120.0,161.3,43.0,161.638,293.996,30.0,59.0,2014-11-11,28
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,-10.0,0.91,0.91,NG/ML,0.30121,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,,184.939,30.0,119.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,0.0,0.84,0.84,NG/ML,0.27804,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,123.772,184.939,30.0,115.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,15.0,1.29,1.29,NG/ML,0.42699,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,167.766,184.939,30.0,130.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,30.0,1.76,1.76,NG/ML,0.58256,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,184.939,184.939,30.0,150.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,60.0,2.05,2.05,NG/ML,0.67855,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,143.913,184.939,30.0,173.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,90.0,2.13,2.13,NG/ML,0.70503,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,142.548,184.939,30.0,180.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 78,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-28,539.0,17.730263158,C-PEPTIDE,120.0,2.41,2.41,NG/ML,0.79771,0.79771,0.86391,-0.0662,120.0,,0.86391,,,162.2,43.8,159.556,184.939,30.0,148.0,2014-11-11,29
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,-10.0,1.28,1.28,NG/ML,0.42368,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,,197.513,15.0,141.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,0.0,1.3,1.3,NG/ML,0.4303,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,137.323,197.513,15.0,135.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,15.0,1.59,1.59,NG/ML,0.52629,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,197.513,197.513,15.0,146.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,30.0,2.13,2.13,NG/ML,0.70503,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,172.405,197.513,15.0,173.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,60.0,2.15,2.15,NG/ML,0.71165,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,143.661,197.513,15.0,186.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,90.0,2.51,2.51,NG/ML,0.83081,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,165.948,197.513,15.0,196.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,120.0,2.61,2.61,NG/ML,0.86391,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,169.595,197.513,15.0,175.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,150.0,2.62,2.62,NG/ML,0.86722,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,166.729,197.513,15.0,160.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,180.0,2.5,2.5,NG/ML,0.8275,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,154.222,197.513,15.0,139.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,210.0,2.27,2.27,NG/ML,0.75137,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,133.813,197.513,15.0,117.0,2014-11-11,30
T1DAL_773800,SUB168923,Week 104,ITN045AI-Rigby,A,1.0,2011-04-19,2011-05-08,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Female,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2012-01-08,Yes,,2013-05-05,728.0,Yes,,,2012-01-08,245.0,Completed study,Completed study drug,Yes,Yes,2013-05-05,728.0,Week 104/Visit 30,2011-02-01,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-05,728.0,23.947368421,C-PEPTIDE,240.0,2.19,2.19,NG/ML,0.72489,0.86391,0.86391,0.0,120.0,0.86722,0.86391,0.00331,150.0,162.3,43.6,128.949,197.513,15.0,97.0,2014-11-11,30
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,-10.0,0.88,0.88,NG/ML,0.29128,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,,129.041,30.0,67.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,0.0,0.76,0.76,NG/ML,0.25156,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,43.997,129.041,30.0,75.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,15.0,0.66,0.66,NG/ML,0.21846,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,88.338,129.041,30.0,62.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,30.0,0.9,0.9,NG/ML,0.2979,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,129.041,129.041,30.0,104.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,60.0,1.2,1.2,NG/ML,0.3972,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,100.066,129.041,30.0,164.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,90.0,1.3,1.3,NG/ML,0.4303,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,104.582,129.041,30.0,177.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,120.0,1.41,1.41,NG/ML,0.46671,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,109.675,129.041,30.0,168.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,150.0,1.36,1.36,NG/ML,0.45016,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,101.316,129.041,30.0,148.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,180.0,1.3,1.3,NG/ML,0.4303,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,93.522,129.041,30.0,122.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,210.0,0.88,0.88,NG/ML,0.29128,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,52.457,129.041,30.0,104.0,2014-11-11,-1
T1DAL_794352,SUB168924,-1,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Screening,-1.0,1000,2010-10-27,-21.0,-0.690789474,C-PEPTIDE,240.0,0.92,0.92,NG/ML,0.30452,0.46671,0.46671,0.0,120.0,0.46671,0.46671,0.0,120.0,181.0,70.4,60.378,129.041,30.0,88.0,2014-11-11,-1
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,-10.0,1.29,1.29,NG/ML,0.42699,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,,202.781,15.0,156.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,0.0,1.28,1.28,NG/ML,0.42368,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,152.604,202.781,15.0,155.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,15.0,1.54,1.54,NG/ML,0.50974,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,202.781,202.781,15.0,194.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,30.0,1.94,1.94,NG/ML,0.64214,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,191.19,202.781,15.0,247.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,60.0,2.01,2.01,NG/ML,0.66531,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,157.988,202.781,15.0,312.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,90.0,2.15,2.15,NG/ML,0.71165,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,163.988,202.781,15.0,331.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 24,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 24,15.0,2015,2011-05-03,167.0,5.4934210526,C-PEPTIDE,120.0,2.11,2.11,NG/ML,0.69841,0.71165,0.46671,0.24494,90.0,,0.46671,,,181.0,69.4,156.386,202.781,15.0,307.0,2014-11-11,15
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,-10.0,1.61,1.61,NG/ML,0.53291,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,,178.544,30.0,102.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,0.0,1.68,1.68,NG/ML,0.55608,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,140.822,178.544,30.0,106.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,15.0,1.64,1.64,NG/ML,0.54284,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,170.428,178.544,30.0,118.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,30.0,1.84,1.84,NG/ML,0.60904,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,178.544,178.544,30.0,135.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,60.0,1.95,1.95,NG/ML,0.64545,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,150.391,178.544,30.0,195.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,90.0,1.86,1.86,NG/ML,0.61566,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,136.989,178.544,30.0,183.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,120.0,1.77,1.77,NG/ML,0.58587,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,126.26,178.544,30.0,186.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,150.0,1.69,1.69,NG/ML,0.55939,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,119.744,178.544,30.0,202.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,180.0,1.66,1.66,NG/ML,0.54946,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,118.845,178.544,30.0,199.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,210.0,1.49,1.49,NG/ML,0.49319,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,103.665,178.544,30.0,187.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 52,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 52,28.0,2028,2011-11-22,370.0,12.171052632,C-PEPTIDE,240.0,1.48,1.48,NG/ML,0.48988,0.64545,0.46671,0.17874,60.0,0.64545,0.46671,0.17874,60.0,181.0,70.7,104.687,178.544,30.0,174.0,2014-11-11,28
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,-10.0,0.5,0.5,NG/ML,0.1655,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,,123.233,30.0,206.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,0.0,0.5,0.5,NG/ML,0.1655,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,69.273,123.233,30.0,212.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,15.0,0.67,0.67,NG/ML,0.22177,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,71.26,123.233,30.0,225.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,30.0,0.72,0.72,NG/ML,0.23832,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,123.233,123.233,30.0,321.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,60.0,1.1,1.1,NG/ML,0.3641,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,91.059,123.233,30.0,406.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,90.0,0.89,0.89,NG/ML,0.29459,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,65.768,123.233,30.0,399.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 78,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 78,29.0,2029,2012-05-23,553.0,18.190789474,C-PEPTIDE,120.0,0.85,0.85,NG/ML,0.28135,0.3641,0.46671,-0.10261,60.0,,0.46671,,,181.0,70.1,58.605,123.233,30.0,370.0,2014-11-11,29
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,-10.0,0.25,0.25,NG/ML,0.08275,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,,93.315,120.0,96.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,0.0,0.22,0.22,NG/ML,0.07282,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,35.849,93.315,120.0,96.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,15.0,0.33,0.33,NG/ML,0.10923,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,45.853,93.315,120.0,99.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,30.0,0.43,0.43,NG/ML,0.14233,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,93.231,93.315,120.0,125.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,60.0,0.76,0.76,NG/ML,0.25156,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,66.114,93.315,120.0,225.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,90.0,1.06,1.06,NG/ML,0.35086,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,91.86,93.315,120.0,255.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,120.0,1.15,1.15,NG/ML,0.38065,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,93.315,93.315,120.0,214.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,150.0,1.08,1.08,NG/ML,0.35748,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,80.999,93.315,120.0,165.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,180.0,0.9,0.9,NG/ML,0.2979,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,60.854,93.315,120.0,119.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,210.0,0.75,0.75,NG/ML,0.24825,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,47.512,93.315,120.0,90.0,2014-11-11,30
T1DAL_794352,SUB168924,Week 104,ITN045AI-Rigby,A,1.0,2010-10-11,2010-11-17,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,White,Not Hispanic or Latino,2010-11-17,2011-05-03,2011-07-12,Yes,,2012-11-14,728.0,No,Other AE, Specify,Other AE,2011-07-12,237.0,Completed study,Discontinued study drug early,Yes,No,2012-11-14,728.0,Week 104/Visit 30,2010-10-03,-45.0,7,No,Yes,Yes,Week 104,30.0,2030,2012-11-14,728.0,23.947368421,C-PEPTIDE,240.0,0.48,0.48,NG/ML,0.15888,0.38065,0.46671,-0.08606,120.0,0.38065,0.46671,-0.08606,120.0,181.0,70.4,24.386,93.315,120.0,65.0,2014-11-11,30
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,-10.0,0.99,0.99,NG/ML,0.32769,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,,259.768,30.0,148.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,0.0,0.95,0.95,NG/ML,0.31445,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,122.312,259.768,30.0,153.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,15.0,1.28,1.28,NG/ML,0.42368,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,179.043,259.768,30.0,161.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,30.0,1.77,1.77,NG/ML,0.58587,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,259.768,259.768,30.0,212.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,60.0,,,NG/ML,,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,193.073,259.768,30.0,255.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,90.0,2.5,2.5,NG/ML,0.8275,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,152.759,259.768,30.0,282.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,120.0,2.19,2.19,NG/ML,0.72489,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,127.247,259.768,30.0,264.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,150.0,2.01,2.01,NG/ML,0.66531,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,109.343,259.768,30.0,245.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,180.0,1.78,1.78,NG/ML,0.58918,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,106.351,259.768,30.0,217.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,210.0,1.7,1.7,NG/ML,0.5627,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,107.798,259.768,30.0,193.0,2014-11-11,-1
T1DAL_794749,SUB168925,-1,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-08-30,-19.0,-0.625,C-PEPTIDE,240.0,1.67,1.67,NG/ML,0.55277,0.8275,0.8275,0.0,90.0,0.8275,0.8275,0.0,90.0,162.3,61.6,,259.768,30.0,175.0,2014-11-11,-1
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,-10.0,0.76,0.76,NG/ML,0.25156,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,,186.85,30.0,121.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,0.0,0.73,0.73,NG/ML,0.24163,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,101.08,186.85,30.0,113.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,15.0,1.03,1.03,NG/ML,0.34093,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,149.087,186.85,30.0,136.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,30.0,1.45,1.45,NG/ML,0.47995,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,186.85,186.85,30.0,200.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,60.0,1.86,1.86,NG/ML,0.61566,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,141.841,186.85,30.0,268.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,90.0,1.99,1.99,NG/ML,0.65869,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,144.109,186.85,30.0,278.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 24,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-03-05,168.0,5.5263157895,C-PEPTIDE,120.0,1.96,1.96,NG/ML,0.64876,0.65869,0.8275,-0.16881,90.0,,0.8275,,,162.2,61.9,133.689,186.85,30.0,252.0,2014-11-11,15
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,-10.0,1.26,1.26,NG/ML,0.41706,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,,133.442,30.0,156.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,0.0,1.26,1.26,NG/ML,0.41706,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,129.275,133.442,30.0,166.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,15.0,1.47,1.47,NG/ML,0.48657,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,133.279,133.442,30.0,164.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,30.0,1.57,1.57,NG/ML,0.51967,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,133.442,133.442,30.0,183.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,60.0,1.63,1.63,NG/ML,0.53953,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,112.234,133.442,30.0,236.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,90.0,1.74,1.74,NG/ML,0.57594,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,119.16,133.442,30.0,284.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,120.0,1.57,1.57,NG/ML,0.51967,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,101.903,133.442,30.0,287.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,150.0,1.42,1.42,NG/ML,0.47002,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,87.84,133.442,30.0,279.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,180.0,1.31,1.31,NG/ML,0.43361,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,80.828,133.442,30.0,264.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,210.0,1.32,1.32,NG/ML,0.43692,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,84.82,133.442,30.0,252.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 52,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-09-16,363.0,11.940789474,C-PEPTIDE,240.0,1.44,1.44,NG/ML,0.47664,0.57594,0.8275,-0.25156,90.0,0.57594,0.8275,-0.25156,90.0,163.4,60.2,97.463,133.442,30.0,245.0,2014-11-11,28
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,-10.0,0.73,0.73,NG/ML,0.24163,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,,136.583,30.0,114.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,0.0,0.78,0.78,NG/ML,0.25818,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,76.451,136.583,30.0,121.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,15.0,0.89,0.89,NG/ML,0.29459,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,122.489,136.583,30.0,145.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,30.0,1.24,1.24,NG/ML,0.41044,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,136.583,136.583,30.0,240.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,60.0,1.44,1.44,NG/ML,0.47664,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,107.313,136.583,30.0,313.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,90.0,1.52,1.52,NG/ML,0.50312,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,105.872,136.583,30.0,341.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 78,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-03-10,539.0,17.730263158,C-PEPTIDE,120.0,1.69,1.69,NG/ML,0.55939,0.55939,0.8275,-0.26811,120.0,,0.8275,,,162.9,59.4,117.639,136.583,30.0,338.0,2014-11-11,29
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,-10.0,0.41,0.41,NG/ML,0.13571,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,,127.005,120.0,123.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,0.0,0.41,0.41,NG/ML,0.13571,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,23.64,127.005,120.0,126.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,15.0,0.37,0.37,NG/ML,0.12247,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,69.009,127.005,120.0,155.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,30.0,0.65,0.65,NG/ML,0.21515,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,106.373,127.005,120.0,187.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,60.0,0.99,0.99,NG/ML,0.32769,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,78.509,127.005,120.0,256.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,90.0,1.34,1.34,NG/ML,0.44354,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,102.067,127.005,120.0,285.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,120.0,1.68,1.68,NG/ML,0.55608,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,127.005,127.005,120.0,290.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,150.0,1.69,1.69,NG/ML,0.55939,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,119.058,127.005,120.0,277.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,180.0,1.57,1.57,NG/ML,0.51967,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,102.22,127.005,120.0,256.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,210.0,1.35,1.35,NG/ML,0.44685,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,82.774,127.005,120.0,236.0,2014-11-11,30
T1DAL_794749,SUB168925,Week 104,ITN045AI-Rigby,A,1.0,2010-08-29,2010-09-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2010-09-18,2011-03-05,2011-05-21,Yes,,2012-09-08,721.0,Yes,,,2011-05-21,245.0,Completed study,Completed study drug,Yes,Yes,2012-09-08,721.0,Week 104/Visit 30,2010-06-13,-97.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-09-08,721.0,23.717105263,C-PEPTIDE,240.0,1.32,1.32,NG/ML,0.43692,0.55608,0.8275,-0.27142,120.0,0.55939,0.8275,-0.26811,150.0,163.3,60.3,82.761,127.005,120.0,207.0,2014-11-11,30
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,-10.0,2.18,2.18,NG/ML,0.72158,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,,754.705,30.0,114.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,0.0,2.22,2.22,NG/ML,0.73482,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,356.561,754.705,30.0,112.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,15.0,2.8,2.8,NG/ML,0.9268,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,633.153,754.705,30.0,120.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,30.0,4.4,4.4,NG/ML,1.4564,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,754.705,754.705,30.0,152.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,60.0,5.52,5.52,NG/ML,1.82712,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,576.427,754.705,30.0,154.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,90.0,6.26,6.26,NG/ML,2.07206,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,624.711,754.705,30.0,157.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,120.0,5.05,5.05,NG/ML,1.67155,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,443.822,754.705,30.0,130.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,150.0,4.26,4.26,NG/ML,1.41006,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,338.678,754.705,30.0,117.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,180.0,3.61,3.61,NG/ML,1.19491,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,283.494,754.705,30.0,104.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,210.0,3.27,3.27,NG/ML,1.08237,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,265.474,754.705,30.0,90.0,2014-11-11,-1
T1DAL_796202,SUB168926,-1,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-06-13,-20.0,-0.657894737,C-PEPTIDE,240.0,2.71,2.71,NG/ML,0.89701,2.07206,2.07206,0.0,90.0,2.07206,2.07206,0.0,90.0,180.9,122.4,215.626,754.705,30.0,,2014-11-11,-1
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,-10.0,2.67,2.67,NG/ML,0.88377,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,,356.484,15.0,250.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,0.0,2.58,2.58,NG/ML,0.85398,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,340.972,356.484,15.0,254.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,15.0,3.32,3.32,NG/ML,1.09892,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,356.484,356.484,15.0,277.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,30.0,3.64,3.64,NG/ML,1.20484,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,319.351,356.484,15.0,310.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,60.0,3.59,3.59,NG/ML,1.18829,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,272.507,356.484,15.0,344.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,90.0,3.33,3.33,NG/ML,1.10223,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,238.899,356.484,15.0,362.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 24,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2010-12-17,167.0,5.4934210526,C-PEPTIDE,120.0,3.14,3.14,NG/ML,1.03934,1.20484,2.07206,-0.86722,30.0,,2.07206,,,181.3,126.6,220.832,356.484,15.0,364.0,2014-11-11,15
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,-10.0,1.98,1.98,NG/ML,0.65538,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,,379.048,30.0,152.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,0.0,1.95,1.95,NG/ML,0.64545,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,273.113,379.048,30.0,157.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,15.0,2.69,2.69,NG/ML,0.89039,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,349.134,379.048,30.0,174.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,30.0,3.42,3.42,NG/ML,1.13202,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,379.048,379.048,30.0,227.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,60.0,3.91,3.91,NG/ML,1.29421,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,299.21,379.048,30.0,269.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,90.0,3.94,3.94,NG/ML,1.30414,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,285.421,379.048,30.0,285.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,120.0,3.28,3.28,NG/ML,1.08568,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,213.966,379.048,30.0,270.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,150.0,3.12,3.12,NG/ML,1.03272,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,200.861,379.048,30.0,253.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,180.0,3.26,3.26,NG/ML,1.07906,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,223.465,379.048,30.0,231.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,210.0,3.28,3.28,NG/ML,1.08568,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,228.47,379.048,30.0,221.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 52,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-07-10,372.0,12.236842105,C-PEPTIDE,240.0,3.29,3.29,NG/ML,1.08899,1.30414,2.07206,-0.76792,90.0,1.30414,2.07206,-0.76792,90.0,181.0,119.6,228.252,379.048,30.0,214.0,2014-11-11,28
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,-10.0,1.65,1.65,NG/ML,0.54615,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,,299.861,30.0,182.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,0.0,1.47,1.47,NG/ML,0.48657,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,253.456,299.861,30.0,182.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,15.0,2.03,2.03,NG/ML,0.67193,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,272.23,299.861,30.0,218.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,30.0,2.26,2.26,NG/ML,0.74806,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,299.861,299.861,30.0,245.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,60.0,2.54,2.54,NG/ML,0.84074,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,241.181,299.861,30.0,291.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,90.0,2.61,2.61,NG/ML,0.86391,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,238.931,299.861,30.0,315.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 78,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-01-01,547.0,17.993421053,C-PEPTIDE,120.0,2.67,2.67,NG/ML,0.88377,0.88377,2.07206,-1.18829,120.0,,2.07206,,,184.3,115.8,239.257,299.861,30.0,307.0,2014-11-11,29
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,-10.0,0.6,0.6,NG/ML,0.1986,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,,140.994,30.0,254.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,0.0,0.58,0.58,NG/ML,0.19198,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,115.489,140.994,30.0,258.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,15.0,0.89,0.89,NG/ML,0.29459,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,134.141,140.994,30.0,291.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,30.0,1.07,1.07,NG/ML,0.35417,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,140.994,140.994,30.0,338.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,60.0,1.19,1.19,NG/ML,0.39389,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,112.13,140.994,30.0,381.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,90.0,1.25,1.25,NG/ML,0.41375,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,113.547,140.994,30.0,403.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,120.0,1.4,1.4,NG/ML,0.4634,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,127.682,140.994,30.0,391.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,150.0,1.29,1.29,NG/ML,0.42699,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,113.987,140.994,30.0,374.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,180.0,1.35,1.35,NG/ML,0.44685,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,118.86,140.994,30.0,362.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,210.0,1.37,1.37,NG/ML,0.45347,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,119.254,140.994,30.0,349.0,2014-11-11,30
T1DAL_796202,SUB168926,Week 104,ITN045AI-Rigby,A,1.0,2010-06-13,2010-07-03,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Male,White,,Not Hispanic or Latino,2010-07-03,2010-12-17,2011-03-04,Yes,,2012-07-03,731.0,Yes,,,2011-03-04,244.0,Completed study,Completed study drug,Yes,Yes,2012-07-03,731.0,Week 104/Visit 30,2010-03-27,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-07-03,731.0,24.046052632,C-PEPTIDE,240.0,1.4,1.4,NG/ML,0.4634,0.4634,2.07206,-1.60866,120.0,0.4634,2.07206,-1.60866,120.0,181.0,111.7,121.962,140.994,30.0,336.0,2014-11-11,30
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,-10.0,0.37,0.37,NG/ML,0.12247,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,,151.825,180.0,128.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,0.0,0.35,0.35,NG/ML,0.11585,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,43.787,151.825,180.0,124.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,15.0,0.47,0.47,NG/ML,0.15557,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,83.659,151.825,180.0,137.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,30.0,0.78,0.78,NG/ML,0.25818,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,131.722,151.825,180.0,169.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,60.0,1.21,1.21,NG/ML,0.40051,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,94.546,151.825,180.0,232.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,90.0,1.72,1.72,NG/ML,0.56932,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,131.986,151.825,180.0,256.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,120.0,1.9,1.9,NG/ML,0.6289,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,136.951,151.825,180.0,256.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,150.0,2.12,2.12,NG/ML,0.70172,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,146.44,151.825,180.0,229.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,180.0,2.25,2.25,NG/ML,0.74475,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,151.825,151.825,180.0,219.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,210.0,2.25,2.25,NG/ML,0.74475,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,146.667,151.825,180.0,190.0,2014-11-11,-1
T1DAL_799347,SUB168927,-1,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-10,-14.0,-0.460526316,C-PEPTIDE,240.0,2.01,2.01,NG/ML,0.66531,0.6289,0.6289,0.0,120.0,0.74475,0.74475,0.0,180.0,169.0,60.1,122.367,151.825,180.0,171.0,2014-11-11,-1
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,-10.0,0.82,0.82,NG/ML,0.27142,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,,327.801,30.0,130.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,0.0,0.79,0.79,NG/ML,0.26149,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,114.736,327.801,30.0,125.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,15.0,1.16,1.16,NG/ML,0.38396,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,248.586,327.801,30.0,139.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,30.0,2.19,2.19,NG/ML,0.72489,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,327.801,327.801,30.0,174.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,60.0,3.06,3.06,NG/ML,1.01286,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,238.859,327.801,30.0,236.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,90.0,3.45,3.45,NG/ML,1.14195,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,250.879,327.801,30.0,255.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 24,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-08,168.0,5.5263157895,C-PEPTIDE,120.0,4.07,4.07,NG/ML,1.34717,1.34717,0.6289,0.71827,120.0,,0.74475,,,168.0,61.5,287.563,327.801,30.0,224.0,2014-11-11,15
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,-10.0,1.2,1.2,NG/ML,0.3972,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,,326.336,120.0,132.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,0.0,1.18,1.18,NG/ML,0.39058,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,153.144,326.336,120.0,129.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,15.0,1.6,1.6,NG/ML,0.5296,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,236.669,326.336,120.0,162.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,30.0,2.3,2.3,NG/ML,0.7613,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,285.451,326.336,120.0,203.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,60.0,2.88,2.88,NG/ML,0.95328,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,215.515,326.336,120.0,240.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,90.0,3.79,3.79,NG/ML,1.25449,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,281.25,326.336,120.0,245.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,120.0,4.49,4.49,NG/ML,1.48619,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,326.336,326.336,120.0,242.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,150.0,3.62,3.62,NG/ML,1.19822,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,226.376,326.336,120.0,216.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,180.0,3.27,3.27,NG/ML,1.08237,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,188.053,326.336,120.0,193.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,210.0,3.24,3.24,NG/ML,1.07244,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,197.48,326.336,120.0,180.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 52,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-29,371.0,12.203947368,C-PEPTIDE,240.0,2.92,2.92,NG/ML,0.96652,1.48619,0.6289,0.85729,120.0,1.48619,0.74475,0.74144,120.0,168.0,64.0,175.874,326.336,120.0,160.0,2014-11-11,28
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,-10.0,1.03,1.03,NG/ML,0.34093,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,,361.113,30.0,142.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,0.0,1.07,1.07,NG/ML,0.35417,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,99.994,361.113,30.0,140.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,15.0,1.19,1.19,NG/ML,0.39389,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,187.462,361.113,30.0,156.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,30.0,1.81,1.81,NG/ML,0.59911,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,361.113,361.113,30.0,190.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,60.0,3.16,3.16,NG/ML,1.04596,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,255.298,361.113,30.0,260.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,90.0,3.69,3.69,NG/ML,1.22139,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,281.292,361.113,30.0,275.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 78,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-20,546.0,17.960526316,C-PEPTIDE,120.0,3.99,3.99,NG/ML,1.32069,1.32069,0.6289,0.69179,120.0,,0.74475,,,169.0,67.2,282.842,361.113,30.0,250.0,2014-11-11,29
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,-10.0,0.69,0.69,NG/ML,0.22839,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,,273.023,30.0,123.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,0.0,0.7,0.7,NG/ML,0.2317,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,76.711,273.023,30.0,121.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,15.0,0.85,0.85,NG/ML,0.28135,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,149.977,273.023,30.0,139.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,30.0,1.38,1.38,NG/ML,0.45678,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,273.023,273.023,30.0,196.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,60.0,2.4,2.4,NG/ML,0.7944,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,192.689,273.023,30.0,236.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,90.0,3.29,3.29,NG/ML,1.08899,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,258.858,273.023,30.0,254.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,120.0,3.26,3.26,NG/ML,1.07906,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,232.153,273.023,30.0,236.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,150.0,3.19,3.19,NG/ML,1.05589,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,209.894,273.023,30.0,220.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,180.0,3.38,3.38,NG/ML,1.11878,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,223.567,273.023,30.0,204.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,210.0,3.01,3.01,NG/ML,0.99631,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,188.926,273.023,30.0,184.0,2014-11-11,30
T1DAL_799347,SUB168927,Week 104,ITN045AI-Rigby,A,1.0,2011-02-03,2011-03-24,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Female,White,White,Not Hispanic or Latino,2011-03-24,2011-09-08,2011-11-24,Yes,,2013-03-21,728.0,Yes,,,2011-11-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-03-21,728.0,Unscheduled Visit,2010-12-16,-98.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-21,728.0,23.947368421,C-PEPTIDE,240.0,2.64,2.64,NG/ML,0.87384,1.08899,0.6289,0.46009,90.0,1.11878,0.74475,0.37403,180.0,169.0,67.4,153.259,273.023,30.0,150.0,2014-11-11,30
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,-10.0,0.87,0.87,NG/ML,0.28797,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,,221.663,15.0,96.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,0.0,0.83,0.83,NG/ML,0.27473,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,83.762,221.663,15.0,96.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,15.0,0.91,0.91,NG/ML,0.30121,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,221.663,221.663,15.0,106.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,30.0,1.8,1.8,NG/ML,0.5958,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,200.742,221.663,15.0,147.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,60.0,1.91,1.91,NG/ML,0.63221,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,161.269,221.663,15.0,193.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,90.0,1.99,1.99,NG/ML,0.65869,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,155.125,221.663,15.0,165.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,120.0,1.83,1.83,NG/ML,0.60573,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,134.226,221.663,15.0,161.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,150.0,2.08,2.08,NG/ML,0.68848,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,157.94,221.663,15.0,147.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,180.0,2.08,2.08,NG/ML,0.68848,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,158.089,221.663,15.0,125.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,210.0,1.86,1.86,NG/ML,0.61566,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,133.101,221.663,15.0,79.0,2014-11-11,-1
T1DAL_799634,SUB168928,-1,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-08-16,-19.0,-0.625,C-PEPTIDE,240.0,1.14,1.14,NG/ML,0.37734,0.65869,0.65869,0.0,90.0,0.68848,0.68848,0.0,150.0,183.3,67.9,62.517,221.663,15.0,101.0,2014-11-11,-1
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,-10.0,1.36,1.36,NG/ML,0.45016,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,,262.552,15.0,140.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,0.0,1.38,1.38,NG/ML,0.45678,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,238.13,262.552,15.0,143.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,15.0,2.04,2.04,NG/ML,0.67524,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,262.552,262.552,15.0,178.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,30.0,2.39,2.39,NG/ML,0.79109,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,201.16,262.552,15.0,236.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,60.0,2.2,2.2,NG/ML,0.7282,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,173.874,262.552,15.0,296.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,90.0,2.19,2.19,NG/ML,0.72489,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,165.816,262.552,15.0,316.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 24,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2012-02-26,175.0,5.7565789474,C-PEPTIDE,120.0,2.07,2.07,NG/ML,0.68517,0.79109,0.65869,0.1324,30.0,,0.68848,,,187.3,72.1,154.567,262.552,15.0,305.0,2014-11-11,15
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,-10.0,1.02,1.02,NG/ML,0.33762,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,,192.625,15.0,181.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,0.0,0.97,0.97,NG/ML,0.32107,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,187.048,192.625,15.0,184.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,15.0,1.52,1.52,NG/ML,0.50312,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,192.625,192.625,15.0,224.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,30.0,1.71,1.71,NG/ML,0.56601,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,175.382,192.625,15.0,290.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,60.0,1.73,1.73,NG/ML,0.57263,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,145.296,192.625,15.0,333.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,90.0,1.42,1.42,NG/ML,0.47002,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,106.531,192.625,15.0,363.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,120.0,1.31,1.31,NG/ML,0.43361,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,95.535,192.625,15.0,360.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,150.0,1.19,1.19,NG/ML,0.39389,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,88.0,192.625,15.0,339.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,180.0,1.19,1.19,NG/ML,0.39389,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,91.577,192.625,15.0,329.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,210.0,1.07,1.07,NG/ML,0.35417,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,81.21,192.625,15.0,324.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 52,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-08-27,358.0,11.776315789,C-PEPTIDE,240.0,1.01,1.01,NG/ML,0.33431,0.57263,0.65869,-0.08606,60.0,0.57263,0.68848,-0.11585,60.0,187.1,80.8,76.22,192.625,15.0,314.0,2014-11-11,28
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,-10.0,0.18,0.18,NG/ML,0.05958,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,,53.374,30.0,99.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,0.0,0.24,0.24,NG/ML,0.07944,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,31.199,53.374,30.0,106.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,15.0,0.26,0.26,NG/ML,0.08606,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,28.096,53.374,30.0,121.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,30.0,0.28,0.28,NG/ML,0.09268,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,53.374,53.374,30.0,169.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,60.0,0.41,0.41,NG/ML,0.13571,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,39.355,53.374,30.0,279.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,90.0,0.45,0.45,NG/ML,0.14895,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,41.172,53.374,30.0,301.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 78,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2013-03-11,554.0,18.223684211,C-PEPTIDE,120.0,0.44,0.44,NG/ML,0.14564,0.14895,0.65869,-0.50974,90.0,,0.68848,,,189.7,86.0,38.43,53.374,30.0,299.0,2014-11-11,29
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,-10.0,0.27,0.27,NG/ML,0.08937,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,,37.966,15.0,202.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,0.0,0.23,0.23,NG/ML,0.07613,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,29.1,37.966,15.0,187.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,15.0,0.28,0.28,NG/ML,0.09268,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,37.966,37.966,15.0,191.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,30.0,0.33,0.33,NG/ML,0.10923,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,34.265,37.966,15.0,229.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,60.0,0.34,0.34,NG/ML,0.11254,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,29.046,37.966,15.0,283.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,90.0,0.32,0.32,NG/ML,0.10592,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,27.822,37.966,15.0,305.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,120.0,0.31,0.31,NG/ML,0.10261,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,24.189,37.966,15.0,292.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,150.0,0.38,0.38,NG/ML,0.12578,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,34.454,37.966,15.0,295.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,180.0,0.36,0.36,NG/ML,0.11916,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,30.864,37.966,15.0,292.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,210.0,0.39,0.39,NG/ML,0.12909,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,33.093,37.966,15.0,292.0,2014-11-11,30
T1DAL_799634,SUB168928,Week 104,ITN045AI-Rigby,P,2.0,2011-08-16,2011-09-04,Yes,Yes,Yes,S/I,14.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-09-12,2012-02-26,2012-05-14,Yes,,2013-09-07,734.0,Yes,,,2012-05-14,253.0,Completed study,Completed study drug,Yes,Yes,2013-09-07,734.0,Week 104/Visit 30,2011-07-16,-50.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-09-07,734.0,24.144736842,C-PEPTIDE,240.0,0.41,0.41,NG/ML,0.13571,0.11254,0.65869,-0.54615,60.0,0.13571,0.68848,-0.55277,240.0,190.4,87.8,36.411,37.966,15.0,277.0,2014-11-11,30
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,-10.0,0.72,0.72,NG/ML,0.23832,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,,514.943,30.0,99.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,0.0,0.7,0.7,NG/ML,0.2317,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,112.87,514.943,30.0,97.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,15.0,1.09,1.09,NG/ML,0.36079,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,257.082,514.943,30.0,102.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,30.0,2.2,2.2,NG/ML,0.7282,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,514.943,514.943,30.0,124.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,60.0,4.32,4.32,NG/ML,1.42992,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,357.823,514.943,30.0,144.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,90.0,4.02,4.02,NG/ML,1.33062,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,301.114,514.943,30.0,125.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,120.0,3.23,3.23,NG/ML,1.06913,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,200.457,514.943,30.0,91.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,150.0,2.11,2.11,NG/ML,0.69841,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,101.805,514.943,30.0,97.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,180.0,1.53,1.53,NG/ML,0.50643,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,66.576,514.943,30.0,92.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,210.0,1.32,1.32,NG/ML,0.43692,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,68.337,514.943,30.0,107.0,2014-11-11,-1
T1DAL_817864,SUB168929,-1,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-28,-17.0,-0.559210526,C-PEPTIDE,240.0,0.85,0.85,NG/ML,0.28135,1.42992,1.42992,0.0,60.0,1.42992,1.42992,0.0,60.0,158.9,66.3,38.827,514.943,30.0,88.0,2014-11-11,-1
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,-10.0,0.44,0.44,NG/ML,0.14564,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,,424.974,15.0,86.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,0.0,0.42,0.42,NG/ML,0.13902,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,177.693,424.974,15.0,84.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,15.0,1.39,1.39,NG/ML,0.46009,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,424.974,424.974,15.0,93.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,30.0,3.38,3.38,NG/ML,1.11878,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,224.223,424.974,15.0,115.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,60.0,2.63,2.63,NG/ML,0.87053,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,194.328,424.974,15.0,106.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,90.0,3.69,3.69,NG/ML,1.22139,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,264.324,424.974,15.0,129.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 24,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-29,167.0,5.4934210526,C-PEPTIDE,120.0,4.15,4.15,NG/ML,1.37365,1.37365,1.42992,-0.05627,120.0,,1.42992,,,159.4,65.2,301.962,424.974,15.0,120.0,2014-11-11,15
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,-10.0,0.38,0.38,NG/ML,0.12578,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,,382.783,30.0,89.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,0.0,0.42,0.42,NG/ML,0.13902,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,149.371,382.783,30.0,91.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,15.0,1.17,1.17,NG/ML,0.38727,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,194.641,382.783,30.0,116.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,30.0,1.7,1.7,NG/ML,0.5627,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,382.783,382.783,30.0,136.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,60.0,3.22,3.22,NG/ML,1.06582,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,265.413,382.783,30.0,177.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,90.0,3.67,3.67,NG/ML,1.21477,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,286.466,382.783,30.0,171.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,120.0,3.76,3.76,NG/ML,1.24456,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,269.091,382.783,30.0,155.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,150.0,3.36,3.36,NG/ML,1.11216,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,221.03,382.783,30.0,128.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,180.0,2.3,2.3,NG/ML,0.7613,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,123.498,382.783,30.0,104.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,210.0,1.45,1.45,NG/ML,0.47995,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,57.638,382.783,30.0,96.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 52,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-05-27,378.0,12.434210526,C-PEPTIDE,240.0,1.09,1.09,NG/ML,0.36079,1.24456,1.42992,-0.18536,120.0,1.24456,1.42992,-0.18536,120.0,162.0,66.6,45.692,382.783,30.0,89.0,2014-11-11,28
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,-10.0,1.22,1.22,NG/ML,0.40382,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,,313.635,30.0,135.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,0.0,1.12,1.12,NG/ML,0.37072,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,128.654,313.635,30.0,135.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,15.0,1.42,1.42,NG/ML,0.47002,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,235.61,313.635,30.0,150.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,30.0,2.23,2.23,NG/ML,0.73813,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,313.635,313.635,30.0,193.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,60.0,3.01,3.01,NG/ML,0.99631,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,235.023,313.635,30.0,218.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,90.0,3.48,3.48,NG/ML,1.15188,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,258.508,313.635,30.0,214.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 78,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-14,549.0,18.059210526,C-PEPTIDE,120.0,3.61,3.61,NG/ML,1.19491,1.19491,1.42992,-0.23501,120.0,,1.42992,,,159.1,66.1,253.202,313.635,30.0,204.0,2014-11-11,29
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,-10.0,0.41,0.41,NG/ML,0.13571,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,,264.648,90.0,110.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,0.0,0.41,0.41,NG/ML,0.13571,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,55.598,264.648,90.0,106.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,15.0,0.58,0.58,NG/ML,0.19198,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,105.582,264.648,90.0,117.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,30.0,0.98,0.98,NG/ML,0.32438,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,236.226,264.648,90.0,139.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,60.0,1.98,1.98,NG/ML,0.65538,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,163.518,264.648,90.0,182.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,90.0,3.25,3.25,NG/ML,1.07575,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,264.648,264.648,90.0,200.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,120.0,2.95,2.95,NG/ML,0.97645,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,214.259,264.648,90.0,213.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,150.0,3,3.0,NG/ML,0.993,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,198.764,264.648,90.0,195.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,180.0,2.86,2.86,NG/ML,0.94666,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,187.262,264.648,90.0,180.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,210.0,2.42,2.42,NG/ML,0.80102,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,146.915,264.648,90.0,157.0,2014-11-11,30
T1DAL_817864,SUB168929,Week 104,ITN045AI-Rigby,A,1.0,2011-04-28,2011-05-15,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,Black or African American,,Not Hispanic or Latino,2011-05-15,2011-10-29,2012-01-14,Yes,,2013-05-19,735.0,Yes,,,2012-01-14,244.0,Completed study,Completed study drug,Yes,Yes,2013-05-19,735.0,Week 104/Visit 30,2011-02-08,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-05-09,725.0,23.848684211,C-PEPTIDE,240.0,1.86,1.86,NG/ML,0.61566,1.07575,1.42992,-0.35417,90.0,1.07575,1.42992,-0.35417,90.0,158.9,64.3,102.623,264.648,90.0,137.0,2014-11-11,30
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,-10.0,1.38,1.38,NG/ML,0.45678,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,,256.895,30.0,136.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,0.0,1.39,1.39,NG/ML,0.46009,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,124.434,256.895,30.0,142.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,15.0,1.41,1.41,NG/ML,0.46671,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,201.316,256.895,30.0,144.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,30.0,1.89,1.89,NG/ML,0.62559,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,256.895,256.895,30.0,164.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,60.0,2.36,2.36,NG/ML,0.78116,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,198.027,256.895,30.0,224.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,90.0,2.72,2.72,NG/ML,0.90032,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,222.36,256.895,30.0,240.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,120.0,2.39,2.39,NG/ML,0.79109,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,175.289,256.895,30.0,248.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,150.0,2.33,2.33,NG/ML,0.77123,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,164.007,256.895,30.0,249.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,180.0,2.28,2.28,NG/ML,0.75468,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,162.926,256.895,30.0,223.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,210.0,2.03,2.03,NG/ML,0.67193,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,139.311,256.895,30.0,195.0,2014-11-11,-1
T1DAL_846752,SUB168930,-1,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-04-10,-27.0,-0.888157895,C-PEPTIDE,240.0,2.02,2.02,NG/ML,0.66862,0.90032,0.90032,0.0,90.0,0.90032,0.90032,0.0,90.0,185.5,77.2,141.784,256.895,30.0,200.0,2014-11-11,-1
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,-10.0,0.51,0.51,NG/ML,0.16881,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,,321.361,30.0,84.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,0.0,0.44,0.44,NG/ML,0.14564,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,73.603,321.361,30.0,90.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,15.0,0.66,0.66,NG/ML,0.21846,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,187.951,321.361,30.0,108.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,30.0,1.4,1.4,NG/ML,0.4634,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,321.361,321.361,30.0,159.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,60.0,2.42,2.42,NG/ML,0.80102,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,225.129,321.361,30.0,226.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,90.0,2.81,2.81,NG/ML,0.93011,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,243.062,321.361,30.0,236.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 24,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-10-22,168.0,5.5263157895,C-PEPTIDE,120.0,2.69,2.69,NG/ML,0.89039,0.93011,0.90032,0.02979,90.0,,0.90032,,,,77.4,207.392,321.361,30.0,228.0,2014-11-11,15
T1DAL_846752,SUB168930,Week 78,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-11-17,560.0,18.421052632,C-PEPTIDE,-10.0,0.35,0.35,NG/ML,0.11585,0.11585,0.90032,-0.78447,-10.0,,0.90032,,,185.8,77.8,,,,,2014-11-11,29
T1DAL_846752,SUB168930,Week 104,ITN045AI-Rigby,A,1.0,2011-04-10,2011-05-07,Yes,Yes,Yes,S/I,33.0,16-35,22-35,22-35,Male,White,White,Not Hispanic or Latino,2011-05-08,2011-10-22,2011-12-24,Yes,,2013-06-23,778.0,No,Other AE, Specify,Other AE,2011-12-24,231.0,Completed study,Discontinued study drug early,Yes,No,2013-06-23,778.0,Week 104/Visit 30,2011-03-11,-57.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-23,778.0,25.592105263,C-PEPTIDE,-10.0,0.52,0.52,NG/ML,0.17212,0.17212,0.90032,-0.7282,-10.0,0.17212,0.90032,-0.7282,-10.0,184.8,79.4,,,,,2014-11-11,30
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,-10.0,0.25,0.25,NG/ML,0.08275,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,,93.056,120.0,106.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,0.0,0.25,0.25,NG/ML,0.08275,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,64.845,93.056,120.0,102.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,15.0,0.47,0.47,NG/ML,0.15557,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,58.427,93.056,120.0,122.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,30.0,0.5,0.5,NG/ML,0.1655,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,48.001,93.056,120.0,207.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,60.0,0.48,0.48,NG/ML,0.15888,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,39.845,93.056,120.0,287.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,90.0,0.7,0.7,NG/ML,0.2317,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,62.854,93.056,120.0,306.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,120.0,0.99,0.99,NG/ML,0.32769,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,93.056,93.056,120.0,298.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,150.0,0.73,0.73,NG/ML,0.24163,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,57.752,93.056,120.0,274.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,180.0,0.71,0.71,NG/ML,0.23501,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,52.088,93.056,120.0,244.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,210.0,0.7,0.7,NG/ML,0.2317,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,54.293,93.056,120.0,228.0,2014-11-11,-1
T1DAL_920806,SUB168931,-1,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-05-24,-31.0,-1.019736842,C-PEPTIDE,240.0,0.8,0.8,NG/ML,0.2648,0.32769,0.32769,0.0,120.0,0.32769,0.32769,0.0,120.0,186.0,92.6,66.547,93.056,120.0,213.0,2014-11-11,-1
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,-10.0,0.99,0.99,NG/ML,0.32769,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,,176.372,15.0,178.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,0.0,0.89,0.89,NG/ML,0.29459,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,163.916,176.372,15.0,174.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,15.0,1.33,1.33,NG/ML,0.44023,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,176.372,176.372,15.0,192.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,30.0,1.52,1.52,NG/ML,0.50312,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,169.823,176.372,15.0,252.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,60.0,1.59,1.59,NG/ML,0.52629,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,138.082,176.372,15.0,266.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,90.0,1.36,1.36,NG/ML,0.45016,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,106.015,176.372,15.0,271.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 24,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-09,168.0,5.5263157895,C-PEPTIDE,120.0,1.25,1.25,NG/ML,0.41375,0.52629,0.32769,0.1986,60.0,,0.32769,,,185.0,96.7,93.295,176.372,15.0,252.0,2014-11-11,15
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,-10.0,0.65,0.65,NG/ML,0.21515,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,,132.147,30.0,146.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,0.0,0.63,0.63,NG/ML,0.20853,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,81.986,132.147,30.0,146.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,15.0,0.76,0.76,NG/ML,0.25156,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,113.846,132.147,30.0,156.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,30.0,0.98,0.98,NG/ML,0.32438,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,132.147,132.147,30.0,225.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,60.0,1.16,1.16,NG/ML,0.38396,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,103.105,132.147,30.0,276.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,90.0,1.19,1.19,NG/ML,0.39389,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,100.165,132.147,30.0,304.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,120.0,1.1,1.1,NG/ML,0.3641,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,85.885,132.147,30.0,276.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,150.0,1.01,1.01,NG/ML,0.33431,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,75.365,132.147,30.0,262.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,180.0,0.98,0.98,NG/ML,0.32438,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,74.091,132.147,30.0,240.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,210.0,0.87,0.87,NG/ML,0.28797,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,64.063,132.147,30.0,218.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 52,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-05,377.0,12.401315789,C-PEPTIDE,240.0,0.81,0.81,NG/ML,0.26811,0.39389,0.32769,0.0662,90.0,0.39389,0.32769,0.0662,90.0,186.0,90.3,59.383,132.147,30.0,205.0,2014-11-11,28
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,-10.0,0.51,0.51,NG/ML,0.16881,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,,120.299,30.0,188.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,0.0,0.51,0.51,NG/ML,0.16881,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,85.924,120.299,30.0,187.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,15.0,0.74,0.74,NG/ML,0.24494,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,100.837,120.299,30.0,182.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,30.0,0.87,0.87,NG/ML,0.28797,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,120.299,120.299,30.0,232.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,60.0,1.05,1.05,NG/ML,0.34755,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,92.62,120.299,30.0,311.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,90.0,1.08,1.08,NG/ML,0.35748,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,90.55,120.299,30.0,324.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 78,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-21,546.0,17.960526316,C-PEPTIDE,120.0,0.94,0.94,NG/ML,0.31114,0.35748,0.32769,0.02979,90.0,,0.32769,,,186.0,86.8,70.015,120.299,30.0,288.0,2014-11-11,29
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,-10.0,0.05,0.05,NG/ML,0.01655,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,,93.266,30.0,92.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,0.0,0.23,0.23,NG/ML,0.07613,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,52.812,93.266,30.0,97.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,15.0,0.37,0.37,NG/ML,0.12247,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,89.737,93.266,30.0,133.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,30.0,0.62,0.62,NG/ML,0.20522,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,93.266,93.266,30.0,200.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,60.0,0.76,0.76,NG/ML,0.25156,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,69.859,93.266,30.0,258.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,90.0,0.97,0.97,NG/ML,0.32107,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,86.18,93.266,30.0,285.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,120.0,0.91,0.91,NG/ML,0.30121,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,74.344,93.266,30.0,281.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,150.0,0.91,0.91,NG/ML,0.30121,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,70.57,93.266,30.0,344.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,180.0,0.73,0.73,NG/ML,0.24163,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,50.861,93.266,30.0,272.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,210.0,0.63,0.63,NG/ML,0.20853,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,42.656,93.266,30.0,250.0,2014-11-11,30
T1DAL_920806,SUB168931,Week 104,ITN045AI-Rigby,P,2.0,2011-05-24,2011-06-24,Yes,Yes,Yes,S/I,27.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-06-24,2011-12-09,2012-02-24,Yes,,2013-06-28,735.0,Yes,,,2012-02-24,245.0,Completed study,Completed study drug,Yes,Yes,2013-06-28,735.0,Week 104/Visit 30,2011-05-17,-38.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-28,735.0,24.177631579,C-PEPTIDE,240.0,0.67,0.67,NG/ML,0.22177,0.32107,0.32769,-0.00662,90.0,0.32107,0.32769,-0.00662,90.0,186.0,88.0,49.845,93.266,30.0,259.0,2014-11-11,30
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,-10.0,1.4,1.4,NG/ML,0.4634,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,,307.374,30.0,106.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,0.0,1.34,1.34,NG/ML,0.44354,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,105.247,307.374,30.0,104.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,15.0,1.39,1.39,NG/ML,0.46009,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,300.478,307.374,30.0,106.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,30.0,2.82,2.82,NG/ML,0.93342,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,307.374,307.374,30.0,154.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,60.0,3.25,3.25,NG/ML,1.07575,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,240.236,307.374,30.0,152.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,90.0,4.17,4.17,NG/ML,1.38027,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,298.04,307.374,30.0,146.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,120.0,3.75,3.75,NG/ML,1.24125,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,246.809,307.374,30.0,116.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,150.0,2.96,2.96,NG/ML,0.97976,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,167.792,307.374,30.0,95.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,180.0,2.35,2.35,NG/ML,0.77785,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,122.472,307.374,30.0,81.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,210.0,1.77,1.77,NG/ML,0.58587,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,86.83,307.374,30.0,70.0,2014-11-11,-1
T1DAL_923889,SUB168932,-1,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-06-03,-15.0,-0.493421053,C-PEPTIDE,240.0,1.62,1.62,NG/ML,0.53622,1.38027,1.38027,0.0,90.0,1.38027,1.38027,0.0,90.0,165.3,48.0,87.488,307.374,30.0,69.0,2014-11-11,-1
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,-10.0,1.63,1.63,NG/ML,0.53953,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,,240.897,15.0,153.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,0.0,1.62,1.62,NG/ML,0.53622,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,207.047,240.897,15.0,149.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,15.0,2.2,2.2,NG/ML,0.7282,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,240.897,240.897,15.0,164.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,30.0,2.62,2.62,NG/ML,0.86722,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,183.251,240.897,15.0,201.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,60.0,2.4,2.4,NG/ML,0.7944,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,159.571,240.897,15.0,221.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,90.0,2.56,2.56,NG/ML,0.84736,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,166.982,240.897,15.0,239.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 24,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-12-03,168.0,5.5263157895,C-PEPTIDE,120.0,2.79,2.79,NG/ML,0.92349,0.92349,1.38027,-0.45678,120.0,,1.38027,,,165.2,51.9,187.093,240.897,15.0,244.0,2014-11-11,15
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,-10.0,1.62,1.62,NG/ML,0.53622,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,,274.723,30.0,162.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,0.0,1.58,1.58,NG/ML,0.52298,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,218.999,274.723,30.0,163.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,15.0,2.27,2.27,NG/ML,0.75137,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,251.916,274.723,30.0,182.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,30.0,2.71,2.71,NG/ML,0.89701,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,274.723,274.723,30.0,207.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,60.0,3.08,3.08,NG/ML,1.01948,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,217.43,274.723,30.0,249.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,90.0,3.01,3.01,NG/ML,0.99631,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,200.533,274.723,30.0,289.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,120.0,3.01,3.01,NG/ML,0.99631,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,194.341,274.723,30.0,274.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,150.0,2.57,2.57,NG/ML,0.85067,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,155.441,274.723,30.0,278.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,180.0,2.75,2.75,NG/ML,0.91025,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,173.761,274.723,30.0,266.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,210.0,2.31,2.31,NG/ML,0.76461,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,139.925,274.723,30.0,240.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 52,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-06-10,358.0,11.776315789,C-PEPTIDE,240.0,2.04,2.04,NG/ML,0.67524,1.01948,1.38027,-0.36079,60.0,1.01948,1.38027,-0.36079,60.0,165.8,51.5,118.103,274.723,30.0,219.0,2014-11-11,28
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,-10.0,1.42,1.42,NG/ML,0.47002,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,,239.113,30.0,146.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,0.0,1.41,1.41,NG/ML,0.46671,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,199.633,239.113,30.0,141.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,15.0,2.04,2.04,NG/ML,0.67524,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,210.553,239.113,30.0,164.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,30.0,2.33,2.33,NG/ML,0.77123,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,239.113,239.113,30.0,196.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,60.0,2.7,2.7,NG/ML,0.8937,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,188.375,239.113,30.0,250.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,90.0,2.74,2.74,NG/ML,0.90694,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,185.17,239.113,30.0,276.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 78,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-12-28,559.0,18.388157895,C-PEPTIDE,120.0,2.76,2.76,NG/ML,0.91356,0.91356,1.38027,-0.46671,120.0,,1.38027,,,166.2,51.0,178.746,239.113,30.0,265.0,2014-11-11,29
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,-10.0,1.13,1.13,NG/ML,0.37403,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,,156.969,30.0,189.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,0.0,1.08,1.08,NG/ML,0.35748,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,89.676,156.969,30.0,191.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,15.0,1.15,1.15,NG/ML,0.38065,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,125.444,156.969,30.0,205.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,30.0,1.43,1.43,NG/ML,0.47333,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,156.969,156.969,30.0,241.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,60.0,1.71,1.71,NG/ML,0.56601,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,123.9,156.969,30.0,317.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,90.0,1.63,1.63,NG/ML,0.53953,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,109.889,156.969,30.0,355.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,120.0,1.59,1.59,NG/ML,0.52629,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,102.964,156.969,30.0,355.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,150.0,1.61,1.61,NG/ML,0.53291,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,103.265,156.969,30.0,333.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,180.0,1.54,1.54,NG/ML,0.50974,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,98.362,156.969,30.0,301.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,210.0,1.46,1.46,NG/ML,0.48326,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,90.864,156.969,30.0,276.0,2014-11-11,30
T1DAL_923889,SUB168932,Week 104,ITN045AI-Rigby,A,1.0,2011-06-03,2011-06-18,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,White,Not Hispanic or Latino,2011-06-18,2011-12-03,2012-02-19,Yes,,2013-06-21,734.0,Yes,,,2012-02-19,246.0,Completed study,Completed study drug,Yes,Yes,2013-06-21,734.0,Week 104/Visit 30,2011-04-29,-50.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-06-21,734.0,24.144736842,C-PEPTIDE,240.0,1.29,1.29,NG/ML,0.42699,0.56601,1.38027,-0.81426,60.0,0.56601,1.38027,-0.81426,60.0,166.3,54.3,78.956,156.969,30.0,254.0,2014-11-11,30
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,-10.0,0.59,0.59,NG/ML,0.19529,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,,224.415,120.0,89.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,0.0,0.72,0.72,NG/ML,0.23832,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,108.898,224.415,120.0,94.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,15.0,1.03,1.03,NG/ML,0.34093,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,130.494,224.415,120.0,97.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,30.0,1.29,1.29,NG/ML,0.42699,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,176.081,224.415,120.0,121.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,60.0,1.72,1.72,NG/ML,0.56932,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,132.296,224.415,120.0,157.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,90.0,2.36,2.36,NG/ML,0.78116,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,182.654,224.415,120.0,166.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,120.0,2.94,2.94,NG/ML,0.97314,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,224.415,224.415,120.0,197.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,150.0,3.08,3.08,NG/ML,1.01948,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,223.458,224.415,120.0,181.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,180.0,2.74,2.74,NG/ML,0.90694,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,181.842,224.415,120.0,159.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,210.0,2.13,2.13,NG/ML,0.70503,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,124.627,224.415,120.0,126.0,2014-11-11,-1
T1DAL_932593,SUB168933,-1,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2010-10-26,-14.0,-0.460526316,C-PEPTIDE,240.0,2.07,2.07,NG/ML,0.68517,0.97314,0.97314,0.0,120.0,1.01948,1.01948,0.0,150.0,171.9,59.0,126.666,224.415,120.0,109.0,2014-11-11,-1
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,-10.0,0.95,0.95,NG/ML,0.31445,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,,224.208,15.0,127.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,0.0,0.96,0.96,NG/ML,0.31776,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,141.53,224.208,15.0,123.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,15.0,1.38,1.38,NG/ML,0.45678,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,224.208,224.208,15.0,160.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,30.0,2.07,2.07,NG/ML,0.68517,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,203.986,224.208,15.0,203.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,60.0,2.17,2.17,NG/ML,0.71827,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,164.092,224.208,15.0,267.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,90.0,2,2.0,NG/ML,0.662,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,136.83,224.208,15.0,268.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 24,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-04-27,169.0,5.5592105263,C-PEPTIDE,120.0,2.22,2.22,NG/ML,0.73482,0.73482,0.97314,-0.23832,120.0,,1.01948,,,174.6,60.1,154.282,224.208,15.0,270.0,2014-11-11,15
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,-10.0,0.28,0.28,NG/ML,0.09268,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,,97.808,210.0,117.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,0.0,0.3,0.3,NG/ML,0.0993,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,38.54,97.808,210.0,120.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,15.0,0.39,0.39,NG/ML,0.12909,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,51.671,97.808,210.0,134.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,30.0,0.51,0.51,NG/ML,0.16881,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,44.983,97.808,210.0,181.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,60.0,0.51,0.51,NG/ML,0.16881,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,37.308,97.808,210.0,215.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,90.0,0.76,0.76,NG/ML,0.25156,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,58.164,97.808,210.0,251.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,120.0,0.87,0.87,NG/ML,0.28797,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,66.167,97.808,210.0,246.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,150.0,1.14,1.14,NG/ML,0.37734,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,86.749,97.808,210.0,272.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,180.0,1.15,1.15,NG/ML,0.38065,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,83.66,97.808,210.0,280.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,210.0,1.35,1.35,NG/ML,0.44685,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,97.808,97.808,210.0,277.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 52,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2011-11-03,359.0,11.809210526,C-PEPTIDE,240.0,1.24,1.24,NG/ML,0.41044,0.28797,0.97314,-0.68517,120.0,0.44685,1.01948,-0.57263,210.0,172.7,62.0,85.366,97.808,210.0,263.0,2014-11-11,28
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,0.0,0.28,0.28,NG/ML,0.09268,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,30.834,78.576,30.0,108.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,15.0,0.32,0.32,NG/ML,0.10592,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,50.128,78.576,30.0,119.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,30.0,0.49,0.49,NG/ML,0.16219,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,78.576,78.576,30.0,175.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,60.0,0.73,0.73,NG/ML,0.24163,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,57.713,78.576,30.0,240.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,90.0,0.73,0.73,NG/ML,0.24163,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,53.808,78.576,30.0,302.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 78,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-04-30,538.0,17.697368421,C-PEPTIDE,120.0,0.95,0.95,NG/ML,0.31445,0.31445,0.97314,-0.65869,120.0,,1.01948,,,171.5,62.7,69.349,78.576,30.0,325.0,2014-11-11,29
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,-10.0,0.12,0.12,NG/ML,0.03972,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,,41.355,30.0,153.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,0.0,0.12,0.12,NG/ML,0.03972,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,9.58,41.355,30.0,157.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,15.0,0.11,0.11,NG/ML,0.03641,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,22.709,41.355,30.0,168.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,30.0,0.21,0.21,NG/ML,0.06951,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,41.355,41.355,30.0,223.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,60.0,0.36,0.36,NG/ML,0.11916,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,29.66,41.355,30.0,268.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,90.0,0.33,0.33,NG/ML,0.10923,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,24.669,41.355,30.0,324.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,120.0,0.35,0.35,NG/ML,0.11585,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,25.318,41.355,30.0,368.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,150.0,0.39,0.39,NG/ML,0.12909,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,27.772,41.355,30.0,371.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,180.0,0.35,0.35,NG/ML,0.11585,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,24.395,41.355,30.0,366.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,210.0,0.41,0.41,NG/ML,0.13571,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,29.6,41.355,30.0,368.0,2014-11-11,30
T1DAL_932593,SUB168933,Week 104,ITN045AI-Rigby,P,2.0,2010-10-26,2010-11-09,Yes,Yes,Yes,S/I,16.0,16-35,12-16,12-21,Female,White,,Not Hispanic or Latino,2010-11-10,2011-04-27,2011-07-13,Yes,,2012-10-24,715.0,Yes,,,2011-07-13,246.0,Completed study,Completed study drug,Yes,Yes,2012-10-24,715.0,Week 104/Visit 30,2010-09-25,-45.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2012-10-24,715.0,23.519736842,C-PEPTIDE,240.0,0.4,0.4,NG/ML,0.1324,0.11916,0.97314,-0.85398,60.0,0.13571,1.01948,-0.88377,210.0,172.2,60.4,26.749,41.355,30.0,350.0,2014-11-11,30
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,-10.0,0.61,0.61,NG/ML,0.20191,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,,196.337,30.0,133.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,0.0,0.72,0.72,NG/ML,0.23832,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,66.356,196.337,30.0,138.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,15.0,0.75,0.75,NG/ML,0.24825,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,118.138,196.337,30.0,143.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,30.0,1.13,1.13,NG/ML,0.37403,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,196.337,196.337,30.0,206.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,60.0,1.77,1.77,NG/ML,0.58587,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,143.203,196.337,30.0,289.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,90.0,1.93,1.93,NG/ML,0.63883,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,148.052,196.337,30.0,311.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,120.0,2.18,2.18,NG/ML,0.72158,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,160.107,196.337,30.0,296.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,150.0,2.1,2.1,NG/ML,0.6951,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,146.761,196.337,30.0,276.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,180.0,2,2.0,NG/ML,0.662,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,133.743,196.337,30.0,245.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,210.0,1.76,1.76,NG/ML,0.58256,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,112.433,196.337,30.0,222.0,2014-11-11,-1
T1DAL_944872,SUB168934,-1,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-28.0,-0.921052632,C-PEPTIDE,240.0,1.65,1.65,NG/ML,0.54615,0.72158,0.72158,0.0,120.0,0.72158,0.72158,0.0,120.0,174.6,61.8,105.257,196.337,30.0,209.0,2014-11-11,-1
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,-10.0,0.66,0.66,NG/ML,0.21846,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,,212.011,30.0,112.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,0.0,0.69,0.69,NG/ML,0.22839,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,87.768,212.011,30.0,112.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,15.0,0.89,0.89,NG/ML,0.29459,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,140.347,212.011,30.0,177.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,30.0,1.31,1.31,NG/ML,0.43361,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,212.011,212.011,30.0,214.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,60.0,1.93,1.93,NG/ML,0.63883,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,155.834,212.011,30.0,272.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,90.0,2.32,2.32,NG/ML,0.76792,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,181.133,212.011,30.0,300.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 24,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-26,170.0,5.5921052632,C-PEPTIDE,120.0,2.5,2.5,NG/ML,0.8275,0.8275,0.72158,0.10592,120.0,,0.72158,,,175.1,63.3,185.32,212.011,30.0,276.0,2014-11-11,15
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,-10.0,0.59,0.59,NG/ML,0.19529,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,,201.541,150.0,110.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,0.0,0.55,0.55,NG/ML,0.18205,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,50.339,201.541,150.0,115.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,15.0,0.6,0.6,NG/ML,0.1986,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,92.876,201.541,150.0,117.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,30.0,0.9,0.9,NG/ML,0.2979,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,147.285,201.541,150.0,187.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,60.0,1.35,1.35,NG/ML,0.44685,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,108.629,201.541,150.0,229.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,90.0,1.89,1.89,NG/ML,0.62559,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,151.087,201.541,150.0,261.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,120.0,2.46,2.46,NG/ML,0.81426,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,193.028,201.541,150.0,269.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,150.0,2.69,2.69,NG/ML,0.89039,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,201.541,201.541,150.0,247.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,180.0,2.44,2.44,NG/ML,0.80764,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,167.171,201.541,150.0,216.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,210.0,1.87,1.87,NG/ML,0.61897,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,110.893,201.541,150.0,188.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 52,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-04-15,372.0,12.236842105,C-PEPTIDE,240.0,1.6,1.6,NG/ML,0.5296,0.81426,0.72158,0.09268,120.0,0.89039,0.72158,0.16881,150.0,174.0,63.5,91.985,201.541,150.0,159.0,2014-11-11,28
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,-10.0,1.01,1.01,NG/ML,0.33431,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,,190.143,120.0,157.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,0.0,0.91,0.91,NG/ML,0.30121,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,91.409,190.143,120.0,150.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,15.0,1.05,1.05,NG/ML,0.34755,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,113.08,190.143,120.0,184.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,30.0,1.25,1.25,NG/ML,0.41375,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,180.016,190.143,120.0,237.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,60.0,1.74,1.74,NG/ML,0.57594,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,135.794,190.143,120.0,315.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,90.0,2.32,2.32,NG/ML,0.76792,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,182.147,190.143,120.0,324.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 78,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-28,538.0,17.697368421,C-PEPTIDE,120.0,2.53,2.53,NG/ML,0.83743,0.83743,0.72158,0.11585,120.0,,0.72158,,,175.7,62.0,190.143,190.143,120.0,321.0,2014-11-11,29
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,-10.0,0.5,0.5,NG/ML,0.1655,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,,108.191,120.0,81.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,0.0,0.59,0.59,NG/ML,0.19529,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,62.548,108.191,120.0,90.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,15.0,0.65,0.65,NG/ML,0.21515,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,83.729,108.191,120.0,132.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,30.0,0.85,0.85,NG/ML,0.28135,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,87.519,108.191,120.0,186.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,60.0,0.94,0.94,NG/ML,0.31114,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,70.26,108.191,120.0,232.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,90.0,1.12,1.12,NG/ML,0.37072,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,83.326,108.191,120.0,272.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,120.0,1.43,1.43,NG/ML,0.47333,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,108.191,108.191,120.0,263.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,150.0,1.22,1.22,NG/ML,0.40382,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,83.581,108.191,120.0,232.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,180.0,1.1,1.1,NG/ML,0.3641,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,68.996,108.191,120.0,202.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,210.0,0.9,0.9,NG/ML,0.2979,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,54.834,108.191,120.0,173.0,2014-11-11,30
T1DAL_944872,SUB168934,Week 104,ITN045AI-Rigby,A,1.0,2011-03-12,2011-04-09,Yes,Yes,Yes,S/I,17.0,16-35,17-21,12-21,Female,White,,Not Hispanic or Latino,2011-04-10,2011-09-26,2011-12-11,Yes,,2013-04-16,738.0,Yes,,,2011-12-11,246.0,Completed study,Completed study drug,Yes,Yes,2013-04-16,738.0,Week 104/Visit 30,2011-01-11,-88.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-16,738.0,24.276315789,C-PEPTIDE,240.0,0.86,0.86,NG/ML,0.28466,0.47333,0.72158,-0.24825,120.0,0.47333,0.72158,-0.24825,120.0,174.0,65.2,52.53,108.191,120.0,150.0,2014-11-11,30
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,-10.0,0.71,0.71,NG/ML,0.23501,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,,459.114,120.0,197.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,0.0,0.75,0.75,NG/ML,0.24825,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,71.78,459.114,120.0,193.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,15.0,0.8,0.8,NG/ML,0.2648,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,89.151,459.114,120.0,205.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,30.0,0.94,0.94,NG/ML,0.31114,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,87.788,459.114,120.0,258.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,60.0,0.98,0.98,NG/ML,0.32438,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,73.413,459.114,120.0,298.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,90.0,0.82,0.82,NG/ML,0.27142,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,55.313,459.114,120.0,303.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,120.0,0.86,0.86,NG/ML,0.28466,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,459.114,459.114,120.0,320.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,150.0,0.78,0.78,NG/ML,0.25818,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,53.199,459.114,120.0,309.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,180.0,0.71,0.71,NG/ML,0.23501,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,46.941,459.114,120.0,289.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,210.0,0.66,0.66,NG/ML,0.21846,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,43.746,459.114,120.0,267.0,2014-11-11,-1
T1DAL_947702,SUB168935,-1,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-03-12,-23.0,-0.756578947,C-PEPTIDE,240.0,0.6,0.6,NG/ML,0.1986,0.32438,0.32438,0.0,60.0,0.32438,0.32438,0.0,60.0,175.0,66.9,39.587,459.114,120.0,256.0,2014-11-11,-1
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,,2.093,0.0,65.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,2.093,2.093,0.0,68.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,2.053,2.093,0.0,89.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,30.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,2.035,2.093,0.0,146.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,60.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,1.795,2.093,0.0,,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,90.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,1.784,2.093,0.0,253.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 24,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-20,169.0,5.5592105263,C-PEPTIDE,120.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,68.7,1.782,2.093,0.0,259.0,2014-11-11,15
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,,2.092,0.0,101.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,2.092,2.092,0.0,104.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,2.052,2.092,0.0,159.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,30.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,2.034,2.092,0.0,194.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,60.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.783,2.092,0.0,338.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,90.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,372.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,120.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,380.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,150.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,372.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,180.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,358.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,210.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,341.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 52,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-07-23,476.0,15.657894737,C-PEPTIDE,240.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,175.0,69.2,1.78,2.092,0.0,328.0,2014-11-11,28
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,,2.606,0.0,119.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.606,2.606,0.0,119.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.556,2.606,0.0,143.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,30.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.532,2.606,0.0,190.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,60.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.233,2.606,0.0,319.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,90.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.22,2.606,0.0,382.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 78,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-10-21,566.0,18.618421053,C-PEPTIDE,120.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,,0.32438,,,175.0,75.2,2.217,2.606,0.0,396.0,2014-11-11,29
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,204.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,218.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,285.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,30.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,400.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,60.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,470.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,90.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,532.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,120.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,553.0,2014-11-11,30
T1DAL_947702,SUB168935,Week 104,ITN045AI-Rigby,A,1.0,2011-03-08,2011-04-04,Yes,Yes,Yes,S/I,18.0,16-35,17-21,12-21,Male,White,,Not Hispanic or Latino,2011-04-04,2011-09-20,2011-12-05,Yes,,2013-04-10,737.0,Yes,,,2011-12-05,245.0,Completed study,Completed study drug,Yes,Yes,2013-04-10,737.0,Week 104/Visit 30,2011-03-04,-31.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-04-10,737.0,24.243421053,C-PEPTIDE,150.0,<0.05,0.025,NG/ML,0.008275,0.008275,0.32438,-0.316105,-10.0,0.008275,0.32438,-0.316105,-10.0,177.8,71.6,,,,614.0,2014-11-11,30
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,-10.0,0.37,0.37,NG/ML,0.12247,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,,162.037,15.0,77.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,0.0,0.34,0.34,NG/ML,0.11254,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,50.594,162.037,15.0,77.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,15.0,0.48,0.48,NG/ML,0.15888,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,162.037,162.037,15.0,84.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,30.0,1.23,1.23,NG/ML,0.40713,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,143.031,162.037,15.0,134.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,60.0,1.32,1.32,NG/ML,0.43692,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,112.283,162.037,15.0,181.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,90.0,1.33,1.33,NG/ML,0.44023,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,101.447,162.037,15.0,205.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,120.0,1.69,1.69,NG/ML,0.55939,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,132.672,162.037,15.0,219.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,150.0,1.74,1.74,NG/ML,0.57594,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,134.164,162.037,15.0,196.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,180.0,1.89,1.89,NG/ML,0.62559,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,143.122,162.037,15.0,173.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,210.0,1.68,1.68,NG/ML,0.55608,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,119.809,162.037,15.0,116.0,2014-11-11,-1
T1DAL_949286,SUB168936,-1,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-26,-16.0,-0.526315789,C-PEPTIDE,240.0,1.39,1.39,NG/ML,0.46009,0.55939,0.55939,0.0,120.0,0.62559,0.62559,0.0,180.0,185.4,63.4,90.46,162.037,15.0,83.0,2014-11-11,-1
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,-10.0,0.47,0.47,NG/ML,0.15557,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,,91.267,15.0,162.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,0.0,0.48,0.48,NG/ML,0.15888,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,70.431,91.267,15.0,166.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,15.0,0.66,0.66,NG/ML,0.21846,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,91.267,91.267,15.0,200.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,30.0,0.85,0.85,NG/ML,0.28135,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,73.273,91.267,15.0,267.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,60.0,0.81,0.81,NG/ML,0.26811,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,62.05,91.267,15.0,345.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,90.0,0.85,0.85,NG/ML,0.28135,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,62.641,91.267,15.0,375.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 24,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-09-01,171.0,5.625,C-PEPTIDE,120.0,0.85,0.85,NG/ML,0.28135,0.28135,0.55939,-0.27804,30.0,,0.62559,,,187.5,62.1,62.15,91.267,15.0,385.0,2014-11-11,15
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,-10.0,0.07,0.07,NG/ML,0.02317,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,,15.341,15.0,224.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,0.0,0.07,0.07,NG/ML,0.02317,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,7.819,15.341,15.0,226.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,15.0,0.08,0.08,NG/ML,0.02648,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,15.341,15.341,15.0,234.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,30.0,0.13,0.13,NG/ML,0.04303,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,11.367,15.341,15.0,302.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,60.0,0.12,0.12,NG/ML,0.03972,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,9.726,15.341,15.0,365.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,90.0,0.13,0.13,NG/ML,0.04303,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,10.0,15.341,15.0,418.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,120.0,0.14,0.14,NG/ML,0.04634,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,10.904,15.341,15.0,422.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,150.0,0.12,0.12,NG/ML,0.03972,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,8.671,15.341,15.0,397.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,180.0,0.13,0.13,NG/ML,0.04303,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,9.636,15.341,15.0,377.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,210.0,0.1,0.1,NG/ML,0.0331,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,6.804,15.341,15.0,368.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 52,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-03-24,376.0,12.368421053,C-PEPTIDE,240.0,0.09,0.09,NG/ML,0.02979,0.04634,0.55939,-0.51305,120.0,0.04634,0.62559,-0.57925,120.0,191.5,65.7,5.919,15.341,15.0,347.0,2014-11-11,28
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,,12.274,30.0,195.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,2.624,12.274,30.0,198.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,2.574,12.274,30.0,211.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,30.0,<0.05,0.025,NG/ML,0.008275,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,12.274,12.274,30.0,236.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,60.0,0.08,0.08,NG/ML,0.02648,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,8.286,12.274,30.0,303.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,90.0,0.05,0.05,NG/ML,0.01655,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,4.827,12.274,30.0,346.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 78,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-14,550.0,18.092105263,C-PEPTIDE,120.0,0.05,0.05,NG/ML,0.01655,0.02648,0.55939,-0.53291,60.0,,0.62559,,,189.1,66.1,4.152,12.274,30.0,366.0,2014-11-11,29
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,-10.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,,7.612,15.0,191.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,0.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.686,7.612,15.0,195.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,15.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,7.612,7.612,15.0,198.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,30.0,0.07,0.07,NG/ML,0.02317,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,1.32,7.612,15.0,227.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,60.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.085,7.612,15.0,303.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,90.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,1.838,7.612,15.0,380.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,120.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.188,7.612,15.0,393.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,150.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.265,7.612,15.0,389.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,180.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.282,7.612,15.0,362.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,210.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.86,7.612,15.0,348.0,2014-11-11,30
T1DAL_949286,SUB168936,Week 104,ITN045AI-Rigby,P,2.0,2011-02-26,2011-03-14,Yes,Yes,Yes,S/I,15.0,12-15,12-16,12-21,Male,White,White,Not Hispanic or Latino,2011-03-18,2011-09-01,2011-11-18,Yes,,2013-03-18,735.0,Yes,,,2011-11-18,249.0,Completed study,Completed study drug,Yes,Yes,2013-03-18,735.0,Week 104/Visit 30,2011-01-12,-61.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-03-18,735.0,24.177631579,C-PEPTIDE,240.0,<0.05,0.025,NG/ML,0.008275,0.02317,0.55939,-0.53622,30.0,0.02317,0.62559,-0.60242,30.0,189.1,70.5,2.287,7.612,15.0,335.0,2014-11-11,30
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,-10.0,0.61,0.61,NG/ML,0.20191,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,,238.763,30.0,121.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,0.0,0.64,0.64,NG/ML,0.21184,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,68.252,238.763,30.0,116.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,15.0,0.76,0.76,NG/ML,0.25156,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,101.216,238.763,30.0,128.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,30.0,1.03,1.03,NG/ML,0.34093,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,238.763,238.763,30.0,147.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,60.0,2.06,2.06,NG/ML,0.68186,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,165.517,238.763,30.0,220.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,90.0,2.47,2.47,NG/ML,0.81757,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,189.916,238.763,30.0,236.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,120.0,2.53,2.53,NG/ML,0.83743,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,176.38,238.763,30.0,245.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,150.0,2.84,2.84,NG/ML,0.94004,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,194.568,238.763,30.0,229.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,180.0,2.84,2.84,NG/ML,0.94004,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,189.112,238.763,30.0,211.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,210.0,2.47,2.47,NG/ML,0.81757,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,150.476,238.763,30.0,190.0,2014-11-11,-1
T1DAL_975187,SUB168937,-1,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Screening,-1.0,1000,2011-01-04,-28.0,-0.921052632,C-PEPTIDE,240.0,2.08,2.08,NG/ML,0.68848,0.83743,0.83743,0.0,120.0,0.94004,0.94004,0.0,150.0,171.9,60.8,116.892,238.763,30.0,146.0,2014-11-11,-1
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,-10.0,0.82,0.82,NG/ML,0.27142,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,,295.058,30.0,127.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,0.0,0.77,0.77,NG/ML,0.25487,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,168.99,295.058,30.0,119.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,15.0,1.5,1.5,NG/ML,0.4965,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,40.562,295.058,30.0,130.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,30.0,0.84,0.84,NG/ML,0.27804,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,295.058,295.058,30.0,165.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,60.0,2.49,2.49,NG/ML,0.82419,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,195.765,295.058,30.0,227.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,90.0,2.76,2.76,NG/ML,0.91356,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,213.668,295.058,30.0,256.0,2014-11-11,15
T1DAL_975187,SUB168937,Week 24,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 24,15.0,2015,2011-07-21,170.0,5.5921052632,C-PEPTIDE,120.0,3.28,3.28,NG/ML,1.08568,1.08568,0.83743,0.24825,120.0,,0.94004,,,171.9,61.3,236.675,295.058,30.0,,2014-11-11,15
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,-10.0,1.01,1.01,NG/ML,0.33431,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,,285.689,30.0,140.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,0.0,0.92,0.92,NG/ML,0.30452,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,90.239,285.689,30.0,135.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,15.0,1.08,1.08,NG/ML,0.35748,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,218.058,285.689,30.0,145.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,30.0,2,2.0,NG/ML,0.662,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,285.689,285.689,30.0,213.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,60.0,2.73,2.73,NG/ML,0.90363,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,210.911,285.689,30.0,265.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,90.0,3.17,3.17,NG/ML,1.04927,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,230.791,285.689,30.0,288.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,120.0,3.3,3.3,NG/ML,1.0923,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,225.443,285.689,30.0,273.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,150.0,3.34,3.34,NG/ML,1.10554,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,218.661,285.689,30.0,268.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,180.0,3.23,3.23,NG/ML,1.06913,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,204.465,285.689,30.0,240.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,210.0,2.53,2.53,NG/ML,0.83743,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,140.887,285.689,30.0,217.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 52,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-07,371.0,12.203947368,C-PEPTIDE,240.0,2.19,2.19,NG/ML,0.72489,1.0923,0.83743,0.25487,120.0,1.10554,0.94004,0.1655,150.0,171.3,60.0,117.082,285.689,30.0,193.0,2014-11-11,28
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,-10.0,0.62,0.62,NG/ML,0.20522,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,,203.908,30.0,108.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,0.0,0.6,0.6,NG/ML,0.1986,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,46.213,203.908,30.0,110.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,15.0,0.6,0.6,NG/ML,0.1986,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,85.517,203.908,30.0,108.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,30.0,0.88,0.88,NG/ML,0.29128,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,203.908,203.908,30.0,132.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,60.0,1.76,1.76,NG/ML,0.58256,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,141.917,203.908,30.0,199.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,90.0,2.24,2.24,NG/ML,0.74144,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,174.803,203.908,30.0,245.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 78,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 78,29.0,2029,2012-07-31,546.0,17.960526316,C-PEPTIDE,120.0,2.54,2.54,NG/ML,0.84074,0.84074,0.83743,0.00331,120.0,,0.94004,,,171.6,62.3,184.901,203.908,30.0,242.0,2014-11-11,29
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,-10.0,0.87,0.87,NG/ML,0.28797,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,,182.033,30.0,171.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,0.0,0.79,0.79,NG/ML,0.26149,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,72.023,182.033,30.0,175.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,15.0,0.88,0.88,NG/ML,0.29128,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,140.138,182.033,30.0,184.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,30.0,1.37,1.37,NG/ML,0.45347,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,182.033,182.033,30.0,227.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,60.0,1.79,1.79,NG/ML,0.59249,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,136.767,182.033,30.0,279.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,90.0,1.89,1.89,NG/ML,0.62559,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,136.773,182.033,30.0,295.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,120.0,2.08,2.08,NG/ML,0.68848,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,144.524,182.033,30.0,308.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,150.0,2.1,2.1,NG/ML,0.6951,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,142.241,182.033,30.0,310.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,180.0,2.08,2.08,NG/ML,0.68848,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,135.761,182.033,30.0,276.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,210.0,1.54,1.54,NG/ML,0.50974,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,84.832,182.033,30.0,265.0,2014-11-11,30
T1DAL_975187,SUB168937,Week 104,ITN045AI-Rigby,P,2.0,2011-01-04,2011-02-01,Yes,Yes,Yes,S/I,32.0,16-35,22-35,22-35,Male,White,,Not Hispanic or Latino,2011-02-01,2011-07-21,2011-10-05,Yes,,2013-02-02,732.0,Yes,,,2011-10-05,246.0,Completed study,Completed study drug,Yes,Yes,2013-02-02,732.0,Week 104/Visit 30,2010-11-07,-86.0,7,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-02,732.0,24.078947368,C-PEPTIDE,240.0,1.41,1.41,NG/ML,0.46671,0.68848,0.83743,-0.14895,120.0,0.6951,0.94004,-0.24494,150.0,171.6,63.5,78.349,182.033,30.0,238.0,2014-11-11,30
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,-10.0,1.04,1.04,NG/ML,0.34424,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,,288.543,150.0,111.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,0.0,1.03,1.03,NG/ML,0.34093,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,111.408,288.543,150.0,109.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,15.0,1.22,1.22,NG/ML,0.40382,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,172.426,288.543,150.0,121.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,30.0,1.69,1.69,NG/ML,0.55939,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,224.582,288.543,150.0,143.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,60.0,2.19,2.19,NG/ML,0.72489,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,170.637,288.543,150.0,187.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,90.0,2.63,2.63,NG/ML,0.87053,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,200.211,288.543,150.0,218.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,120.0,3.19,3.19,NG/ML,1.05589,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,240.325,288.543,150.0,224.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,150.0,3.84,3.84,NG/ML,1.27104,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,288.543,288.543,150.0,224.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,180.0,3.2,3.2,NG/ML,1.0592,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,214.71,288.543,150.0,215.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,210.0,3.21,3.21,NG/ML,1.06251,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,208.966,288.543,150.0,202.0,2014-11-11,-1
T1DAL_975329,SUB168938,-1,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Screening,-1.0,1000,2011-02-12,-16.0,-0.526315789,C-PEPTIDE,240.0,3.16,3.16,NG/ML,1.04596,1.05589,1.05589,0.0,120.0,1.27104,1.27104,0.0,150.0,166.4,71.5,210.702,288.543,150.0,186.0,2014-11-11,-1
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,-10.0,0.94,0.94,NG/ML,0.31114,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,,347.217,30.0,108.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,0.0,0.99,0.99,NG/ML,0.32769,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,134.338,347.217,30.0,107.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,15.0,1.32,1.32,NG/ML,0.43692,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,204.192,347.217,30.0,136.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,30.0,1.89,1.89,NG/ML,0.62559,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,347.217,347.217,30.0,172.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,60.0,3.03,3.03,NG/ML,1.00293,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,249.747,347.217,30.0,238.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,90.0,3.18,3.18,NG/ML,1.05258,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,245.708,347.217,30.0,250.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 24,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 24,15.0,2015,2011-08-18,171.0,5.625,C-PEPTIDE,120.0,3.34,3.34,NG/ML,1.10554,1.10554,1.05589,0.04965,120.0,,1.27104,,,166.7,76.3,241.258,347.217,30.0,256.0,2014-11-11,15
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,-10.0,1.91,1.91,NG/ML,0.63221,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,,368.478,30.0,170.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,0.0,2.03,2.03,NG/ML,0.67193,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,204.397,368.478,30.0,166.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,15.0,2.25,2.25,NG/ML,0.74475,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,300.817,368.478,30.0,176.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,30.0,2.98,2.98,NG/ML,0.98638,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,368.478,368.478,30.0,221.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,60.0,3.66,3.66,NG/ML,1.21146,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,285.276,368.478,30.0,271.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,90.0,3.37,3.37,NG/ML,1.11547,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,240.343,368.478,30.0,310.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,120.0,3.5,3.5,NG/ML,1.1585,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,242.268,368.478,30.0,305.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,150.0,3.36,3.36,NG/ML,1.11216,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,229.385,368.478,30.0,298.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,180.0,3.18,3.18,NG/ML,1.05258,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,211.808,368.478,30.0,273.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,210.0,2.76,2.76,NG/ML,0.91356,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,175.016,368.478,30.0,251.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 52,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 52,28.0,2028,2012-02-16,353.0,11.611842105,C-PEPTIDE,240.0,2.7,2.7,NG/ML,0.8937,1.21146,1.05589,0.15557,60.0,1.21146,1.27104,-0.05958,60.0,166.5,78.6,175.426,368.478,30.0,231.0,2014-11-11,28
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,-10.0,1.42,1.42,NG/ML,0.47002,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,,363.784,30.0,145.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,0.0,1.49,1.49,NG/ML,0.49319,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,146.574,363.784,30.0,147.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,15.0,1.64,1.64,NG/ML,0.54284,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,256.678,363.784,30.0,152.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,30.0,2.43,2.43,NG/ML,0.80433,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,363.784,363.784,30.0,209.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,60.0,3.34,3.34,NG/ML,1.10554,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,271.288,363.784,30.0,266.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,90.0,3.64,3.64,NG/ML,1.20484,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,277.479,363.784,30.0,300.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 78,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 78,29.0,2029,2012-09-03,553.0,18.190789474,C-PEPTIDE,120.0,3.83,3.83,NG/ML,1.26773,1.26773,1.05589,0.21184,120.0,,1.27104,,,166.5,78.8,279.197,363.784,30.0,298.0,2014-11-11,29
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,-10.0,0.49,0.49,NG/ML,0.16219,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,,342.013,30.0,119.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,0.0,0.59,0.59,NG/ML,0.19529,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,63.442,342.013,30.0,114.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,15.0,0.67,0.67,NG/ML,0.22177,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,57.282,342.013,30.0,132.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,30.0,0.67,0.67,NG/ML,0.22177,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,342.013,342.013,30.0,195.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,60.0,2.55,2.55,NG/ML,0.84405,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,224.508,342.013,30.0,261.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,90.0,3.05,3.05,NG/ML,1.00955,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,258.406,342.013,30.0,295.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,120.0,3.33,3.33,NG/ML,1.10223,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,253.059,342.013,30.0,286.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,150.0,3.24,3.24,NG/ML,1.07244,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,228.813,342.013,30.0,270.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,180.0,2.49,2.49,NG/ML,0.82419,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,150.76,342.013,30.0,245.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,210.0,2.37,2.37,NG/ML,0.78447,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,144.748,342.013,30.0,218.0,2014-11-11,30
T1DAL_975329,SUB168938,Week 104,ITN045AI-Rigby,A,1.0,2011-02-12,2011-02-28,Yes,Yes,Yes,S/I,23.0,16-35,22-35,22-35,Female,White,White,Hispanic or Latino,2011-03-03,2011-08-18,2011-11-04,Yes,,2013-02-25,728.0,Yes,,,2011-11-04,249.0,Completed study,Completed study drug,Yes,Yes,2013-02-25,728.0,Week 104/Visit 30,2010-11-24,-96.0,8,Yes,Yes,Yes,Week 104,30.0,2030,2013-02-25,728.0,23.947368421,C-PEPTIDE,240.0,2.23,2.23,NG/ML,0.73813,1.10223,1.05589,0.04634,120.0,1.10223,1.27104,-0.16881,120.0,166.7,79.6,145.064,342.013,30.0,198.0,2014-11-11,30
